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 Abbreviations 
 
All units of measurement are abbreviated according to the International System of units 
(SI). 
 
A      Adenosine 
Amp     Ampicillin 
APS     Ammonium persulfate 
ATP     Adenosine triphosphate 
BSA     Bovine Serum Albumine 
bp     basepair 
C      Cytosine 
CalBP     Calmodulin Binding Peptide 
DAPI    4’,6-Diamidino-2-phenylindole  
DBD     DNA binding domain 
DNA     Deoxyribonucleic acid 
DMEM      Dulbecco’s Minimal Essential Medium  
DMSO      Dimethylsulfoxid  
DTT     1,4 Dithiothreitol 
E1      SUMO or ubiquitin activating enzyme 
E2      SUMO or ubiquitin conjugating enzyme  
E3      SUMO or ubiquitin ligases 
EDTA     Ethylenediamine tetraacetic acid 
et al.     and others 
EtOH     Ethanol 
FCS      Fetal Calf Serum 
Fig       Figure 
G      Guanosine 
GFP       Green Fluorescent Protein 
EGFP       Enhanced Green Fluorescent Protein 
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HA     Hemagglutinin epitope 
HRP     Horseradish peroxidase 
K      Lysin  
Kan      Kanamycin 
kb      kilobases 
kDa      Kilodalton  
LB     Luria-Bertani-Medium 
ORF      Open Reading Frame 
PCR     Polymerase Chain Reaction 
PIAS     Protein Inhibitor of Activated STAT 
PIC     Protease Inhibitor Cocktail 
PML     Promyelocytic Leukemia protein      
PMSF     Phenylmethylsulfonyl fluoride 
rpm      rounds per minute 
RT      Room temperature 
SDS     Sodium dodecyl sulphate 
Sp1      Specificity protein1  
Sp3      Specificity protein3  
SUMO     Small Ubiquitin-like Modifier 
T      Thiamine 
TAP      Tandem Affinity Purification 
TE     Tris-EDTA 
TEMED    N, N, N‘, N‘-Tetramethylene diamine 
TEV     Tobacco Etch Virus 
U      Unit 
Ubc9     Ubiquitin conjugating enzyme 9 
wt      Wild type 
www     World Wide Web 
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 Summary 
 
A group of sequence-specific DNA-binding proteins related to the transcription 
factor Sp1 (specificity protein 1) has been implicated in the regulation of many 
different genes, since binding sites for these transcription factors (GC/GT boxes) are a 
recurrent motif in regulatory sequences of these genes. In contrast to the transcriptional 
activators Sp1 and Sp4, the ubiquitously expressed Sp3 protein can both activate and 
repress transcription. The complex activity of Sp3 depends on two glutamine-rich 
activation domains, similar to those found in Sp1 and Sp4, and, adjacent to these, on an 
inhibitory domain unique to Sp3. The critical lysine residue in the Sp3 inhibitory 
domain lies within a consensus motif (IK551EE) that targets proteins for SUMO 
modification. SUMO (small ubiquitin-related modifier) is covalently attached to lysine 
residues in target proteins via an isopeptide linkage in a multi-step process that is 
analogous to ubiquitination. SUMOylation is a dynamic, reversible process, and 
distinct enzymes are responsible for adding or removing SUMO from target proteins.  
The present work analyses various aspects of SUMO conjugation to Sp3 in vivo. 
Studying modification of Sp3 by SUMO is complicated by the existence of a number of 
Sp3 isoforms. Immunoblot analyses revealed four distinct Sp3 proteins, two slow 
migrating of more than 100 kDa and two fast migrating species. Seven to eight Sp3 
bands appeared, when cells were lysed in denaturing conditions. The additional protein 
species represent SUMO modified Sp3 isoforms. Currently, it is not known whether the 
relative distribution of the different Sp3 isoforms is regulated. However, a significant 
shift towards the long isoforms of Sp3, however, is observed in Sp1-/- ES cells 
demonstrating that Sp3 isoform expression principally can change in vivo. In addition, 
this observation suggests that the long isoforms of Sp3 may take over Sp1 functions 
under Sp1 knockout conditions. 
When Sp3 is overexpressed along with SUMO1 and SUMO2 in cells in culture, 
attachment of both SUMO paralogues to Sp3 occurred with almost equal efficiency. 
Beside lysine 551 within the inhibitory domain, there are two other potential 
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SUMOylation sites in Sp3 (VKQE at position 9 and IKDE at position 120). This study 
revealed that SUMOylation takes place exclusively at K551, present in all four 
isoforms.  
The Sp3 transcription factor is located predominantly in the nucleus. Visualization 
of endogenous Sp3 by immumofluorescence showed a sponge-like, diffuse appearance. 
Evolutionally closely related Sp family members Sp1 and Sp2 are also located in the 
nucleus and the subcellular localization patterns are similar to Sp3. Ectopic expression 
of SUMO1 fused to GFP (green fluorescent protein) led to the accumulation of this 
fusion protein within subnuclear “dots” or PODs (promyelocytic leukemia oncogenic 
domains), whereas endogenous Sp3 remained diffusely distributed throughout nuclei. 
In addition, the wild-type Sp3 isoforms and the SUMOylation-deficient mutants of 
Sp3were located in the nucleus exhibiting also a sponge-like, diffuse appearance.   
Analyzing the Sp3 expression in different cell lines and mouse organs revealed that 
the relative level of Sp3 modification by SUMO is not cell line or organ dependent. In 
addition, no variation in Sp3 expression pattern after serum starvation, serum induction 
and heat shock was observed.  
Ultraviolet radiation or Tumor Necrosis Factor alpha and Cycloheximide treatment 
of mammalian cells did not alter the SUMOylation level of Sp3 protein in our 
experimental conditions. A significant reduction in Sp3 SUMO modification was 
observed upon treatment with MG-132, a cell-permeable inhibitor of the proteasome. 
Possibly this proteasome inhibitor prevents proteasome degradation of SUMO specific 
isopeptidase, which subsequently remove the Sp3-SUMO moiety. 
PIAS1 (protein inhibitor of activated STAT) was previously cloned in a two-hybrid 
screen by using the inhibitory domain of Sp3. Moreover, it was shown that PIAS1 
strongly enhances SUMO-modification of Sp3 in vitro and thus acts as an SUMO E3 
ligase towards Sp3.  Nuclear extract fractionation studies suggested that PIAS1 is part 
of (a) high molecular weight complex(es). PIAS1-associated proteins might confer 
substrate specificity towards Sp3 and other transcription factors and/or regulate PIAS1 
activity in vivo. For the purification and identification of PIAS1-associated proteins, a 
number of C-terminal tagged expression plasmids were constructed for constitutive 
Summary 
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and inducible expression. The dual-tag affinity purification system established in this 
thesis work contains a small 15 amino acid artificial tag (BiotinTAG) that becomes 
biotinylated by the BirA ligase upon co-transfection of an appropriate expression 
construct. To enhance specificity, a second tag was included in the expression vectors 
(Calmodulin Binding Peptide or alternatively FLAG or Triple-FLAG). In addition, 
dual tags expression plasmids for Sp3 were constructed.  
The establishment of stable cell lines expressing these fusion proteins in an 
inducible manner was initiated. Such cell lines might be ideal for further analyzes of 
PIAS1 activities and to purify PIAS1 (Sp3) associated factors.  
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 Zusammenfassung 
 
Bei einer Gruppe von sequenzspezifischen DNA-Bindeproteinen, die mit dem 
Transkriptionsfaktor Sp1 (Specificity Protein 1) verwandt sind, wird eine Beteiligung 
an der Regulation verschiedener Gene vermutet, da die Bindestellen dieser 
Transkriptionsfaktoren (GC/GC-Boxen) ein wiederkehrendes Motiv in regulatorischen 
Sequenzen von Genen darstellen. Im Gegensatz zu den transkriptionellen Aktivatoren 
Sp1 und Sp4 kann das ubiquitär exprimierte Sp3 die Transkription sowohl aktivieren, 
als auch reprimieren.  
Die komplexe Aktivität von Sp3 ist abhängig von zwei glutamin-reichen 
Aktivierungs-Domänen, ähnlich denen von Sp1 und Sp4, sowie von einer neben den 
Aktivierungs-Domänen liegenden inhibitorischen Domäne, die nur in Sp3 gefunden 
wurde. Der kritische Lysin-Rest in der inhibitorischen Domäne von Sp3 liegt innerhalb 
einer Konsensus-Sequenz, welche das Ziel für die SUMOylierung des Proteins 
darstellt. SUMO (small ubiquitin-related modifier) wird in einem Mehrschrittprozeß 
analog der Ubiquitinierung über eine Isopeptid-Bindung mit einem Lysin-Rest des 
Zielproteins kovalent verknüpft. Die SUMOylierung ist ein dynamischer und 
reversibler Prozeß. Mehrere Enzyme sind für die Verknüpfung bzw. Loslösung von 
SUMO an bzw. von Zielproteinen verantwortlich.  
In der vorliegenden Arbeit werden verschiedene Aspekte der SUMO-Konjugation 
an Sp3 in vivo analysiert. Die Untersuchungen zur SUMOylierung von Sp3 wurden 
durch die Existenz verschiedener Sp3 Isoformen verkompliziert. Die 
Immunoblot-Analyse deckte die Existenz vier verschiedener Isoformen auf: zwei im 
Gel langsam migrierende Formen mit einem Molekulargewicht über 100 kDa, sowie 
zwei schnell migrierende Formen. Es erschienen sieben bis acht Sp3-Banden, wenn die 
Zellen unter speziellen Bedingungen lysiert wurden. Die hier zusätzlichen Banden 
stellen die SUMOylierten Isoformen dar. Derzeit ist noch nicht bekannt, ob die relative 
Verteilung der verschiedenen Isoformen reguliert wird. Eine deutliche Verschiebung zu 
den langen Isoformen konnte in Sp1-/- ES-Zellen beobachtet werden, was darauf 
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hindeutet, daß die Expression der verschiedenen Sp3 Isoformen in vivo veränderbar ist. 
Außerdem läßt diese Beobachtung die Vermutung zu, daß die langen Isoformen von 
Sp3 die Funktionen von Sp1 unter Sp1-defizienten Bedingungen übernehmen. 
Bei der Überexpression von Sp3 sowie SUMO1 und SUMO2 in vivo erfolgte die 
Bindung beider SUMO-Proteine an Sp3 mit ähnlicher Effizienz.  
Neben dem Lysin-Rest an Stelle 551 innerhalb der inhibitorischen Domäne gibt es 
noch zwei weitere potentielle SUMOylierungsstellen in Sp3 (VKQE an Position 9 und 
IKDE an Position 120). Die vorligende Studie hat gezeigt, daß die SUMOylierung nur 
an K551 stattfindet, die in allen vier Isoformen vorhanden ist.  
Der Transkriptionsfaktor Sp3 ist hauptsächlich im Nukleus lokalisiert. Die 
Visualisierung des endogenen Sp3 mit Hilfe der Immunfluoreszenz zeigte eine 
schwamm-ähnliche, diffuse Erscheinung. Die evolutionär eng verwandten Sp-Faktoren 
Sp1 und Sp2 sind ebenfalls im Nukleus lokalisiert und zeigen ähnliche subzelluläre 
Verteilungsmuster wie Sp3. Die Überexpression eines Fusionsproteins aus SUMO1 
und GFP (green fluorescent protein) führte zur Akkumulierung dieses Fusionsproteins 
in subnuclearen PODs (promyelocytic leukemia oncogenic domains), während 
endogenes Sp3 weiterhin eine diffuse Verteilung im Nukleus zeigte. Die Wildtyp-Sp3 
Isoformen und die Sp3 SUMOylierungs-defizienten Mutanten sind ebenfalls 
schwamm-ähnlich und diffus im Nukleus verteilt. 
Die Analyse der Sp3-Expression in verschiedenen Zelllinien und Mausorganen 
zeigte, daß das Ausmaß der Sp3-Modifikation mit SUMO nicht zelllinien- bzw. 
organspezifisch ist. Außerdem führten Serum-Entzug, Serum-Induktion und 
Hitzeschock zu keinerlei Veränderungen im Sp3-Expressionsmuster. 
Die ultraviolette Bestrahlung oder der Tumor Nekrose Faktor alpha und die 
Cycloheximid-Behandlung von Säugetierzellen-Zellen veränderten den 
SUMOylierungs-Gehalt von Sp3 unter den hier gestellten experimentellen 
Bedingungen nicht. Eine signifikante Reduktion der Sp3-SUMO-Modifikation zeigte 
sich nach der Behandlung mit MG-132, einem zell-permeablen Inhibitor des 
Proteasoms. Möglicherweise ist dieser Proteasom-Inhibitor mit dafür verantwortlich, 
daß SUMO-spezifische Proteasen nicht abgebaut werden und diese deshalb das 
Zusammenfassung 
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SUMOylierte Sp3 entfernen können. 
PIAS1 (protein inhibitor of activated STAT) war in einem Yeast-Two-Hybrid 
Screen identifiziert, bei dem die inhibitorischen Domäne von Sp3 als Köder diente. 
Darüber hinaus wurde gezeigt, daß PIAS1 die SUMOylierung von Sp3 in vitro 
verstärkt und deshalb als SUMO-E3 Ligase bei der Sp3-SUMOylierung wirkt. Studien 
zur Fraktionierung von Kernextrakten deutenten darauf hin, daß PIAS1 in vivo Teil 
eines Komplexes mit hohem Molekulargewicht ist. PIAS1-assoziierte Proteine trugen 
möglicherweise zur Substratspezifität bei der Sp3-SUMOylierung bzw. SUMOylierung 
anderer Transkriptionsfaktoren bei und/oder regulierten zudem die Aktivität von 
PIAS1 in vivo.  
Zur Reinigung und Identifizierung von PIAS1-assoziierten Proteinen wurde eine 
Anzahl C-terminal getagter Expressionsplasmide mit konstitutiver und induzierbarer 
Expression konstruiert. Das Dual-Tag Affinitäts-Reinigungs-System, das während 
dieser Arbeit etabliert wurde, beinhaltet ein kleines 15 Aminosäuren-umfassendes 
artifizielles Tag (BiotinTAG), welches von der BirA Ligase nach Kotransfektion eines 
geeigneten Expressionskonstruktes biotinyliert werden kann. Um die Spezifität zu 
erhöhen, wurde ein zweites Tag in die Expressionsvektoren kloniert (Calmodulin 
Bindepeptid oder alternativ FLAG oder Triple-FLAG). Zusätzlich erfolgte die 
Konstruktion von Dual-Tag-Expressionsplasmiden für Sp3. Die Etablierung von 
stabilen Zelllinien, die diese Fusionsproteine induzierbar exprimieren, wurde initiiert. 
Derartige Zelllinien wären ideal für weitere Analysen der Aktivität von PIAS1 und für 
die Reinigung von PIAS1 (Sp3) assoziierten Faktoren. 
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1. Introduction 
 
1.1. Properties of Sequence-Specific DNA Binding Transcription Factors 
In eukaryotes, there are tens of thousands of protein-coding genes, each of which 
has its own specific program of transcriptional control. Much of the specificity of these 
programs is regulated by sequence-specific DNA binding proteins that bind to the 
proximal promoter and distal transcriptional regulatory regions (such as enhancers and 
silencers). Sequence-specific DNA binding transcription factors (henceforth termed 
“sequence-specific factors”) interpret and transmit the information that is encoded in 
the primary DNA sequence to the factors and cofactors that mediate the synthesis of 
RNA transcripts from the DNA template (Kadonaga, 2004). Thus, the sequence- 
specific factors collectively function as the key interface between genetic regulatory 
information and the transcription system (Fig.1.1). 
 
       
  
Fig.1.1. Sequence-Specific DNA Binding Transcription Factors Interpret and 
Transmit Genetic Regulatory Information. 
In this diagram, sequence-specific factors are depicted as the apex at the interface of 
the vast array of genetic regulatory information and the inverted cone of the RNA 
polymerase II transcriptional machinery and coregulators.  
(After Kadonaga, 2004). 
 
Transcription is succinctly defined as the process of RNA synthesis complementary 
to a DNA template. Transcription is a complex process that relies on the collective 
action of sequence-specific factors along with the core RNA polymerase II 
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transcriptional machinery, an assortment of coregulators that bridge the DNA binding 
factors to the transcriptional machinery, a number of chromatin-remodeling factors that 
mobilize nucleosomes, and a variety of enzymes that catalyze the covalent 
modification (e.g., acetylation, deacetylation, phosphorylation, dephosphorylation, 
methylation, ubiquitination, deubiquitination, SUMOylation and ADP-ribosylation) of 
histones and other proteins. 
1.1.1. Sequence-Specific Transcription Factors Are Modular 
A typical sequence-specific factor has a DNA binding module linked to one or 
more activation or repression modules as well as in certain cases, a multimerization 
module and a regulatory module (Fig.1.2.-A). 
      
 
Fig.1.2. Some properties of sequence-specific DNA Binding transcription factors 
A. Sequence-specific factors are composed of functional modules. 
B. Chromatin is an integral component in the function of sequence-specific factors. 
Nucleosomes are depicted in yellow. 
C. Recognition sites for sequence-specific factors tend to be located in clusters 
(After Kadonaga, 2004). 
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The first well-defined DNA binding module was the helix-turn-helix motif, which 
was originally discovered in prokaryotic DNA binding proteins. It later became 
apparent, however, that nature has generated many distinct DNA binding modules, 
which include the homeodomains (a variant of the helix-turn-helix), zinc fingers (of 
which there are different types), leucine zippers, helix-loop-helix motifs, HMG1 
domains and others (Pabo and Sauer, 1992). Both the leucine zipper (Landschultz et al., 
1988) and helix-loop-helix (Murre et al., 1989) motifs with their associated basic 
regions are able to perform dual DNA binding and dimerization functions. The first of 
the nonacidic activation regions was found in transcription factor Sp1 (Specificity 
protein1), which contains multiple glutamine-rich activation motifs (Courey and Tjian, 
1988). Other transcriptional activation motifs include proline-rich regions (Mermod et 
al., 1989) and hydrophobic β sheets (Leuther et al., 1993; Van Hoy et al., 1993). 
Some transcription factors are controlled by regulatory modules. For example, 
nuclear receptors are transcription factors that contain a regulatory module that is 
located on the same polypeptide as the DNA binding and transcriptional activation 
modules. IkB is an example of a regulatory module that is not covalently attached to 
the transcription factor (NF-kB proteins) that it regulates. Instead, IkB functions as a 
detachable regulatory subunit that modulates the activity and cellular location of 
NF-kB (Baeuerle and Baltimore, 1988). 
1.1.2. Sequence-Specific Factors Regulate Transcription via Recruitment of 
Coactivators and Corepressors 
How do sequence-specific factors work? Current evidence indicates that the 
sequence-specific factors function mainly by recruitment of transcriptional coactivators 
and corepressors to the DNA template via protein-protein interactions (Ptashne and 
Gann, 1997). These cofactors then act both directly and indirectly to regulate the 
activity of the RNA polymerase II transcriptional machinery at the core promoter. 
Many but not all of these coactivators and corepressors are recruited to the DNA 
template via interactions with the sequence-specific factors. Some coregulators are 
direct intermediaries between the sequence-specific factors and the general/basal 
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transcriptional machinery. For instance, there are specific interactions between 
sequence-specific factors and TAF’s (TBP-associated factors) subunits of the TFIID 
component of the basal machinery. In addition to TAFs, many other coactivator 
complexes (which include TRAP, SMCC, Mediator, SRB complex, CRSP, DRIP, NAT, 
p300/CBP, and others) can serve as a bridge between the sequence-specific factors and 
the general/basal transcriptional machinery.  
Another distinct class of cofactors are chromatin-related coregulators, which are 
also thought to be recruited by the sequence-specific factors. The chromatin-related 
coregulators affect transcription indirectly by remodeling nucleosomes or by covalent 
modification of histones (e.g., by acetylation, methylation, phosphorylation, 
ubiquitination, and ADP-ribosylation) or the DNA template (McKenna and O’Malley, 
2002; Narlikar et al., 2002; Freiman and Tjian, 2003). 
Other coregulators are not recruited by the sequence specific factors, but instead 
interact directly with RNA polymerase II and modulate the efficiency of transcriptional 
elongation (Hampsey and Reinberg, 2003). 
1.1.3. Sequence-Specific Factors Can Be Regulated by Posttranslational 
Modifications 
Some sequence-specific factors have been found to be regulated by 
posttranslational modifications. An excellent example is the phosphorylation of CREB 
(cyclic AMP response element binding protein) (Gonzalez and Montminy, 1989). 
CREB activates transcription of cyclic AMP-inducible genes via binding to CRE 
(cyclic AMP response element) motifs. First, cAMP stimulates protein kinase A, which 
phosphorylates CREB at serine residue 133. Upon phosphorylation, CREB becomes 
activated and stimulates transcription from cAMP-responsive promoters. Another 
example of posttranslational modification of transcription factors is the O-linkage of 
N-acetylglucosamine in many sequence-specific factors, which include Sp1, AP-1, 
AP-2, CTF/NF-I, Zeste, GAGA factor, and Adf-1 (Jackson and Tjian., 1988). The 
function of the O-linked N-acetylglucosamine monosaccharide residues remains to be 
clarified. Some results suggest a role of this modification in transcriptional repression 
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(Yang et al., 2002). Sequence-specific factors can also be acetylated. For example, 
acetylation of p53 increases the affinity of its binding to DNA (Gu and Roeder, 1997). 
Many transcription factors, which include the sequence-specific proteins, are 
ubiquitinated (Freiman and Tjian, 2003) or are modified by ubiquitin family proteins 
(Hilgarth et al., 2004; Watts, 2004). 
1.1.4. Sequence-Specific Factors Are Members of Multiprotein Families 
Many sequence-specific factors are members of multiprotein families. For instance, 
nuclear receptors are members of a superfamily of related proteins (Evans, 1988). AP-1 
consists of Fos, Jun, and many other Fos and Jun related proteins as well as ATF and 
CREB-like proteins. CTF/NF-I is a family of proteins that appear to result from 
alternative RNA splicing (Santoro et al., 1988). NF-kB is yet another family of proteins 
(Baldwin, 1996). p53, p63, and p73 are also a protein family (Yang et al., 2002). Even 
the original Sp1 has turned out to be a member of the Sp family of proteins (Suske et 
al., 2005). Thus, there are many families of transcription factors. Within each family, 
the members often display closely related or essentially identical DNA binding 
properties but distinct activation functions. It remains a significant challenge to 
elucidate the molecular bases for the unique functional specificities of individual 
members of each transcription factor family. 
1.1.5. Chromatin Is an Integral Component in the Function of Sequence-Specific 
Factors 
Chromatin is the natural state of the DNA template. For many years, chromatin had 
been commonly viewed as an unimportant subject area with no role in general 
understanding of gene regulation. One early concept was that transcription factors 
function primarily to counteract chromatin-mediated global repression of basal 
transcription in the absence of activators. This “antirepression” model is distinct but 
not mutually exclusive from a “true activation” model in which sequence-specific 
factors function to increase the rate of the intrinsic transcription process (Adams and 
Workman, 1993; Paranjape et al., 1994).  
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 Current data support both of these hypotheses, but also reveal an unforeseen 
complexity in the involvement of chromatin in transcriptional regulation that includes 
chromatin-remodeling factors (ATP-dependent enzymes that mobilize nucleosomes) 
and a variety of histone-modifying enzymes. It appears that sequence-specific factors 
recruit chromatin-remodeling factors and histone-modifying enzymes, which in turn 
function to rearrange chromatin structure (for instance, to relieve chromatin-mediated 
repression) as well as to modify histones in a specific fashion that promotes the desired 
gene activation or repression (Li, 2002). 
1.1.6. Recognition Sites for Sequence-Specific Factors Tend to Be Located in 
Clusters 
Individual eukaryotic sequence-specific factors generally bind to DNA with 
relatively low specificity. Thus, the precise control of gene transcription requires a 
higher degree of specificity than that typically afforded by the binding of a single 
sequence-specific factor to DNA. Instead, the high degree of specificity and potency of 
promoter and enhancer binding factors appears to be accomplished by the utilization of 
multiple factor recognition sites in composite cis-regulatory arrays (Fig.1.2. C). Hence, 
a cluster of several short (about 6 to 8 bp) recognition sites, such as in an enhancer 
region, would be rarely encountered in the genome, even though a single recognition 
site might be common. It is also relevant to note that multiple sequence-specific factors 
in a cluster typically function synergistically and activate transcription more strongly 
than each factor on its own (Laybourn and Kadonaga, 1992).  
 In this manner, the specificity of gene activation by sequence-specific factors 
derives from the use of multiple, clustered cis binding sites in conjunction with the 
synergistic enhancement of transcription that is achieved with multiple trans-acting 
factors.  
1.1.7. Other Properties of Sequence-Specific Transcription Factors 
First, sequence-specific factors have been found to interact with transcriptional 
insulator (also known as “boundary”) elements, which function to block the spreading 
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of the influence of either positive DNA elements (such as enhancers) or negative DNA 
elements (such as a silencers, or heterochromatin-like repressive effects) (Bell et al., 
2001). Sequence-specific factors that have been found to act at insulator elements 
include BEAF-32, suppressor of Hairy-wing and Zw5 in D. melanogaster and CTCF in 
mammalians (Moon at al., 2004). It will be important to determine the specific features 
of these factors that enable them to function in transcriptional insulation. 
Second, sequence-specific activators can stimulate transcription initiation as well 
as elongation (Blau et al., 1996). In fact, some factors primarily stimulate initiation, 
whereas other factors stimulate predominantly elongation or both initiation and 
elongation.  
Third, a subset of sequence-specific activators, which include Sp1 and CBF/NF-Y, 
are commonly found in the proximal promoter region of genes (-250 to -30 relative to 
the +1 transcription start site). Some of these proximal promoter factors might function 
most effectively near the start site because they interact with the core transcriptional 
machinery. Moreover, some of the promoter proximal factors might also act as a 
conduit between distal enhancers and the basal/general transcriptional machinery, 
possibly as tethering factors that link or loop enhancer complexes to the core 
transcription complex (Calhoun et al., 2002). 
 
1.2. Basic Classification of Sp Family Transcription Factors 
1.2.1. The Sp/KLF Zinc Finger Transcription Factors 
The zinc finger transcription factors are the most widely evolved family of 
transcription factors in eukaryotes. Among these factors, the Sp/KLF (Specificity 
Protein/Krüppel-Like Factor) family of transcription factors has received attention due 
to important roles in development, differentiation, and oncogenic processes (Suske, 
1999; Philipsen and Suske, 1999; Bouwman and Philipsen, 2002). 
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Fig.1.3 Relationships between the SP and KLF factors of human, Drosophila and 
C. elegans  
Of each factor, the 110 aa domain containing the BTD/zinc finger motifs was used for 
the multiple alignment with ClustalW (http://www.ebi.ac.uk/clustalw/). This alignment 
was used to construct the cladogram.  
*: The current sequence of C. elegans F45H11.1 only contains the BTD motif and the 
first finger.  
**: one amino acid was removed from finger 3 of Ce-T22C8.5 (HXXXH instead of 
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HXXXXH), because the extra amino acid is not handled appropriately in the multiple 
alignment generated with ClustalW.  
***: The sequence of D-CG3065 is deduced from the Drosophila genome sequence; 
the current annotation does not contain the complete BTD/zinc finger motif.  
(After Suske et al., 2005). 
 
For long it has been known that the general transcription factor Sp1 (Specificity 
protein 1) can bind and act through GC/GT boxes, and Sp1 was therefore thought to be 
an extremely versatile protein essential for many different functions of the mammalian 
nucleus. More recently, however, it has become clear that Sp1 is not the only 
transcription factor binding and acting through these elements. It simply represents the 
first identified and cloned protein of a new and still growing family of transcription 
factors. Family members contain a highly conserved DNA-binding domain consisting 
of three zinc fingers. The availability of near complete genome sequences of mouse 
and human greatly facilitates the unambiguous assignment of names to all the members 
of the SP/KLF family (Suske et al., 2005). Currently this family of transcription factors 
comprises at least 25 different mammalian members (Fig.1.3). 
The 81 amino acid DNA-binding domain that is found close to the C-termini of all 
members essentially defines the Sp/XKLF family of transcription factors. It consists of 
three C2H2-type zinc fingers arranged similar to those found in the Drosophila 
melanogaster regulator protein Krüppel. Accordingly, some of the proteins have been 
named Krüppel-like factors. 
The striking similarity of the linker amino acids between the individual fingers as 
well as the identical length of the DNA-binding domain strongly suggest that the 
higher order structure of the three fingers is crucial for the biological function of the 
proteins (Fig.1.4). Structural studies on zinc finger peptides bound to DNA have 
provided information that allows predictions on the DNA sequence recognized by 
finger domains. The amino acids of the Sp1 zinc fingers that are most likely to make 
specific contacts with the DNA are the amino acids KHA within the first, RER within 
the second and RHK within the third zinc finger domain. These critical amino acids are 
conserved in Sp3, Sp4, BTEB1, TIEG1 and TIEG2 proteins (Fig.1.4). Consistent with 
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this conservation, Sp3, Sp4, BTEB1 and TIEG2 recognize classical Sp1-binding sites. 
In addition, the relative affinity for the GC box is very similar, if not identical, between 
these proteins. GT or CACCC boxes are also recognized by these proteins but with 
slightly lower affinities. In Sp2, a leucine residue replaces the critical histidine residue 
within the first zinc finger (Fig.1.4). 
 
 
Fig.1.4. Protein sequence alignment of the zinc finger domains of mammalian 
Sp/XKLF family members.  
All sequences are human sequences with the exception of LKLF, AP-2rep, BKLF and 
IKLF, which are of mouse origin. The cysteine and histidine residues that are involved 
in zinc coordination are in blue. Arrows point to the amino acid positions that probably 
determine the recognition specificity of the fingers by contacting specific bases of the 
DNA. Black lines indicate a-helices; b-sheets are shown as zig-zag lines. The amino 
acids that are thought to make base contacts are boxed. Residues conserved between all 
family members are indicated (*). 
(After Philipsen and Suske, 1999). 
 
Contrary to initial expectations that this family of factors would likely have 
redundant functions, they in fact have important individual biological functions as 
shown by gene knockout studies (e.g. EKLF/KLF1, LKLF/KLF2 and KLF5). However, 
the underlying mechanisms governing their specific functions and regulation are 
poorly understood. 
Within the Sp factors, Sp1, Sp2, Sp3, and Sp4 form a subgroup based on their 
similar modular structure (Fig.1.5). Sp1, Sp3, and Sp4 contain two major 
Introduction 
 28
glutamine-rich transactivation domains A and B that are essential for transcriptional 
activation. Next to these A and B domains, serine/threonine-rich sequences are located 
that may be a target for post-translational modification. 
 
 
Fig.1.5. Structural motifs in Sp factors. Sp-proteins bind to GC/GT boxes and are 
involved in the expression of many genes including house keeping genes, 
tissue-specifically expressed genes, viral genes, cell-cycle-regulated genes as well as 
growth factor genes. The upper drawing depicts schematically the four human 
Sp-family members Sp1, Sp2, Sp3 and Sp4. Their length in amino acids is indicated on 
the right. The length of Sp3 refers to the full-length isoform. Red boxes indicate 
activation domains that are rich in glutamine residues and yellow boxes indicate 
serine/threonine-rich regions. Sp and Btd boxes are marked by green and orange boxes, 
respectively. The region preceding the first zinc finger (+/-) is rich in charged amino 
acids. The black boxes represent the zinc fingers. ID in the blue box indicates the 
inhibitory domain of Sp3 that contains the IKEE SUMOylation site. 
 Abbreviations: topoisomerase (topo)-II–DNA or topo-I–DNA complexes; human 
upstream binding factor (hUBF); transcription-coupled nucleotide excision repair 
(TC-NER); TATA-binding protein (TBP)–TATA box complex; transcriptional 
activation factors (TAFs); RNA polymerase II (RNAP II).  
 
All the Sp transcription factors contain a so-called Buttonhead box immediately 
N-terminal to the zinc finger domain This conserved stretch of 11 amino acid residues 
was originally identified in the Drosophila Sp1 homologue Buttonhead (Btd) (Wimmer 
et al., 1996). It may contribute to the transactivation potential of the factors, since a 
deletion of an overlapping region results in reduced activity of Sp1 in vitro (Courey 
and Tjian, 1988). Furthermore, domain C (Yieh et al., 1995), and more specifically the 
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Btd element within domain C (Athanikar et al., 1997), are involved in synergistic 
activation by Sp1 or Sp3 with sterol-regulatory element-binding proteins (SREBP). 
Harrison and coworkers (2000) identified another stretch of conserved amino acids 
consisting of the sequence SPLALLAATCSR/KI (Sp box) that is located at the 
N-terminus of the proteins. This element contains an endoproteolytic cleavage site and 
is situated close to a region at the N-terminus of Sp1 that targets proteasome-dependent 
degradation in vitro (Su et al., 1999). Although not required to direct cleavage, the fact 
that the Sp box is highly conserved indicates that it may have a function in regulation 
of proteolysis of Sp factors. Another possible role for the Sp box may lie in the control 
of transactivation potential via interaction with a putative repressor (Murata et al., 
1994). Although the functions of the Btd and Sp boxes are not clear at the moment, 
their absence in the XKLF subgroup confirms the relationship between the Sp 
transcription factors.  
1.2.2. Sp3: Activator versus Repressor 
Unraveling the transcriptional role of Sp3 was complicated by the fact that four 
Sp3 isoforms exist, two 110-115 kDa Sp3 proteins and two approximately 60-70 kDa 
Sp3 species observed in immunoblots. Four isoforms of Sp3 are expressed in vivo that 
differ in the extent of the amino terminal part. Detailed mutational analyses suggest 
that all four isoforms derive from alternative translational start sites. Moreover, an 
upstream open reading frame regulates expression of the two long isoforms 
(Sapetschnig et al., 2004).  
Reports on the transcriptional properties of Sp3 appear, at first sight, contradictory. 
Sp3 has been shown to act as a transcriptional activator similar to Sp1 (Udvadia et al., 
1995; Ihn and Trojanowska, 1997; Ding et al., 1999). In other experiments, Sp3 
remained inactive or acted only as a very weak activator (Hagen et al., 1994; Majello 
et al., 1994; Dennig et al., 1995 and others). Most of these reports are based on 
co-transfection experiments into the insect cell line SL2. Usually, a distinct promoter 
fragment containing appropriate Sp-binding sites fused to a reporter gene was 
co-transfected along with Sp1 and Sp3 or both together. If Sp3 is expressed to the same 
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extent as Sp1 but does not act as a strong activator, it will compete for the same 
binding site and thus lower Sp1-mediated activation. The experimental conditions 
which are needed for Sp3 to act as a strong activator or a transcriptional inactive 
molecule which represses Sp1-mediated activation are not completely understood. The 
structure and the arrangement of the recognition sites appear to determine whether Sp3 
is transcriptionally inactive and can repress Sp1-mediated activation or whether it acts 
as a strong activator. Promoters containing a single binding site are activated, whereas 
promoters containing multiple binding sites often are not activated or respond weakly 
to Sp3 (Birnbaum et al., 1995; Dennig et al., 1996). Purified recombinant Sp3 
expressed in SL2 cells (Braun and Suske, 1999) act in an in vitro system as strong 
activator similar to Sp1 (Braun et al., 2001). Whether Sp3 acts as an activator or as a 
repressor of Sp1-mediated activation might also depend of the cellular context. 
Transfected Sp3 stimulated transcription from the HERV-H long-terminal repeat in the 
teratocarcinoma cell line NTera2-D1 but acted as a repressor in HeLa and insect cells 
(Sjottem et al., 1996). 
It has been suggested that the two small Sp3 isoforms might act as repressor 
molecules whereas the full length Sp3 isoform does act as an activator (Kennett et al., 
1997). Although attractive and simple, this model does not seem to hold true. 
Exclusive expression of full length Sp3 triggered by an artificial leader sequence can 
also represses Sp1-mediated activation (Dennig et al., 1996). It is clear that both 
N-terminal glutamine-rich regions can act as strong activation domains on their own in 
both insect and in mammalian cells (Dennig et al., 1996; Majello et al., 1997). 
The molecular basis for the inactivity of Sp3 under certain conditions has been 
mapped to an inhibitory domain located between the second glutamine-rich activation 
domain and the first zinc finger. The amino acid triplet KEE within this domain is 
absolutely essential for repressor function (Dennig et al., 1996). Mutation of these 
amino acids to alanine residues converted almost inactive Sp3 to a strong activator. 
The inhibitory domain of Sp3 acts as an independent module in cis. It can be 
transferred to other activation domains which in turn lose their activation properties 
(Dennig et al., 1996).  
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This domain resides in a highly charged stretch of amino acids that is not present in 
the comparable region of Sp1 (domain C). It resembles repressor domains present in C/ 
EBPa, C/EBPb (Angerer et al., 1999), c-Fos and FosB (Brown et al., 1995). The 
presence of a repressive module explains the earlier observed inactivity of the 
N-terminal region of Sp3, despite the presence of glutamine-rich domains that 
resemble the Sp1 transactivation domains A and B (Hagen et al., 1994). Mutation of a 
critical KEE amino acid triplet results in relief of repression and potentates Sp3 
transactivation, especially of promoters containing multiple binding sites (Dennig et al., 
1996). Furthermore, it was shown that the lysine residue K551 within inhibitory 
domain is a target for modification by SUMO (Sapetschnig et al., 2002). 
 
1.3. SUMO Small Ubiquitin-like MOdifier 
A multitude of mechanisms determine the in vivo function of proteins. Among 
them are the regulation of protein levels via control of expression levels and turnover 
and regulation of protein activity, and localization and/or interactions by constitutive or 
reversible post-translational modifications. These modifications, usually accomplished 
via enzymatic reactions, result, for example, in acetylation, methylation, 
phosphorylation, ADP ribosylation, carboxylation, adenylylation, and glycosylation or 
prenylation of amino acid side chains. Among these is also ubiquitination, a 
post-translational modification that was first discovered in 1987 and has since been 
extensively studied (Bonifacino and Weissman, 1998; Hershko and Ciechanover, 
1998). 
Ubiquitination is the enzymatically catalyzed formation of an isopeptide bond 
between the C terminus of the 9-kDa polypeptide ubiquitin and ε-amino groups in 
lysines of the acceptor proteins. In principle, the modification is reversible, because the 
ubiquitin moiety can be removed from the acceptor molecule by deubiquitinating 
enzymes (isopeptidases). Ubiquitination is best known for its role in regulated protein 
degradation via the 26S proteasome. Commitment of a protein to the 
ubiquitin-dependent degradation pathway involves assembly of a polyubiquitin chain 
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on the target, usually via isopeptide bonds between lysine 48 of one ubiquitin and the 
C-terminal glycine residue of the neighboring ubiquitin. Although tagging a protein 
with ubiquitin chains usually leads to its complete degradation, it is sometimes also 
used for controlled activation of the protein via limited proteolysis. In addition, 
monoubiquitination plays a role in receptor mediated endocytosis (Hicke, 1997). 
A number of proteins related to ubiquitin have been isolated over the years. These 
proteins fall into two groups, proteins that are not available for conjugation (e.g. Rad23, 
Dsk2p, Elongin B), and proteins that, like ubiquitin, are attached to other proteins 
(Ciechanover, 1998; Hodges et al., 1998; Hochstrasser, 2000; Jentsch and Pyrowolaski, 
2000). To this second group belong the interferon-inducible ubiquitin cross-reacting 
proteins UCRP/ISG15, Nedd8, and SUMO1, which are 36, 57, and 18%, respectively, 
identical to ubiquitin at their primary sequence. Whether the 21-kDa yeast protein 
Apg12 that is required for autophagy in yeast, also belongs to this family or whether it 
is the first member of a new group of attachable proteins is presently unclear. Although 
Apg12 does not show any discernible homology to ubiquitin at the level of its primary 
sequence, it is attached to Apg5 by a mechanism that closely resembles ubiquitination 
(Ohsumi, 1999).  
The significance of ubiquitin-related proteins remained rather obscure until the first 
targets, the SUMO1 target RanGAP1 (Matunis et al., 1996), and the Nedd8/Rub1 
target Cdc53 (Lammer et al., 1998) were discovered. Only than did it becomes clear 
that these proteins are not simply variations on the ubiquitin theme, they play 
important role outside of protein degradation. Unlike the ubiquitin system, which 
primarily targets substrate proteins to the proteasome, SUMO1 conjugation has diverse 
cellular functions being implicated in a vast number of cellular processes, including 
nuclear transport, signal transduction, apoptosis, autophagy, cell cycle control, and 
regulation of ubiquitin-dependent degradation (Fig.1.6).  
1.3.1. What is SUMO? 
 SUMO is the acronym for small ubiquitin-like modifier, also known as sentrin, 
GMP1, UBL1 and PIC1. SUMO1 family members are expressed throughout the 
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eukaryotic kingdom. 
 
 
Fig.1.6. Signaling function of SUMO. Some of the known functions of 
SUMOylation are indicated with respect to transcriptional regulation. 
(After Verger et al., 2002) 
 
Members of the SUMO protein family appear to be present in protozoa, metazoa, 
plants, and fungi (Melchior, 2000). SUMO proteins from metazoa can be divided into 
two families: SUMO1 proteins and SUMO2/SUMO3 proteins. Within a given species, 
SUMO1 and SUMO2/3 proteins are about 50% identical to each other. Plant SUMO 
proteins and SUMO proteins from fungi and yeast fall into two groups distinct from 
both SUMO1 and SUMO2/3 proteins. S. cerevisiae contains a single essential SUMO 
gene, SMT3 (Johnson et al., 1997). In contrast, the Schizosaccharomyces pombe 
homolog Pmt3 is not truly essential (Tanaka et al., 1999). However, disruption leads to 
severe growth defects and phenotypes such as aberrant mitosis, increase in telomere 
length, and defects in chromosome segregation.  
Analysis of an expressed sequence tag (EST) and genomic databases indicates the 
presence of at least one SUMO family member in Aspergillus nidulans, Botrytis 
cinerea, Dictyostelium discoideum, Candida albicans and C. trypanosoma. The 
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best-characterized plant SUMO protein is T-SUMO from tomato (Hanania et al., 1999). 
It was identified through its interaction with ethylene-inducing xylanase from the 
fungus Trichoderma viride and has been implicated through antisense experiments in 
plant defense responses that lead to programmed cell death. ESTc-DNAs encoding 
SUMO proteins have been found in libraries from many plant species (e.g. soja, maize, 
rice, pine tree, cedar, etc), and was reported the presence of at least three different 
expressed SUMO species in Arabidopsis. Zebrafish and Xenopus laevis have both 
SUMO1 and SUMO2/3 proteins. Caenorhabditis elegans has apparently only a 
SUMO1 family member (Choudhury and Li., 1997), whereas silk worm expresses 
cDNAs for a SUMO2/3 protein. A Drosophila melanogaster SUMO2 protein has been 
described (Bhaskar et al 2000, Huang et al 1998), but there is currently no strong 
evidence for a SUMO1 in this organism. While Northern blot analysis revealed two 
different SUMO transcripts in Drosophila embryos, larvae, and adult tissue, it is 
currently unknown whether these derive from the same SUMO genes. Both mice and 
humans have at least three different SUMO proteins, SUMO1, SUMO2, and SUMO3. 
Although SUMO2 and SUMO3 are very similar at the amino acid level (87% sequence 
identity for the human proteins), they are only 47% identical to SUMO1. Transcripts 
for SUMO1, SUMO2, and SUMO3 can be detected in all human and mouse tissues, 
indicating that these proteins are ubiquitously expressed (Chen et al., 1998; Howe et al., 
1998).  
SUMO4 was discovered recently as potential transcript with homologies to the 
SUMO gene family, after database searches in intron 6 of MAP3K7IP2 gene (Guo et 
al., 2004). SUMO4 has a restricted pattern of expression with highest levels reported in 
the kidney (Bohren et al., 2004). Currently, the mechanisms that determine selective 
modification by specific SUMO isoforms are not known, and the functional 
significance of modification by specific SUMO isoforms also remains to be 
determined. 
 Compared to posttranslational modifiers such as a phosphate or acetyl group, 
ubiquitin and ubiquitin-related proteins are structurally complex. Specific surface 
residues of ubiquitin participate in different ubiquitin dependent interactions such as 
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binding to the proteasome or components of the endocytic machinery (Sloper-Mould et 
al., 2001). NMR (nuclear magnetic resonance) studies have shown that SUMO1 has a 
similar protein fold. Importantly, despite the similar protein fold, the distribution of 
charged residues on the surface of SUMO is very different from that of ubiquitin or 
other ubiquitin-like proteins. In addition, SUMO has an N-terminal extension not 
found in ubiquitin (Fig.1.7). These differences likely account for the finding that 
distinct enzymes mediate SUMO conjugation and deconjugation as well as the unique 
activities attributed to SUMO. 
 Alignments of ubiquitin and SUMO1 indicate that although only 18 % identical in 
amino acid sequence, these two proteins have remarkably similar secondary structures. 
In addition, 3D protein backbone overlays of their core structures show that the tertiary 
structures of ubiquitin and SUMO1 bear close resemblance to each other. However, 
there are significant differences between the two proteins. A flexible 20-residue 
N-terminal extension in SUMO1 is absent from ubiquitin and the two proteins also 
have a dramatically different surface charge distribution (Fig.1.7).  
SUMO is conjugated to target proteins by a pathway that is distinct from, but 
analogous to, ubiquitin conjugation (Fig.1.8). The same pathway appears to be used by 
SUMO1, -2 and -3 (Johnson and Gupta, 2001). 
In SUMOylation, the target lysine generally falls within a recognizable consensus, 
namely ϕ -Lys-X-Glu (where ϕ is a large hydrophobic amino acid, most commonly 
isoleucine or valine, and X is any residue).  
SUMO is first activated by a heterodimeric E1 enzyme (SAE1–SAE2 in humans or 
Uba2–Aos1 in S. cerevisiae) that uses ATP to adenylate the C-terminal glycine residue 
of SUMO. A thioester bond is then formed between the C-terminus of SUMO and a 
cysteine residue in SAE2, releasing AMP. In a transesterification reaction, SUMO is 
then transferred from SAE to the E2 SUMO-conjugating enzyme Ubc9.  
In yeast, two SUMO proteases have been identified, Ulpl and Ulp2/Smt4, both of 
which are specific for SUMO and display compartmentalization, with Ulp1 being 
present at the nuclear pore complex and Upl2/Smt4 present in the nucleoplasm. 
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Fig.1.7. SUMO is highly related to ubiquitin.  
A. Amino acid sequence alignments of ubiquitin and the four SUMO homologs from 
human. Identities are indicated in bold and similarities are shaded. A consensus motif 
for SUMOylation present in SUMO2, SUMO3, and SUMO4 is boxed in yellow; the 
SUMO acceptor lysine (K) in this motif is boxed in red. Ubiquitin Lys 48 and Lys 63, 
which serve as common sites for ubiquitin polymerization, are boxed in red. The site of 
cleavage to produce the mature proteins with C-terminal glycine–glycine residues is 
also indicated. A polymorphism at position 55 in SUMO4 (M55V) has been described 
in the human population. 
B. Ribbon diagrams highlight the similarity of the three-dimensional structures of 
SUMO1 and ubiquitin. Secondary structure elements are indicated: β-sheets are green 
and α-helices are red. Notably, SUMO has an N-terminal extension not found in 
ubiquitin.  
(After Gill, 2004). 
 
In mammals, several SUMO proteases have been confirmed with the possibility of 
many more being present due to alternative splice variants (Melchior et al., 2003). As 
with yeast, many of the mammalian SUMO proteases are localized to different cellular 
compartments, which may function to regulate the balance of protein SUMOylation in 
these compartments.  
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Fig.1.8. The SUMO conjugation pathway.  
SUMO is synthesized as a precursor and processed by hydrolases to make the 
carboxy-terminal double-glycine motif available for conjugation (vertical arrow). It is 
subsequently conjugated to proteins by means of E1 activating (SAE1 (AOS1) / SAE2 
(UBA2)), E2 conjugating (Ubc9) and E3 ligating enzymes. The E3-like proteins might 
serve to increase the affinity between Ubc9 (E2) and the substrates by bringing them 
into close proximity in catalytically favorable orientations, allowing sumoylation to 
occur at a maximum rate. The resulting isopeptide bond is stable and its disruption 
requires a desumoylating enzyme. (After Verger et al., 2002) 
 
The thioester linked Ubc9–SUMO conjugate then catalyses formation of an 
isopeptide linkage between the C-terminus of SUMO and a ε-amino group of a lysine 
residue in the target protein.  
The unusual aspect of SUMOylation is that the E1 and E2 enzymes (together with 
ATP and SUMO) appear to be sufficient in vitro for relatively robust modification of 
proteins at precisely the lysines that are preferred in vivo. For ubiquitin, an additional 
factor, called an E3 or ubiquitin-protein ligase, is almost always necessary for efficient 
substrate ubiquitination, both in vitro and in vivo.  
The final step of SUMOylation also involves ligation of SUMO to the target 
protein. Until recently there was speculation as to whether SUMO ligation to target 
proteins involved E3 ligase-like proteins such as is required for ubiquitination. 
However, it is now clear that such E3 ligases do exist for the SUMO1 modification 
pathway and that they play important roles in modulating the efficiency of SUMO 
attachment to target proteins (Melchior et al., 2003). As with the ubiquitin system, 
SUMO E3 proteins are defined by 3 characteristics: binding to the substrate protein 
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either directly or indirectly, binding to the E2 conjugation enzyme, and ability to 
stimulate transfer of the modifier to the substrate or to another modifier in the case of 
modifier chain formation. Three different general types of SUMO E3 ligases have been 
described (Takahashi et al., 2001; Kotaja et al., 2002; Pichler et al., 2002). The first E3 
group comprises the PIAS family of proteins. In yeast only two E3 proteins have been 
identified (Siz1 and Siz2) which have sequence similarity to mammalian PIAS proteins, 
of which at least five members have SUMO E3 activity for substrates, such as p53, Jun, 
Lef-1 and the nuclear androgen receptor (AR), (Seeler and Dejean, 2003).  
More recently, it was shown that the nucleoporin RanBP2 (RAN-Binding Protein 2) 
also functions as a SUMO E3 ligase for three substrates - the promyelocytic leukemia 
(PML) nuclear body (NB) protein SP100, the histone deacetylase HDAC4 (Kirsh et al., 
2002) and the p53 ubiquitin ligase MDM2. Although RanBP2 does not interact directly 
with the substrate, but possibly through Importins and Ubc9, it fulfils the above criteria 
for E3 ligases (Pichler et al., 2002). 
A very recent report showed that the Polycomb Protein Pc2 is SUMO modified and 
as it enhances the modification of the transcriptional corepressors CtBP and CtBP2, can 
be considered as a third type of SUMO E3 ligase (Kagey et al., 2003). Given that this 
now makes three quite unrelated proteins that function in this capacity, it is likely that 
additional proteins with E3 ligase activity await discovery. 
1.3.2. The Eukaryotic Family of PIAS Proteins 
The eukaryotic family of protein inhibitor of activated STATs (PIAS) proteins 
represents a group of proteins that play a pivotal role in the control of various 
important cellular pathways. The acronym PIAS stems from the initial finding that 
members of this family act as inhibitors of STAT-transcription factors. Work by many 
research groups during the last few years has demonstrated that the cellular function of 
PIAS proteins goes far beyond inhibition of STATs.  
The eukaryotic family of PIAS proteins is evolutionarily conserved from yeast to 
humans. In the yeast Saccharomyces cerevisiae two members of the family (Siz1/Siz2) 
are found. In higher eukaryotes the family is more diversified. The human family of 
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PIAS proteins consists of at least five members, PIAS1, PIAS3, the a and b splice 
variants of PIASx, and PIASy.  
PIAS1 was isolated by Liu and coworkers (1998) from a human JY112 B cell 
cDNA library and by Tan and coworkers (2000) from a HeLa cell library using yeast 
two-hybrid screening for STAT1 and AR interacting proteins respectively. PIAS1 was 
shown to bind STAT1 and inhibit STAT1 binding to its consensus response element. 
PIAS1 inhibition of activated STAT1 signaling was demonstrated in cotransfection 
assays with interferon γ stimulated 293 cells using a STAT1 reporter gene (Liu et al., 
1998). In an earlier study we reported that PIAS1 is a transcriptional coactivator with 
(AR) androgen receptor and (GR) glucocorticoid receptor but a repressor with (PR) 
progesterone receptor (Tan et al., 2000). PIAS1 is expressed predominantly in testis 
including cell types that express AR and mediate the actions of androgen on 
spermatogenesis. In addition to PIAS1 that inhibits STAT1, another member of the 
PIAS family, PIAS3 has been shown to be an inhibitor of STAT3 signaling. PIAS3 
mRNA was also abundant in human testis, but unlike PIAS1, it was expressed at 
similar levels in other organs (Chung et al., 1997). PIASxα (ARIP3) was also isolated 
as an AR interacting protein by two-hybrid screening of a mouse embryo library and 
found to be highly expressed in rat testis (Moilanen et al., 1999). 
With a length of 651-amino acid residues PIAS1 is the largest protein within this 
family, whereas PIASy is the smallest with 510 residues. With the exception of a 
variable C-terminal region the family members are highly homologous, showing an 
overall identity ranging from 50 to 60% at the amino acid level. Together with their 
orthologues from yeast or Drosophila, all mammalian PIAS forms share a 
characteristic domain structure that is schematically depicted in Fig.1.9. Within the 
N-terminus of PIAS a region of about 35 amino acids spans a so-called SAP module. 
The acronym SAP refers to three of the defining members of the class of 
SAP-containing proteins, scaffold attachment factor (SAF), acinus, and PIAS. The 
SAP domain shows a bipartite distribution of conserved hydrophobic and polar amino 
acids that are separated by a region containing an invariant glycine residue. Secondary 
structure modelling predicts that the module forms two amphiphatic helices that fold 
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into a hook like structure sharing significant homology with the orientation of helix 1 
and helix 2 of the homeodomain. A common feature of SAP-containing proteins is 
their ability to bind to chromatin. In particular, the SAP module in SAF recognizes 
distinct A-T-rich DNA sequence known as matrix or scaffold attachment regions 
(MARs/SARs). MARs/SARs are operationally defined as DNA regions that are 
associated with the nuclear matrix, a proteinaceous meshwork, which mediates the 
organization of higher-order chromatin structures. MAR sequences are involved in 
chromatin remodelling and transcriptional regulation (Schmidt and Müller, 2003). 
Another characteristic feature of Siz/PIAS proteins is the presence of a 
cysteine/histidine-rich domain, known as Miz-zinc finger or SP-RING domain. This 
domain is related to the classical zinc-binding RING motif, which is defined by the 
consensus sequence CX2CX(9–39)CX(1–3)HX(2–3)C/HX2CX(4–48)CX2C. The 
RING-finger domain characterizes a subclass of ubiquitin E3 ligases. E3s or 
ubiquitin-protein ligases stimulate the attachment of ubiquitin to target proteins and are 
largely responsible for substrate selection. An alignment of the RING finger region 
from the c-cbl ubiquitin ligase with the SP-RING motif from PIAS is shown in Fig.1.9. 
When compared with the canonical RING finger, the SP-RING motif lacks the third 
and sixth cysteine residues that are part of the first and third pair of cysteine/histidine 
residues in the RING motif. In a so-called cross-brace arrangement this first and third 
pair of cysteine/histidine residues forms one zinc binding site, while the second and 
fourth pairs form the second binding site in the RING motif.  
   
 
Fig.1.9. Domain structure of the Siz/PIAS family. On the left the N-terminal SAP 
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module from SAF-A is aligned with the SAP region from the human PIAS-family 
members. A schematic representation of the predicted secondary structure (two 
amphiphatic helices) is shown above. On the right the RING-finger region from the 
c-cbl ubiquitin ligase is aligned with the SP-RING motif from the human PIAS family 
members. The ‘cross-brace’ arrangement of the zinc coordinating residues in c-cbl is 
shown above. (After Schmidt and Müller, 2003). 
 
The evidence concerning SUMO E3 ligases highlights another difference with the 
ubiquitin system. Although the SUMO E3 enzymes are able to undergo a process 
similar to the ubiquitin E3 ‘substrate-independent modification’, in that PIAS proteins, 
RanBP2 and Pc2 are all SUMOylated themselves (Seeler and Dejean, 2003), there is 
no evidence that they form thioesters as do the HECT-domain ubiquitin ligases. So, 
like the RING-finger ubiquitin ligases, PIAS proteins, RanBP2 and Pc2 seem to 
function exclusively as additional platforms that bring the SUMO charged E2 to the 
substrate protein.  
 
1.4. Aim of the Project 
Small Ubiquitin-related Modifier (SUMO) is a protein moiety that is ligated to 
lysine residues in a variety of transcriptional regulators. Sp3, a member of the family 
of GC-box binding proteins, is one case of transcription factors to be modified by 
SUMO. SUMO modification of Sp3 occurs, in vitro, specifically at a SUMO consensus 
sequence (IK551EE) which has been mapped to a previously described inhibitory 
domain of the protein. Consequently, it was projected to determine if Sp3 is also a 
target in vivo for SUMO1 or for SUMO2/3 by employing overexpression experiments 
in mammalian cell lines. For this purpose, gene constructs encoding GFP-Sp3WT or a 
mutant thereof (GFP-Sp3-551K/R) should be co-transfected along with expression 
constructs coding for GFP-SUMO1 or GFP-SUMO2/3.  
It was also acknowledged that three Sp3 isoforms exist, a 110-115 kDa Sp3 protein 
and two approximately 60-70 kDa Sp3 species. The next purpose should be finding out 
the complete isoforms expression pattern of Sp3 and whether Sp3 isoforms may 
undertake SUMOylation by improving conditions for endogenous Sp3 detection in 
immunoblot analysis. Additionally, subcellular localization of different isoformes 
should be surveyed. 
SUMOylation is not a terminal modification, and instead there is an intracellular 
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steady state that reflects a dynamic SUMOylation–deSUMOylation process. It was 
necessary to perceive conditions whether Sp3 SUMOylation level could be altered. 
Sp3 expression level in different cell lines and in different mice organs should be 
investigated in conditions that preserve SUMOylation. Moreover, the level of SUMO 
modification of Sp3, from cells exposed to different stress conditions or drugs should 
be analyzed. 
Depending on the target protein, SUMOylation can occur in the cytoplasm or 
nucleus, and this modification is involved in regulating the subcellular localization of a 
number of substrate proteins. Therefore, it was required to institute conditions for 
visualization of Sp3 in order to detect the true Sp3 localization pattern. In order to 
accomplish this objective, the subcellular distribution of endogenous or overexpressed 
Sp3 by immumofluorescence will be determinate as well as comparison in subnuclear 
localization with other Sp family members. In addition, it should be investigated 
whether, upon SUMO modification, the Sp3 is redistributed, like many other 
transcription factors in specific and distinct nuclear subcompartments, such as nucleoli, 
speckles and promyelocitic leukemia (PML) bodies. 
PIAS1, previously cloned by a two-hybrid screen, does act as a SUMO E3 ligase 
towards Sp3 and it was demonstrated that PIAS1 strongly enhances 
SUMO-modification of Sp3 in vitro. Preliminary nuclear extract fractionation studies 
suggested that PIAS1 is part of (a) high molecular weight complex(es) in vivo. 
PIAS1-associated proteins might confer substrate specificity towards Sp3 and other 
transcription factors and/or regulate PIAS1 activity in vivo. Consequently, another 
purpose will be the cloning and subsequent characterisation of PIAS1-associated 
proteins. We suspect the identification of PIAS1-associated proteins to be an important 
step towards understanding PIAS1 protein functions and specificities in vivo. 
As a prerequisite for the purification and identification of PIAS1-associated 
proteins, we will establish cell lines that express epitope-tagged PIAS1. It might not be 
possible to express PIAS1 ectopically using strong constitutively active promoters 
(CMV or ubiquitin promoters). Therefore, we want to use tetracycline-inducible 
promoters that can be stably integrated into already existing HeLa cell lines expressing 
the Tet-repressor fused to the VP16 activation domain. 
The so-called tandem affinity purification (TAP) method can be employed allowing 
a two-step purification of appropriate tagged PIAS1. Although there is no doubt that 
the TAP-method allows the efficient isolation of protein complexes from S. cerevisiae, 
there remain some potential disadvantages. We thus would like to propose an 
Introduction 
 43
alternative method that might present some advantages over the currently favoured 
Calmodulin/Protein A TAP method. Important for the choice of the tags is their affinity 
and their specificity for the ligands used in affinity purification. The strongest 
non-covalent interaction known in nature is that between Biotin and Avidin or 
Streptavidin. Biotin is a naturally occurring co-factor for some metabolic enzymes, 
which is only active, when covalently attached to the enzymes. Small 15 amino acid 
artificial tags are known to be specifically biotinylated at a central lysine residue by the 
E.coli BirA ligase. The main goal is constructing PIAS1 expression plasmids with a 
C-terminal tag that can be biotinylated by the BirA ligase upon co-transfection of an 
appropriate expression construct. To enhance specificity, a second tag will be included 
in the PIAS1 vector (Calmodulin Binding Peptide or alternatively FLAG or 
Triple-FLAG).  
A Triple-FLAG epitope might be appropriate since it has a very high affinity for 
commercially available anti-FLAG antibodies (200-fold higher than a single FLAG 
epitope). Both epitopes should contain N-terminally a recognition site for a protease 
(TEV, enterokinase or thrombin protease) to enable elution from the affinity matrices 
by proteolysis.  
At first, the “Biotin system” will be tested in transient transfections. These 
preliminary experiments will advise us, (I) whether the tagged PIAS1 fusion protein 
will be biotinylated efficiently upon co-transfection of BirA ligase, (ii) whether tagged 
PIAS1 can be isolated efficiently with Streptavidin beads and (iii) whether the protease 
recognition sites are accessible. Next step will be establishing stably transfected cell 
lines. To avoid a constitutive over-expression of PIAS1 that might be toxic, employing 
inducible vectors is suggested. Tet-VP16 expressing HeLaS3 cells will be stably 
transfected with tetracycline-inducible expression vectors for tagged PIAS1 and BirA. 
Single clones that express biotinylated PIAS1 then will become the starting point for 
further analyses. 
Prior to the purification of PIAS1 and associated proteins, we will analyse whether 
ectopically expressed biotinylated PIAS1 is present in (a) pre-formed complex(es) 
similar to endogenous PIAS1. For this, we will prepare nuclear extracts from induced 
HeLa Tet-OFF cells and fractionate the proteins through a Superose6 resin. Fractions 
will be analysed by Western blotting using Streptavidin-horseradish peroxidase (HRP) 
conjugates. 
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2. Materials and Methods  
2.1. Materials 
2.1.1. Chemicals and Equipment 
Chemicals were purchased from the following companies: 
Amersham Pharmacia Biotech (Freiburg, Germany), Biomol (Hamburg, Germany), 
Bio-Rad (Boston, USA), Boehringer (Mannheim), Difco Laboratories (Detroit, U.S.A), 
Eppendorf (Hamburg, Germany), Fluka (Buchs, Switzerland), Gibco BRL (Berlin, 
Germany), Gilson (Villiers-le-Bel, France), Integra Biosciences (Hamburg, Germany), 
Invitrogen (NV Leek, The Netherlands), MBI Fermentas (St. Leon-Rot, Germany), 
Merck (Darmstadt, Germany), New England Biolabs (Beverly, U.S.A), Pierce 
(Rockford, U.S.A.), Promega (Madinson, U.S.A.), Qiagen (Hilden, Germany), Roche 
Diagnostics (Mannheim), Roth (Karlsruhe, Germany), Serva (Heidelberg, Germany), 
Sigma (Munich, Germany), Stratagene (Amsterdam, The Netherlands; La Jolla, U.S.A.) 
Restriction enzymes and other DNA-modifying enzymes were obtained from New 
England Biolabs (NEB, (Frankfurt), Amersham (Braunschweig), or Invitrogen (NV 
Leek, The Netherlands). 
In some experiments it was required to use a reagent from a specific supplier. In 
those cases the supplier’s name is indicated. 
 
Equipment Manufacturer 
Agarose gel electrophoresis chambers Biorad, München 
AutoLumat 953 luminometer Berthold Technologies, Bad Wildbad 
Cell culture incubator BBD6220 Kendro, Hanau 
Clean bench HA2448GS Kendro, Hanau 
GeneAmp® PCR system 9700 Applied Bioystems, Darmstadt 
Fluorescence microscope DMLB Leica, Bensheim 
Power supply units Biorad, München 
Sorvall Superspeed refrigerated centrifuge Kendro, Hanau 
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Miscellaneous Manufacturer 
Bio-Rad Protein Assay Biorad, München 
DNA and protein size markers Roche, Mannheim 
Hybond ECL nitrocellulose membrane Amersham Biosciences, Freiburg 
Kodak BioMax X-ray film Integra Biosciences, Fernwald 
Sterile plastic ware for cell culture Greiner, Germany 
 
Kits used in this study 
 
Kit Manufacturer 
ECL™ Plus detection system Amersham Biosciences, Freiburg 
Nucleobond® AX Macherey-Nagel, Düren 
QuikChange® Site-Directed Mutagenesis Kit  Stratagene, USA 
QIAquick® PCR Purification Kit Qiagen, Hilden 
Ready To Go™ PCR Beads Amersham Pharmacia Biotech, USA 
Rapid Ligation Kit MBI Fermentas, St. Leon-Rot 
 
2.1.2. Mammalian and Insect Cell Lines 
Mammalian cell lines were maintained at 37ºC in a humidified 5% CO2-containing 
atmosphere. SL2-Cells (Drosophila Schneider Cells) were incubated at 25°C without 
necessity of CO2-containing atmosphere.  
 
Caco-2.  An adenocarcinoma cell line derived from human (caucasian male 72 
years old), colon metastasis. Morphology and growth: continuous culture, grown as 
monolayer, morphology epithelial-like.  Culture conditions: DMEM (Dulbecco’s 
Minimal Essential Medium) with 10% FCS (Fetal Calf Serum ), 2mM L-Glutamine, 1% 
non-essential amino acids, Penicillin (100U/ml) and Streptomycin (100µg/ml). Split 
confluent cultures 1:3-1:6 using trypsin/EDTA; seed at 2-4x104 cells/cm2. After thawing, 
cells might grow slowly.  
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HaCaT. A keratinocyte cell line with human origin. Morphology and growth: 
continuous culture, grown as monolayer, morphology epithelial-like. Culture conditions: 
DMEM with 10% FCS, 2mM L-Glutamine, Penicillin (100U/ml) and Streptomycin 
(100µg/ml). Split confluent culture 1:5-1:10 using trypsin/EDTA; seed at 2-4 x 104 
cells/cm2.  
 
HeLa. The HeLa cell line was the first continuously cultured human epitheloid cell 
line established in 1951 from an adenocarcinoma of the cervix of a 31-year-old black 
female named Henrietta Lacks (Gey et al., 1952). HeLa cells are aneuploid and steroid 
hormone receptor negative. HeLa cells were cultured as monolayer in DMEM with 10% 
FCS, 2 mM L-Glutamine, Penicillin (100U/ml) and Streptomycin (100µg/ml). The cells 
were passaged after they reached 80% confluency. Confluent cultures were split 1:4 to 
1:6 using trypsin/EDTA. 
 
HeLa Tet-OffTM Stable Cell Lines. Express a Tet-Repressor-VP16 fusion protein.  
In the absence of Tetracycline, this fusion protein binds to the Tet-Operator expressed by 
response plasmid and activates the corresponding promoter (Yin et al., 1996). Cell lines 
HeLa Tet-OffTM were cultured as monolayer in DMEM with 10% Tet System Approved 
FBS (BD Biosciences Clontech), 2 mM L-Glutamine, Penicillin (100U/ml) and 
Streptomycin (100µg/ml), 100 µg/ml Geneticin G-418 (selection antibiotic for HeLa 
Tet-OffTM Stable Cell Lines) and 2 µg/ml Tetracycline in order to keep transcription of 
Gene X turned “off”. The cells were passaged after they reached 80% confluency. 
Confluent cultures were split 1:4 to 1:6 using trypsin/EDTA. 
 
HEK293.  A human embryonic kidney cell line. 
Phoenix™. A human embryonic kidney based cell lines, created as helper-free 
retrovirus producer by transforming with adenovirus E1 and carrying a temperature 
sensitive T antigen. 
Morphology and growth: continuous culture, grown as monolayer, morphology 
fibroblast. Culture conditions: DMEM with 10% FCS, 2mM L-Glutamine, Penicillin 
(100U/ml) and Streptomycin (100µg/ml). Split confluent cultures 1:5-1:10 using 
trypsin/EDTA; seed at 1-3 x 104 cells/cm2. 
 
IMR-32. A neuroblastoma cell line with human origin (caucasian male 13 months 
old). Morphology and growth: continuous culture, grown as monolayer, morphology 
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fibroblast-like and neuroblast-like. Culture conditions: RPMI 1640 with 10% FCS, 
2mM L-Glutamine, 1mM Na pyruvate, 1% non-essential amino acids, Penicillin 
(100U/ml) and Streptomycin (100µg/ml). Split confluent cultures 1:3-1:5 using 
trypsin/EDTA; seed at 2-4x104 cells/cm2.  
 
Ishikawa cells were derived from a well differentiated human endometrial 
adenocarcinoma from a 39 year old woman. (Nishida et al., 1985). Cells were cultured 
as monolayer in MEM-E medium (prescription: 500 ml MEM-E, Gibco, Karlsruhe; 20 
ml 7,5% NaHCO2; 5 ml Penicillin/ Streptomycin (10000 IU/ml; 10000 UG/ml); 5 ml 
non-essential amino acids; 5 ml 200 mM L-Glutamine; 55 ml FCS). Cells were passaged 
after they reached 80% confluency. Confluent cultures were split 1:4 to 1:6 using 
trypsin/EDTA. 
 
NIH3T3.  An embryonic cell line derived from Swiss albino mouse. 
Morphology and growth: Continuous culture, grown as monolayer, morphology 
fibroblast. Culture conditions: DMEM with 10% FCS, 2mM L-Glutamine, Penicillin 
(100U/ml) and Streptomycin (100µg/ml). Split confluent cultures 1:5-1:10 using 
trypsin/EDTA; seed at 1-3 x 104 cells/cm2. 
 
Saos-2. An osteosarcoma cell line derived from human (caucasian female 11 years 
old), bone metastasis. Morphology and growth: continuous culture, grown as monolayer, 
morphology epithelial. Culture conditions: DMEM with 10% FCS, 2mM L-Glutamine, 
Penicillin (100U/ml) and Streptomycin (100µg/ml). Split confluent cultures 1:3-1:6 
using trypsin/EDTA. 
  
SW620. An adenocarcinoma cell line derived from human (caucasian male 51 years 
old), colon metastasis. Morphology and growth: continuous culture, grown as 
monolayer, morphology epithelial-like. Culture conditions: DMEM with 10% FCS, 
2mM L-Glutamine, Penicillin (100U/ml) and Streptomycin (100µg/ml). Split confluent 
culture 1:5-1:10 using trypsin/EDTA; seed at 2-4 x 104 cells/cm2.  
 
Wild type , Sp1- and  Sp3- deficient ES (embryonic stem) cells (Bouwman et al., 
2000; Göllner et al., 2001), were maintained in culture in ES medium. At 15 min before 
plating the ES cells on 9 cm diameter cell culture Petri dishes were treated with 1% 
sterile Gelatine solution. In order to prevent diffrentiation, LIF (Leukemia inhibitory 
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factor) was added to medium. 
Culture conditions ES medium; When cells reaches 60% confluiency, split confluent 
cultures 1:3-1:5 using trypsin/EDTA.  
 
ES cells -medium:                             Final concentration    50 ml 
10xDMEM (with 0,45% Glucose)      1x       5 ml 
Penicilline/Streptomycine (100x)      1x         0,5 ml 
L-Glutamin (100x)         1x          0,5 ml 
Fetal Bovine Serum (FBS)        15%        7,5 ml 
(embryonic stem cells qualified 
from Sigma- Aldrich) 
β-Mercaptoethanol         10-4M       0,5 ml 
(7µl in 10 ml 1×PBS; sterile filtered) 
Leukaemia inhibitory factor (LIF) 106U/ml      50 µl        1000U/ml 
(ESGRO® Chemicon International, Inc., USA) 
H2O                             up to 50 ml 
The pH was adjusted  with  7,5% NaHCO3 (steril filtered). 
  
Wild type and Sp3-deficient mouse embryonic fibroblasts (MEF) were 
maintained in culture in Fibroblast medium. Split confluent culture 1:5-1:10 using 
trypsin/EDTA; seed at 2-4 x 104 cells/cm2. 
 
Fibroblast medium:    Final concentration   450 ml 
DMEM with Glutamax-I    44,4%     200 ml 
Ham’s F 10       44,4%     200 ml 
FCS           10%      45 ml 
Penicillin/Streptomycin (100x)        1,1x               5 ml 
  
SL2- Cells. Drosophila Schneider Cell line 2, (Schneider, 1972).  
Cells were cultured as monolayer in Schneider Drosophila Medium. (For 500 ml 
Drosophila Schneider medium (Life Technologies, Inc.) add 50 ml (10%)  fetal calf 
serum (insect cell qualified; Life Technologies, Inc.), 5 ml Penicillin/ Streptomycin 
(10000 IU/ml; 10000 UG/ml), Gibco, Karlsruhe, 5 ml 200 mM L-Glutamine, Gibco, 
Karlsruhe. Incubate the SL2- Cells at 25°C without CO2-containing atmosphere 
requirement.  
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2.1.3. Buffers and Solutions 
6×Gel-loading Buffer: 0,25% (w/v) bromophenol blue; 0,25% (w/v) Xylen- 
Cyanol; 30% (v/v) glycerol in H2O. 
PBS (pH 7.4): Dissolve 8 g of NaCl; 0,2 g of KCl; 1.44 g of Na2HPO4 and 0.24 g of 
KH2PO4 in 800 ml of distilled H2O. Adjust the pH to 7,4 with HCl. Add H2O to 1 liter. 
Sterilize them by autoclaving and store at room temperature. The final concentrations of 
the ingredients are 137 mM NaCl; 2,7 mM KCl; 4,3 mM Na2HPO4; 1,4 mM KH2PO4. 
TE (pH 8.0): 10 mM Tris (pH 8); 1 mM EDTA (pH 8). 
6×SDS Gel-loading buffer: 280 mM Tris-Cl (pH 6.8), 12 % (v/v) SDS, 60 % (v/v) 
glycerol, 0.25% bromophenol blue. 
TAE (pH 8.0): 40 mM Tris-acetate; 2 mM EDTA (pH 8). 
TBE: 90 mM Tris; 90 mM boric acid; 2 mM EDTA. 
10×SDS electrophoresis buffer: 1,92 M glycine; 0,25 M Tris base; 1% SDS.  
Tris-glycine SDS buffer: 25 mM Tris-Cl; 250 mM glycine; 0,1% SDS. 
 
2.1.4. Enzymes and Antibodies 
All restriction endonucleases, T4 DNA ligase, T4 DNA polymerase and Klenow 
fragment were supplied by Gibco Invitrogen, New England Biolabs, Roche and 
Boehringer. 
The following antibodies were used: 
-Rat anti-HA High Affinity antibody (3F10) recognizes the HA peptide sequence 
[YPYDVPDYA] derived from the human hemagglutinin protein. (Roche Diagnostics 
GmbH, Mannheim).  
-Rabbit HA-probe (Y-11). Polyclonal IgG – (Santa Cruz Biotechnology). 
-Mouse anti-FLAG (M2, Sigma). 
-Living Colors (anti-GFP) Monoclonal Antibody (JL-8) - (Clontech). 
-Anti PIAS 1 (C-20): sc-8152 is an affinity purified goat polyclonal antibody raised 
against a peptide mapping at the carboxy terminus of PIAS 1 of human origin (differs 
from corresponding mouse sequence by a single amino acid) (Santa Cruz 
Biotechnology). 
-Rabbit polyclonal anti Sp1 and anti Sp3 antibodies (Hagen et al., 1994). 
-Anti Sp3 (D-20) is provided as a rabbit (sc-644) affinity purified polyclonal 
antibody raised against a peptide mapping at the carboxy terminus of Sp3 of human 
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origin from Santa Cruz Biotechnology, Inc USA. 
-Anti SUMO1 (FL-101): sc-4273 WB Rabbit polyclonal IgG - (Santa Cruz 
Biotechnology). 
-Mouse anti-GMP-1(SUMO1). This monoclonal antibody can be used to 
specifically detect the unconjugated (~17 kDa) form of GMP1, as well as proteins 
covalently ligated to GMP1 (e.g. RanGAP-1) (Zymed Laboratories Inc). 
 
Secondary antibodies used for immunofluorescence:  
-Cy3 Conjugated Affinipure goat anti rabbit (GAR) IgG (H+L)- (Jackson 
Immunoresearch). 
-Fluorescein (FITC) Conjugated Affinipure GAR IgG (H+L)- (Jackson 
Immunoresearch). 
-Alexa Fluor 568 Conjugated Affinipure GAR IgG (H+L) – (Molecular Probes). 
-Texas Red Conjugated Affinipure goat anti mouse GAM IgG (H+L) - (Jackson 
Immunoresearch). 
The concentrations suggested by the suppliers are only starting recommendations. 
Optimal concentrations of the antibodies were determined “empirically” for each 
specific application. 
 
2.1.5. Oligonucleotides  
The oligonucleotides used for PCR, cloning, subcloning and mutagenesis are listed 
below. Oligonucleotides or were supplied by MWG-Biotech and Eurogentec. 
 
CBPtev-for: 
5’-ATTAGTCGACTCCATGGAAAAGAGAAGA-3’ 
CBPtev ALAspacer-rev:  
5’-ATATCCGCGGGGCTTCATCGTGTTGCGCAAGAGCAGCGGTT-3’ 
CBP-NOT-FOR: 
5’-ATATGCGGCCGCTCCATGGAAAAGAGAAGA-3’  
CBP-CLA-REV:  
5’-ATATATCGATTTATTCGTGCCATTCGAT-3’ 
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Sp3-AUG-T: 
5’-TAAACGAATTCTATGGCTGCCTTGGACGTG -3’ 
Sp3-STOP: 
5’-TATTAAGGATCCCTCCATTGTCTCATTTCC-3’ 
NEU 5'-Sp3 I: 
5’- ACTCGGAATTCCCTTTTGTGTTTCCCGCACAGTCA-3’ 
Sp3newXho-FOR: 
5’- TAATATCTCGAGCTATGACCGCTCCCGAAAAG-3’ 
Sp3- MLU-FOR: 
5’- TATAACGCGTCTTTTGTGTTTCCCGCAC-3’ 
SP3NOT-REV:  
5’- CTGCGGCGGCCGCCTCCT-3’ 
Sp3Sal-End-REV: 
5’-TATAGTCGACCTCCATTGTCTCATTTCC-3’ 
PIAS1-Mlu-K 5'-3': 
5’-TATTACGCGTCGCCACCATGGCGGACAGTGCGGAA-3’ 
PIAS1-Not-rev: 
5’-AATAGCGGCCGCTGTCCAATGAAATAATGTCTGG-3’ 
PIAS1-EcoRI-K-5'-3':   
5'-TATTGAATTCCGCCACCATGGCGGACAGTGCGGAA-3’ 
PIAS1-Sal-rev:   
5’-TATTGTCGACGTCCAATGAAATAATGTCTGG-3’  
 
 
Double strand oligos for cloning: 
The oligonucleotides used for tags cloning were 5’ phosphorylated and and annealed 
as indicated in Fig.2.1. 
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Fig.2.1. Schematic drawiong of double strand oligonucleotides and restriction sites 
used for construction of  FLAG /3XFLAG-BiotinTAG basic vectors. 
 
 
Materials and Methods 
 53
1.A. Not-Sal-3XFLAG-Sac2-Cla-5': 
5’-GGCCGCGTCGACCTGGTTCCGCGTGGATCTGACTACAAAGACCATGACG
GTGATTATAAAGATCATGACATCGACTACAAGGATGACGATGACAAGCCGCG
GAAT-3’ 
1.B. Not-Sal-3XFLAG-Sac2-Cla-3':    
5’-CGATTCCGCGGCTTGTCATCGTCATCCTTGTAGTCGATGTCATGATCTTTATA
ATCACCGTCATGGTCTTTGTAGTCAGATCCACGCGGAACCAGGTCGACGC-3’ 
 
2.A. pN3-Sac2-AviTag-Sma-5': 
5’-GGGGTGGCGGTCTGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCA
CGAATAACCC-3’ 
2.B. pN3-Sac2-AviTag-Sma-3': 
5’-GGGTTATTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTCAGACC
GCCACCCCGC-3’ 
 
3.A. pTRE2-Cla-AviTag-EcoV-5':  
5’-CGATATGGTGGCGGTCTGAACGACATCTTCGAGGCTCAGAAAATCGAATG
GCACGAATAAGAT-3’ 
3.B. pTRE2-Cla-AviTag-EcoV-3':     
5’-ATCTTATTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTCAGACC
GCCACCATAT-3’ 
 
4.A. Sal-FlagAvi-Sma-5': 
5’-TCGACGACTACAAGGATGACGATGACAAGGGTGGCGGTCTGAACGACAT
CTTCGAGGCTCAGAAAATCGAATGGCACGAATAACCC-3’ 
4.B. Sal-FlagAvi-Sma-3': 
5’-GGGTTATTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTCAGACC
GCCACCCTTGTCATCGTCATCCTTGTAGTCG-3’ 
 
5.A. Not-FlagAvi-EcoRV:5': 
5’-GGCCGCGACTACAAGGATGACGATGACAAGGGTGGCGGTCTGAACGACA
TCTTCGAGGCTCAGAAAATCGAATGGCACGAATAAGAT-3’ 
5.B. Not-FlagAvi-EcoRV-3': 
5’-ATCTTATTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTCAGACC
GCCACCCTTGTCATCGTCATCCTTGTAGTCGC-3’ 
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Oligonucleotides used for PIAS1 mutagenesis: 
 
P1-rep∆C-for 
5’-ACATGACACCCATGCCTTAcGACTTACAAGGATTAGATT-3’ 
P1-rep∆C-rev 
5’-AATCTAATCCTTGTAAGTCgTAAGGCATGGGTGTCATGT-3’ 
 
2.1.6. Plasmids 
 Detailed descriptions of the cloning strategies were provided for my own constructs. 
2.1.6.1. Expression Plasmids for Mammalian Cells 
Basic vectors: 
pMCS-HA (Lange et al., 2002) derivates from pEGFP-N1 (Clontech), in which the 
GFP part of pEGFP is replaced by the HA epitope which was cloned between BamHI 
and NotI. The HA tag is in the same ORF as GFP. 
 
pHA-MCS (Lange et al., 2002) derivates from pEGFP-C1 (Clontech), in which the 
GFP part of pEGFP is replaced by the HA epitope which was cloned between NheI and 
BglII. The HA tag is in the same ORF as GFP. 
 
pEGFP-N3 (Fig.2.2) encodes a red-shifted variant of wild-type GFP which has been 
optimized for brighter fluorescence and higher expression in mammalian cells. 
(Excitation maximum = 488 nm; emission maximum = 507 nm). 
 
 Fusions to the N terminus of EGFP retain the fluorescent properties of the native 
protein allowing the localization of the fusion protein in vivo. The target gene was 
cloned into pEGFP-N3 so that it is in frame with the EGFP coding sequences. The 
inserted cDNA should include an ATG codon. The recombinant EGFP vector can be 
transfected into mammalian cells using any standard transfection method. pEGFP-N3 
can also be used simply to express EGFP in a cell line of interest (e.g., as a transfection 
marker). 
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Fig.2.2. Restriction Map and Multiple Cloning Site (MCS) of pEGFP-N3 (Unique 
restriction sites are in bold). The Not I site follows the EGFP stop codon. The Xba I site 
(*) is methylated in the DNA provided by Clontech. (pEGFP-N3 Vector Information, 
www.bdbiosciences.com). 
 
pN3 was constructed by removing of the GFP moiety from pEGFP-N3 (Fig.2.2) 
with BamHI and NotI followed by Klenow filling and religation. 
 
pN3-FB. CMV-basic vector for high expression of C-terminal FLAG-BiotinTAG 
tagged proteins in mammalian cells. BiotinTAG can be removed by Enterokinase. 
 
The pN3-FB was constructed by inserting of the double strand DNA tag sequence 
into the corresponding SalI-SmaI -restricted pN3 plasmid (see Fig.2.1.C).  
 
pN3-3xFB. CMV-basic vector for high expression of C-terminal 
triple(3x)FLAG-BiotinTAG  tagged proteins in mammalian cells. BiotinTAG can be 
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removed by Enterokinase and 3XFLAG by Thrombin.  
 
The pN3-3xFB was constructed by inserting of the double strand DNA tag 
sequences (3XFLAG-SalI-SacII and Biotintag-SacII-SmaI) into the corresponding 
SalI-SmaI -restricted pN3 plasmid (see Fig.2.1.A). 
 
pN3-CTB. CMV-basic vector for high expression of the gene of interest fused with 
CTB (Calmodulin-TEV- BiotinTAG) tag in mammalian cells. C-terminal BiotinTAG 
can be removed by TEV. The CalBP-TEV fragment was insert generated by PCR using 
as template pBS1479 (Rigaut et al., 1999) using the following primers: sense 
CBPtev-for and antisense CBPtev ALAspacer-rev. The PCR product was digested with 
SalI and SacII, and cloned into the corresponding SalI-SacII restricted pN3 vector. 
 
The double strand DNA tag sequence BiotinTAG- SacII-SmaI was cloned into the 
corresponding SacII-SmaI-restricted pN3 plasmid (see Fig.2.1.A for cloning).  
 
Expression plasmids:  
pEGFP-C1-Sp3fl encoding wild-type full-length Sp3 fused at N-terminal to GFP 
was constructed as follows. The Sp3 ORF was amplified by PCR using the following 
primers: sense Sp3-AUG-T and antisense Sp3-STOP. The PCR product was digested 
with EcoRI and BamHI, and cloned into the corresponding EcoRI and 
BamHI-restricted pEGFP-C1 plasmid (Clontech).  
 
pEGFP-C1-Sp3fl-K/R mutant plasmid was obtained by replacing a 750 bp 
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Bst11071-BamHI wild-type fragment with a corresponding fragment obtained by PCR 
amplification from pPacUSp3K/R plasmid, which contained the lysine to arginine 
mutation at the IKEE motif. 
 
pMCS-Sp3NEW-HA 
Sp3NEW insert generated by PCR using as template pN3-Sp3FLnew using the 
following primers: sense  NEU 5'-Sp3 I  and antisense SP3-STOP. The PCR product 
was digested with EcoRI and BamHI, and cloned into the corresponding EcoRI and 
BamHI -restricted pMCS-HA vector. 
 
pMCS-Sp3 K/RNEW-HA 
The mutant plasmid was obtained by replacing a 750bp Bst11071-BamHI fragment 
from wildtype pMCS-Sp3FLn-HA by a corresponding Bst11071-BamHI fragment from 
pEGFP-N3-Sp3K/R that contain the mutation in the IKEE motif. 
 
pHA Sp3Fl* Sp3 insert was cut with XhoI and BamHI from pEGFP-C1-Sp3fl and 
was cloned into the corresponding XhoI and BamHI -restricted pHA-MCS vector. 
 
pHA Sp3K/RFl* Sp3 insert was cut with XhoI and BamHI from 
pEGFP-C1-Sp3fl-K/R and was cloned into the corresponding XhoI and BamHI 
-restricted pHA-MCS vector. 
 
pHA-Sp3NEW. The first 250 bp fragment of pHA Sp3 Fl* was cut with XhoI 
-NotI and replaced with 280bp PCR generated fragment containing additional first 
13AA of Sp3new sequence by using as template: pSPT 18-Sp3new and the following 
primers: sense Sp3newXho-FOR and antisense SP3NOT-REV. The PCR product was 
digested with XhoI and NotI. 
 
pHA-Sp3NEW K/R. The first 250 bp fragment of pHA Sp3 K/R Fl* was cut with 
XhoI-NotI I and replaced with 280bp PCR generated fragment containing additional 
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first 13 aa of Sp3new sequence by using pSPT 18-Sp3new as template and the 
following primers: sense Sp3newXho-FOR and antisense SP3NOT-REV. The PCR 
product was digested with XhoI and NotI. 
 
pN3-Sp3fl* = (∆13 Sp3). CMV-driven expression vector for full-length Sp3 (still 
not full-length (Sp3FL*), 13 aa at the N-term missing (second AUG)). Sp3new insert 
as 2600 bp fragment from pSPT18-Sp3FL* was digested EcoRI – SalI and cloned into 
the corresponding EcoRI - SalI restricted pN3 vector. Also K to R mutation in the 
IKEE motiv available - pN3-Sp3 K/R fl* = (∆13 Sp3 K/R). 
 
pN3-Sp3 NEW. CMW-driven expression vector for full-length Sp3 (with both 
upstream AUGs). Sp3new insert as 2800 bp fragment from pSPT18-Sp3FL-NEW was 
digested EcoRI - SalI and cloned into the corresponding EcoRI - SalI restricted pN3 
vector. Also K to R mutation in the IKEE motiv available - pN3-Sp3 K/R NEW. 
 
pN3-PIAS1-FB. CMV-driven expression vector for PIAS1-FLAG-BiotinTAG. 
PIAS1wt insert generated by PCR using as template pGEX-PIAS1using the 
following primers: sense: PIAS1-Eco-K-5' and antisense PIAS1-Sal-rev. The PCR 
product was digested with EcoRI and SalI, and cloned into the corresponding EcoRI 
and SalI -restricted pN3-FB vector.  
 
pN3-PIAS1-3xFB. CMV-driven expression vector for PIAS1-FLAG-BiotinTAG. 
PIAS1wt insert generated by PCR using as template pGEX-PIAS1using the 
following primers: sense: PIAS1-Eco-K-5' and antisense PIAS1-Sal-rev. The PCR 
product was digested with EcoRI and SalI, and cloned into the corresponding EcoRI 
and SalI -restricted pN3-3xFB vector.  
 
pN3-PIAS1-CTB. CMV-driven expression vector for PIAS1-CalBP-BiotinTAG. 
PIAS1wt insert generated by PCR using as template pGEX-PIAS1using the 
following primers: sense: PIAS1-Eco-K-5' and antisense PIAS1-Sal-rev. The PCR 
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product was digested with EcoRI and SalI, and cloned into the corresponding EcoRI 
and SalI -restricted pN3-CTB vector.  
 
pN3-Sp3-CTB. CMV-driven expression vector for Sp3new-CalBP-BiotinTAG. 
Sp3new insert generated by PCR using as template pMCS-Sp3new-HA using the 
following primers: sense: NEU 5'-Sp3 I and antisense Sp3Sal-End-REV. The PCR 
product was digested with EcoRI and SalI, and cloned into the corresponding EcoRI 
and SalI -restricted pN3-CTB vector.  
 
pN3- Sp3-FB. CMV-driven expression vector for Sp3-FLAG-BiotinTAG. 
Sp3new insert generated by PCR using as template pMCS-Sp3new-HA using the 
following primers: sense: NEU 5'-Sp3 I and antisense Sp3Sal-End-REV. The PCR 
product was digested with EcoRI and SalI, and cloned into the corresponding EcoRI 
and SalI -restricted pN3-FB vector.  
 
pN3- Sp3-3xFB. CMV-driven expression vector for Sp3-FLAG-BiotinTAG. 
Sp3new insert generated by PCR using as template pMCS-Sp3new-HA using the 
following primers: sense: NEU 5'-Sp3 I and antisense Sp3Sal-End-REV. The PCR 
product was digested with EcoRI and SalI, and cloned into the corresponding EcoRI 
and SalI -restricted pN3-3xFB vector.  
 
pN3-FL-Ubc9. High level expression of FLAG-Ubc9. Obtained from Stamminger 
lab, Erlangen. 
 
pN3 -FLAG-SUMO1. High level expression of FLAG-SUMO1. 
 
pSG5LINK-EGFP-SUMO1 and pSG5LINK-EGFP-SUMO2. High level 
expression of EGFP- tagged from SUMO1and SUMO2. Obtained from Stamminger 
lab, Erlangen. 
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pBudCE4.1. –Bir A BirA biotin ligase (Boer et al., 2003) cloned in high level 
expression vector (Invitrogen). Provided by Philipsen lab., Erasmus MC, Department 
of Cell Biology, Rotterdam, The Netherlands. 
 
2.1.6.2. Expression Plasmids for Generation of Stable Cell Lines: 
Basic vectors: 
pTRE2pur (Fig.2.3) is a response plasmid that can be used to express a gene of 
interest (Gene X) in Clontech’s Tet-OnTM and Tet-OffTM Gene Expression Systems and 
Tet-On and Tet-Off Cell Lines (Gossen and Bujard, 1992). pTRE2pur contains an MCS 
immediately downstream of the Tet-responsive PhCMV-1 promoter. cDNAs or genes 
inserted into the MCS will be responsive to the tTA and rtTA regulatory proteins in the 
Tet-Off and Tet-On systems, respectively. PhCMV-1 contains the Tet response element 
(TRE), which consists of seven copies of the 19-bp tet operator sequence (tetO). The 
TRE element is just upstream of the minimal CMV promoter (Pmin CMV), which lacks 
the enhancer that is part of the complete CMV promoter. Consequently, PhCMV-1 is 
silent in the absence of binding of TetR or rTetR to the tetO sequences. 
The Puromycin resistance gene is under the control of SV40 promoter and is used to 
directly select for stable transformants. 
 
Fig.2.3. Map and Multiple Cloning Site (MCS) of pTRE2pur Vector. Unique 
restriction sites are in bold. (pTRE2 pur Vector Information, www.bdbiosciences.com). 
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pTRE2pur-Luc Control Vector, contains an additional 1649 bp encoding firefly 
luciferase inserted into the MCS. This vector can be used as a reporter for induction 
efficiency using standard luciferase detection reagents. It is not intended as a cloning 
vector. 
pTet-Off regulatory plasmid encodes the tetracycline-controlled transactivator 
(tTA). In the Tet-Off System, Tet repressor (TetR), a 37-kDa protein is a fusion of amino 
acids 1–207 of TetR and the C-terminal 127 aa of the Herpes simplex virus VP16 
activation domain. Addition of the VP16 domain converts the TetR from a 
transcriptional repressor to a transcriptional activator, and the resulting hybrid protein is 
known as the tetracycline-controlled transactivator (tTA). The pTet-Off regulatory 
plasmid also includes a neomycin-resistance gene to permit selection of stably 
transfected cells (see pTet-Off Vector Information, www.bdbiosciences.com). 
 
pTRE2pur-CTB is a response plasmid that can be used to express a gene of interest 
fused with CTB tag in Clontech's Tet-On and Tet-Off Gene Expression Systems and 
Tet-On and Tet-Off Cell Lines. CalBP-TEV-BiotinTag generated by PCR using as 
template pN3-PIAS1-CTB using the following primers: sense: CBP-NOT-FOR and 
antisense CBP-CLA-REV.  
The PCR product was digested with NotI-ClaI, and cloned into the corresponding 
NotI-ClaI -restricted pTRE2pur vector.  
 
Expression plasmids:  
pTRE2pur- PIAS1CTB is a response plasmid that expresses PIAS1fused with CTB 
tag in Clontech's Tet-On and Tet-Off Gene Expression Systems and Tet-On and Tet-Off 
Cell Lines. PIAS1-CTB PCR fragment was generated by PCR using as template 
pN3-PIAS1-CTB using the following primers: sense: PIAS1-Mlu-K-5' and antisense 
CBP-CLA-REV.  
pTRE2pur-Sp3-CTB is a response plasmid that expresses Sp3 fused with CTB tag 
in Clontech's Tet-On and Tet-Off Gene Expression Systems and Tet-On and Tet-Off Cell 
Lines. Sp3 PCR fragment was generated by PCR using as template pN3-Sp3 CTB using 
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the following primers: sense: Sp3- MLU-FOR and antisense CBP-CLA-REV.  
 
pBudCE4.1.-rtTA–Bir A. is a response plasmid that expresses BirA biotin ligase 
(Boer et al., 2003) in the tetracycline-controlled system. Provided by Philipsen lab., 
Erasmus MC, Department of Cell Biology, Rotterdam, The Netherlands. 
 
2.1.6.3. Expression plasmids for insect cells: 
pPac-Sp3flNEW 
Drosophila expression vector for full-length Sp3 (with both upstream AUGs). 
 
pPac-Sp3K/RflNEW 
   Drosophila expression vector for full-length Sp3 K/R mutant. 
 
pPAC-Sp3-K-mut 
Drosophila expression vector for lysin mutants (from inhibitory domain) of Sp3 
sequence. Available mutants: K to R (additiional EcoRI site); K to D (additional ClaI 
site); K to A (additional EcoRV site). 
 
pPAC-Sp3 and pPAC-Sp3-K-D. Drosophila expression vector for wt and lysin 
mutant (K to R from inhibitory domain) of small isoforms Sp3 (Hagen et al., 1994). 
 
2.2. Methods 
2.2.1. Molecular Biological Methods 
2.2.1.1. PCR 
Polymerase chain reaction (PCR) was performed with with Ready To Go™ PCR 
Beads (Amersham Pharmacia Biotech, USA). In provided reaction tubes, 15 pmol of 
each primer were mixed with 50 pg  template DNA and H2O to 25 µl total volume. In 
principle, the PCR reactions were carried out for 30 cycles of 1 min at 94°C, 40 sec at 
58°C and 1 min at 72°C, followed by an extension at 72°C for 7 min. 
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2.2.1.2. Purification of Nucleic Acids 
2.2.1.2.1. DNA Agarose Gel Electrophoresis 
2% to 0,5% agarose gels were routinely used to separate DNA fragments in a size 
range of 100 to 10.000 bp (Sambrook and Russell, 2001). The appropriate amount of 
agarose was dissolved in 1× TBE-buffer by boiling for a few minutes in a microwave 
oven. When the gel solution has cooled down to 60°C, ethidium bromide was added to a 
End concentration of 0,1 µg/ml. The clear solution was then poured into a gel mold 
using a suitable comb for generating the sample wells and allowed to harden for some 
30-45 min. The gel was mounted in the electrophoresis chamber which was filled with 
1x TBE running buffer until the gel was just submersed. DNA samples and a suitable 
size standard (DNA marker an EcoRI-HindIII cut λ DNA) were mixed with 0.2 volume 
of 6xloading buffer and applied to the wells. A voltage of 2-10V/cm was applied until 
the bromophenol blue had migrated an appropriate distance through the gel. After 
completion of electrophoresis the gel was examined on a 305 nm UV transilluminator 
and photographed using gel documentation system (Intas, Göttingen). 
 
2.2.1.2.2. Electrophoretic Separation of DNA in Agarose Gels 
DNA molecules were separated by horizontal agarose gel electrophoresis in TBE 
buffer. 0,8%-1,2% (w/v) agarose gels, containing 0,1 µg/ml ethidium bromide, were 
used for analysis of digested plasmids and for separation and isolation of PCR bands. 
DNA samples were loaded into the gels in 1 x DNA loading buffer and run at 5-10 V/cm 
of gel. Generally samples were run in parallel with a DNA marker. Linear fragments 
used for further enzymatic treatments were isolated from agarose gels after 
electrophoresis. Agarose pieces containing the desired DNA fragment were visualized 
on UV light (for short time at 254 nm in order to avoid DNA degradation) and were 
excised with a scalpel blade. 
 
2.2.1.2.3. Extraction of DNA and Isolation from Agarose Gels 
For separation of DNA from proteins, phenol/chloroform extraction was performed 
followed by ethanol precipitation washing (Sambrook et al., 1989). In the final steps of 
vector preparation, purification of PCR products and purification of gel isolated DNA 
fragments, QIAquick pre-packed Micro Spin columns were used following the 
instructions of the supplier (QIAGEN).  
 
Materials and Methods 
 64
2.2.1.3. Enzymatic Manipulation of DNA 
2.2.1.3.1. Digestion of DNA with Restriction Endonuclease 
DNA samples (200 ng–1 µg) were digested by restriction endonucleases using 
corresponding reaction buffers. Generally, restriction digests were prepared in 20 µl 
total volume, with 0.5-1 µl restriction enzyme (1-5 U/µl) and incubated at 37°C from 1 
h to 3 h. In other cases, enzyme, DNA, buffer volumes and reaction times varied 
depending on the specific requirements. For enzyme inactivation, samples were 
incubated at 65°C for 10 min or were mixed with 0.2 volume of 6xloading buffer. 
 
2.2.1.3.2. Dephosphorylation of DNA with Alkaline Phosphatase 
For insertion of the DNA fragment of interest into a plasmid, a modification of the 
vector is required. One such modification is dephosphorylation with calf intestine 
phosphatase (CIP), which catalyzes the hydrolysis of the 5‘phosphate residue, thus 
preventing self ligation of vector termini.  The reaction components were  the buffer 
(50 mM Tris HCl pH 8.0, 1 mM ZnCl2, 1 mM MgCl2), 1-20 pmol DNA termini, and 0,1 
U CIP. The reaction (50 µl) was performed at 37°C for 30 minutes and stopped for 10 
minutes at 75°C.  
The phosphatase treatment was done directly following cleavage by a restriction 
endonuclease.  A conversion factor for calculation of amount of the DNA was that 1 µg 
of a 3-kb linear DNA contains 1 pmol of 5‘termini. 
 
2.2.1.3.3. Ligation 
Ligations were done by using a vector to insert ratio 3 : 1,  with 200 ng vector-DNA 
in 20 mM Tris/HCl, pH 7,5; 10 mM MgCl2; 10 mM DTT; 1 mM ATP with 1 U 
T4-DNA-Ligase over night at 16°C. 
Rapid Ligation Kit (MBI Fermentas) or Fast LinkTM System (Biozym, Hessisch 
Oldendorf) were used following the instructions of the suppliers.  
 
2.2.1.3.4. Hybridizing of Synthetic Oligonucleotides for Cloning 
Equimolar amount of complementary synthetic oligonucleotides (1 µg to 5 µg of 
each) were incubated for 20 min at 75°C in 30 µl 10 mM Tris/HCl; 1 mM EDTA; 30 mM 
NaCl; pH 8. The hybridization reaction was cooled down by unplugging the incubator.  
 
2.2.1.3.5. Site-Directed Mutagenesis  
Stratagene’s QuikChange® site-directed mutagenesis kit allows site specific mutation in  
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Fig.2.4. Overview of the QuikChange® XL site-directed mutagenesis method. 
 (After Stratagene, QuikChange® XL Site-Directed Mutagenesis Kit, Instruction 
Manual, www.stratagene.com). 
 
virtually any double-stranded plasmid. The QuikChange site-directed mutagenesis kit is 
used to insert point mutations, switch amino acids, and delete or insert single or multiple 
amino acids. PfuTurbo DNA polymerase replicates both plasmid strands with high 
fidelity without displacing the mutant oligonucleotide primers. The basic procedure 
Materials and Methods 
 66
utilizes a supercoiled double-stranded DNA (dsDNA) vector with an insert of interest 
and two synthetic oligonucleotide primers containing the desired mutation (see Fig.2.1). 
The oligonucleotide primers, each complementary to opposite strands of the vector, are 
extended during temperature cycling by PfuTurbo DNA polymerase. Incorporation of 
the oligonucleotide primers generates a mutated plasmid containing staggered nicks. 
Following temperature cycling, the product is treated with DpnI. DNA isolated from 
almost all E. coli strains is dam methylated and therefore susceptible to DpnI digestion. 
The nicked vector DNA containing the desired mutations is then transformed into 
XL1-Blue supercompetent cells.  
For correcting a point mutation in PIAS1 sequence, we used as oligos: 
P1-rep∆C-for and P1-rep∆C-rev, following the manufacturer protocol, schematically 
illustrated in Fig 2.1. 
2.2.2. Microbiological Methods 
2.2.2.1. Cultivation and Growing of Microorganisms 
Media for E. coli were prepared as previously described (Sambrook et al., 1989), and 
supplemented in function of each experiment, with antibiotics and necessary reagents. 
Ingredients were added to bidistilled H2O water, poured into bottles with loosen caps 
and autoclaved at 120°C for 20 min. For solid media, 15 g agar per liter was added. 
Glassware and porcelain was sterilized in the heat sterilizer for 3 h at 180°C. 
Heat-sensitive solutions such as antibiotics, were filer-sterilized with 0.22 µm pore filter 
membrane (Millipore, France), and added to the media after autoclaving. 
 
2.2.2.1.2. Growth Conditions and Storage of Transformed E. coli Strains 
Cultures of transformed E. coli strains were overnight cultivated on LB plates with 
appropriate antibiotics at 37°C. Liquid culture was inoculated from a single colony and 
incubated in LB medium containing appropriate antibiotics at 37°C with 180 rpm 
overnight shaking. For storage of E. coli strains, freshly grown bacterial suspension was 
adjusted to 15% end concentration of sterile glycerol and frozen at –80°C. 
 
2.2.2.1.3. Transformation of the Competent Cells with Plasmid DNA 
E. coli strains were transformed in order to clone recombinant plasmid or to express 
recombinant proteins following the protocol described in Hanahan, 1983. 
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Preparation of competent E. coli and transformation 
For preparation of competent E. coli, use an inoculating loop to streak E. coli DH 5α 
strain directly from a frozen stock onto the surface of an SOB agar plate. Incubate the 
plate for 16 hours at 37°C. Pick one colony and let it grow in 3 ml LB medium overnight, 
and then inoculate 30 ml SOB culture containing 20 mM MgSO4 with 100 µl overnight 
culture. Grow the cells for 2.5-3.0 hours at 37°C, monitoring the growth of the culture 
each 20 minutes. When the culture reached an OD600 = 0,5 - 0,1, the cells were stored on 
ice for 10 minutes. The cells were collected at 2500 rpm for 10 minutes at 4°C in one 50 
ml falcon tube. Discard the medium and stand the tubes in an inverted position to allow 
the last traces of medium to drain away. Resuspend in 10 ml TFB buffer and centrifuge 
at 2500 rpm for 10 minutes at 4°C. Discard the medium and resuspend in 2,4 ml TFB 
buffer. After gently mixing the buffer with 84 µl DMSO (7% v/v), the mixture was kept 
on ice 5 minutes, then with 84 µl 1M DTT and stored on ice for 10 minutes. Finally, 84 
µl DMSO was added and after 5 minutes incubation on ice, the mixture was dispensed 
200 µl aliquots into 1.5ml chilled, sterile microfuge tubes. Immediately snap-freeze the 
competent cells by immersing the tightly closed tubes in a bath of liquid nitrogen. Store 
the competent cells at -800C until needed. 
Using no more than 25 ng transforming plasmids in a volume not exceeding 3 µl for 
200 µl competent cells, swirl the tubes gently to mix the DNA and bacteria. Set up at 
least two control tubes for each transformation experiment, including a tube of 
competent bacteria that receives a known amount of a standard preparation of 
superhelical plasmid DNA and a tube of cells that receives no plasmid DNA at all. Store 
the tubes on ice for 30 minutes. Transfer the tubes to a preheated 42°C heatblock. After 
exactly 45 seconds, rapidly transfer the tubes to an ice bath. Add 800 µl of SOC medium 
to each tube after 1-2 minutes cooling. Incubate the tubes for 45 minutes in the shaking 
incubator to allow the bacteria to recover and to express the antibiotic resistance marker 
encoded by the plasmid. Transfer 200 µL transformed competent cells culture onto 90 
mm agar LB plate containing the appropriate antibiotic. Store the plates at room 
temperature until the liquid has been absorbed. The plates were inverted and incubated 
at 37°C overnight. The positive colony was screened by restriction enzyme analysis or 
direct DNA sequence analysis. 
TFB buffer: 10mM KMES, 45 mM MnCl2, 10 mM CaCl2, 100mM KCl, before 
adding MnCl2 adjust pH to 6.7 with KOH 
SOB medium: For 500 ml: 10g Select Peptone; 2,5g Select Yeast Extract; 0.292 g 
NaCl; 0,093 g KCl.  
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SOC medium: For 10 ml: 10 ml SOB; 100 µl MnCl2 (2M); 200 µl glucose (1M).  
LB Medium (Luria-Bertani Medium):  For 1000 ml: 10 g Select Peptone; 10 g    
NaCl; 5 g Select Yeast Extract. 
Antibiotics for E. coli media (end concentrations): 
Ampicillin  (Sigma, München)    -100 µg/ml     
Kanamycin  (Sigma, München)    -50 µg/ml     
Zeocin™ (Cayla, France)           -100 µg/ml     
 
2.2.2.2. Plasmid DNA Preparation from E. coli  
For isolation of plasmid or cosmid DNA (Sambrook et al., 1989) an alkali-lysis 
method was used. Buffers from Nucleobond® Plasmid DNA Purification Kit 
(Macherey-Nagel) were used. For DNA small volumes (miniprep), 1.5 ml of overnight 
liquid culture was centrifuged 1 min at 13000 rpm, the pellet resuspended in 100 µl S1 
Buffer (50 mM Tris/HCl; 10 mM EDTA; 100 µg (A/ml) RNase, pH 8,0), then 100 µl of 
S2 Buffer (200 mM NaOH; 1% SDS) added and gently mixed, followed by addition of 
100 µl S3 Buffer (2,8 M KAcetate; pH 5,1). After 10 min incubation in ice and 10 min 
centrifugation, plasmid DNA-containing supernatant was precipitated with 0.7 vol. 
isopropanol, followed by 70% EtOH washing. The dried pellet was resuspended in 10/1 
TE buffer. For large DNA volumes (midipreps), plasmid DNA from 100 ml E. coli 
overnight liquid culture was extracted using a Macherey-Nagel Nucleobond® Plasmid 
DNA Purification Kit, according to the manufacturer protocols.  
Plasmid DNA concentration was determined via absorption measurement with 260 
and 280 nm in a spectrophotometer (Pharmacia LKB), with a quartz cuvette or by 
comparison between the intensity of ethidium bromide DNA bands on agarose gels and 
the intensity of defined standards. 
Plasmid DNA for transfections was prepared from transformed E. coli DH5α using 
Nucleobond PC 500 columns (Macherey & Nagel, Düren). The quality of all plasmids 
(ratio supercoiled vs. nicked better than 70:30) was checked by agarose gel 
electrophoresis before transfection. 
 
2.2.3. Working with Eukaryotic Cell Lines 
Establishment and maintenance of mammalian cell cultures require a regular routine 
for preparation of media, and feeding, and subculturing the cells. 
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Cultures should be examined regularly to check for signs of contamination and to 
determine if the culture needs feeding or subculturing. 
 
2.2.3.1. Trypsinizing and Passaging Cells 
1.  Aspirate the medium and discard. 
2.  Wash cells with PBS, aspirate, and discard. The volume of PBS should be 
approximately the same as the volume of medium used for culturing the cells. 
3.  Repeat step 2. 
4.  Add enough 1x trypsin-EDTA solution (Gibco, Neu Isenburg) to cover the 
monolayer, and rock the flask/dish 4–5 times to coat the monolayer. 
5.  Loosen the flask cap and place the flask/dish in a CO2 incubator at 37°C for 1–2 
min. 
6.  Remove flask/dish from incubator, tighten the flask cap, and firmly rap the side 
of the flask/dish with palm of hand to assist detachment. 
If cells have not dislodged, loosen the flask cap and return the flask/dish to the 
incubator for a few minutes more. 
7.  Once dislodged, resuspend the cells in growth medium containing serum. 
Use medium containing the same percentage of serum as used for growing the cells. 
The serum inactivates the trypsin activity. 
8.  Gently pipet the cells up and down to disrupt cell clumps, and replate at desired 
density in fresh flasks/dishes. 
If pipetted too vigorously, the cells will become damaged. Ensure that pipetting does 
not create foam. 
2.2.3.2. Cell Freezing 
1. Check that cells are healthy, not contaminated, and have the correct morphological 
characteristics. 
2.  Change the medium 24 h before freezing the cells. 
Adherent and suspension cell cultures should not be at a high density for freezing. It 
is recommended to use cells in logarithmic growth phase. 
3.  For adherent cells, trypsinize cells, resuspend in medium containing serum, 
pellet cells by centrifugation at 100 rpm for 5 min, and resuspend cells in freezing 
medium (corresponding cell line medium with 10% DMSO). 
4.  Transfer 1.5 ml of cells into freezing vial (Cryotube- Gibco, Neu Isenburg). 
Label vials with name of cell line, date, passage number and growth medium. 
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5.  Place freezing vials on canes and transfer to a polystyrene box (with walls 
approximately 15 mm thick) lined with cotton wool. Store box in a –80°C freezer 
overnight. 
6.  On the next day, quickly transfer the vials to the liquid nitrogen chamber, making 
sure that the vials do not begin to thaw. 
2.2.3.3. Cell Thawing 
1. Run tap water to 37°C and place a beaker under the tap. 
2. Remove a vial of frozen cells from liquid nitrogen, and place in beaker 
containing 37°C water until fully thawed. 
3. Wash the outside of the vial with 70% ethanol or another suitable disinfectant. 
4. Prewarm a suitable amount of medium to 37°C in an appropriately sized flask or 
Petri dish. The size of flask or Petri dish depends on the cell type as well as the cell 
density. 
5. Slowly pipet the cell suspension into the prewarmed medium. Mix during 
addition of the cells to the medium. 
1. Immediate removal of DMSO may sometimes be necessary, especially for 
suspension cells. Following the addition of the thawed cell suspension to the prewarmed 
medium, the cells should be centrifuged and resuspended in fresh, prewarmed medium. 
6. Incubate cells at 37°C overnight, and then change medium. 
 
2.2.4. Transient Transfection and Transfection Methods 
Transfection — delivery of foreign molecules such as DNA into eukaryotic cells — 
has become a powerful tool for the study and control of gene expression, for example for 
biochemical characterization, mutational analyses, or investigation of the effects of 
regulatory elements or cell growth behavior. Two principally different transfection 
approaches can be used - transient transfection and stable transfection (Freshney, 1993). 
When cells are transiently transfected, the DNA is introduced into the nucleus of the 
cell but does not integrate into the chromosomes. This means that many copies of the 
gene of interest are present, leading to high levels of expressed protein. Transient 
transfection is most efficient when supercoiled plasmid DNA is used. Expression of the 
transfected gene can typically be analyzed within 24–96 hours after introduction of the 
DNA, depending on the construct used.  
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2.2.4.1. Calcium Phosphate  
Calcium phosphate forms an insoluble precipitate with DNA, which attaches to the 
cell surface and is taken into the cells by endocytosis (Jordan et al., 1996). Twenty-four 
hours before transfection, harvest exponentially growing cells and replate them at a 
density of 1x105 to 4x105 cells/cm2 Tissue culture flasks in fresh medium. Incubate the 
cultures for 20-24 hours at 37°C in a humidified incubator with an atmosphere of 5% 
CO2. Change the medium 1 hour before transfection. 
Prepare the calcium phosphate-DNA coprecipitate as follows: combine 250 µL of 
2xCalcium Chloride with 5 µg of plasmid DNA in a sterile 5-ml plastic tube. Mix 1 
volume of the 2xCalcium Chloride-DNA solution with an equal volume of 2xHeBS 
solution at room temperature. Mix the ingredients by vortexing for 1 minute and allow 
the solution to stand for another 1 minute. 0,5 ml of calcium phosphate-DNA suspension 
was immediately transferred into 4,5 ml medium above the cell monolayer. Rock the 
flasks gently to mix the medium, which will become yellow-orange and turbid. Carry 
out this step as quickly as possible because the efficiency of transfection declines rapidly 
once the DNA precipitate. Change the medium 24 hours after transfection. If 
morphological characteristics of cells are changed, replace the medium after 8 hours 
post-transfection. Assay the transfected cells for transient expression of the introduced 
plasmids by harvesting the cells 48 hours after transfection. 
2xCalcium Chloride: 250 mM CaCl2, 1 mM HEPES, pH 7.08. 
2xHEPES-buffered saline (HeBS): 21 mM HEPES (4-(2-hydroxyethyl)- 
1-piperazineethanesulfonic acid), 0.7 mM Na2HPO4, 137mM NaCl, 5 mM KCl, 6 mM 
dextrose, pH 7.08 (very critical). 
 
2.2.4.2. DEAE-Dextran  
Diethylaminoethyl (DEAE)-dextran is one of the older methods for introducing 
nucleic acids into cultured mammalian cells (Vaheri et al., 1965).   
The positively charged DEAE-dextran molecule interacts with the negatively 
charged phosphate backbone of the nucleic acid. The DNA–DEAE-dextran complexes 
appear to adsorb onto the cells and are taken up by endocytosis. The advantages of this 
technique are its relative simplicity and reproducibility of results. 
Disadvantages include cytotoxic effects and the fact that the serum in the culture 
medium must be temporarily reduced during the transfection procedure. In addition, the 
DEAE-dextran method is preferably used for transient transfection only. 
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DNA preparation: The indicated volumes are for 6-wells plates (35 mm diameter). 
1. Mix the desired amount (5µg) of DNA in an Eppendorf tube. 
2. Resuspend in 150 µl 1x TBS. 
3. Add slowly 300 µl of pre-warmed DEAE-dextran solution (10 mg/ml in 1x TBS). 
Transfection: 
1. Wash cells twice with 1x TBS. 
2. Add the DNA solution and incubate 30 min at RT. 
3. Add 2 ml of complete medium and incubate the cells for 4 hours. 
4. Add 2 ml of the DMSO solution (10% in 1x PBS). Incubate 1 min at RT and rinse 
twice with 1x PBS. 
5. Add 2 ml of fresh complete medium. 
6. Change the medium 8 hours after transfection. 
Cells are now ready to be treated as desired the following day. 
 
2.2.4.3. PEI  
Polyethylenimine (PEI) cationic polymer was introduced in 1995 as a versatile 
transfection reagent. It was successfully used for gene transfer and antisense 
oligonucleotide delivery both in vitro and in vivo. PEI binds tightly to DNA forming 
small globular or toroidal complexes that enter cells by endocytosis. Being in the 
endosome, PEI acts as a “proton sponge,” effectively buffering the endosomal interior, 
facilitating endosome disruption, and thus enabling the release of the complex into the 
cell cytoplasm. 
Prepare PEI stock solution by solving 9 mg Polyethylenimine (Sigma) in 10 ml water. 
Vortex vigorously. Filter through 0.22µm filter. 
 
Transfection: 
1. To transfect 3 dishes of  21 cm2 each take two 2 ml Eppendorf cups: 
Cup nr.1: mix 10 µg plasmid DNA with 750 µl 150 mM NaCl (sterile filtered). 
Cup nr.2: mix 100 µl PEI stock with 650 µl 150 mM NaCl. 
2. Leave at RT for 10 min.  
3. Transfer PEI (Cup nr.1) dropwise to the DNA solution (Cup nr.2), do not mix! 
4. Leave at RT for 10 min.  
5. Rinse cells with 1x PBS change the medium of the cells. 
6. Mix the PEI/DNA solution by pipetting it up and down and transfer 500 µl to each 
culture-dish dropwise. 
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7.Incubate the cells for 4 hours. 
8.Rinse cells with 1x PBS and change the medium of the cells. 
9.Return the cells to the incubator until the time of harvesting. 
 
2.2.4.4. FuGENE6  
Plate the cells one day before experiment. The appropriate plating density for 
Ishikawa cells that are 50-80% confluent on the day of experiment -1,5-2 x 10 5 cells in 4 
ml medium in a 60 mm culture dish. 
  Preparation of the complex: 
1. In a 1.5ml sterile tube add 200 µl serum free medium as diluant for FuGENE6 
transfection reagent (Roche Applied Science). Add 15 µl of FuGENE6 directly into this 
medium. Tap gently to mix. 
2. Add 3 µg DNA solution (0,5 µg/µl) to the prediluted transfection reagent. Gently 
tap the tube to mix the contents. 
3. Incubate for 30 min at room temperature. 
4. While the complex-formation takes place, gently aspirate the growth medium 
from the plate, and wash the cells once with PBS. Add 4 ml fresh growth medium (can 
contain serum and antibiotics) to the cells. 
5. Dropwise, add the complex mixture to the cells, distributing it around the well. 
Swirl the wells to ensure even dispersal. 
Return the cells to the incubator until the time of harvesting. 
 
2.2.4.5. Effectene  
The following protocol is for transfection of adherent cells in 60 mm dishes with 
Effectene Transfection Reagent (Qiagen GmbH, Hilden).  
1. The day before transfection, seed 2–8 x 105 cells (depending on the cell type) per 
60 mm dish in 5 ml appropriate growth medium containing serum and antibiotics. 
2. Incubate the cells under their normal growth. The dishes should be 60–80% 
confluent on the day of transfection. 
3. The day of transfection, dilute 3 µg DNA dissolved in TE pH 8 with the 
DNA-condensation buffer, Buffer EC, to a total volume of 200 µl. Add 20 µl Enhancer 
and mix by vortexing for 1 second. 
4. Incubate at room temperature (15–25°C) for 2–5 min then spin down the mixture 
for a few seconds to remove drops from the top of the tube. 
Materials and Methods 
 74
5. Add 50 µl Effectene Transfection Reagent to the DNA-Enhancer mixture. Mix by 
pipetting up and down 5 times, or by vortexing for 10 seconds.  
6. Incubate the samples for 5–10 min at room temperature (15–25°C) to allow 
transfection-complex formation. 
7. While complex formation takes place, gently aspirate the growth medium from 
the plate, and wash cells once with 4 ml PBS. Add 4 ml fresh growth medium (can 
contain serum and antibiotics) to the cells. 
8. Add 1 ml growth medium (can contain serum and antibiotics) to the tube 
containing the transfection complexes. Mix by pipetting up and down twice, and 
immediately add the transfection complexes drop-wise onto the cells in the 60 mm 
dishes. Gently swirl the dish to ensure uniform distribution of the transfection 
complexes. 
9. Incubate the cells with the transfection complexes under their normal growth 
conditions for an appropriate time for expression of the transfected gene. The incubation 
time is determined by the assay and gene used. 
In many cases, removal of transfection complexes is not necessary. However, if 
cytotoxicity is observed, remove the Effectene–DNA complexes after 6–18 h, wash the 
cells once with PBS, and add 5 ml fresh growth medium. 
 
2.2.4.6. Lipofectin  
The protocol is designed for the transient or stable transfection of adherent cells in 
24-well plates, with Lipofectin reagent (Gibco/BRL). 
1. The day before transfection, trypsinize and count the cells, plating them at 1-3 × 
105 cells per well so that they are 40-65% confluent on the day of transfection. Cells are 
plated in 5 ml of their normal growth medium containing serum. 
2. For each well of cells to be transfected, dilute 1 to 3 µg of DNA into 100 µl of 
medium without serum. This can be prepared in bulk for multiple wells. 
Some serum-free media formulations can inhibit cationic lipid-mediated transfection. 
Test media for compatibility with transfection reagent before use. 
3. For each well of cells, dilute 2-20 µl of Lipofectin Reagent into 100 µl medium 
without serum and incubate for 30 min at room temperature. 
4. Combine the diluted DNA (from step 2) with the diluted Lipofectin Reagent (from 
step 3). Incubate at room temperature for 20 min to allow DNA- Lipofectin Reagent 
complexes to form. The solution may appear cloudy but this will not impede the 
transfection. 
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5. Add the DNA- Lipofectin Reagent complexes directly to each well and mix gently 
by rocking the plate back and forth. 
6. Incubate the cells at 37°C in a CO2 incubator for a total of 24-48 h until they are 
ready to assay for transgene expression. It is not necessary to remove the complexes or 
change the medium. Alternatively, growth medium may be replaced after 4-6 h without 
loss in transfection activity. 
7. A similar procedure can be used to transfect DNA for stable expression. At 24 h 
after transfection, passage the cells at a 1:10 or higher dilution into fresh growth medium. 
The next day, add selective medium for the antibiotic resistance gene transfected.  
2.2.5. Stable Transfection 
With stable or permanent transfection, the transfected DNA is either integrated into 
the chromosomal DNA. Cells that have successfully integrated the DNA can be 
distinguished by using selectable markers. In some cases, stable transfection causes a 
morphological change which can be used as a selectable trait (Spector et al., 1998). 
To obtain a stably transfected homogenous cell population, a selectable marker gene 
(usually a eukaryotic antibiotic resistance gene) is transfected into cells together with the 
gene of interest. Approximately one of 104 cells will stably integrate DNA, although the 
efficiency varies with cell type.  
Preceding starting stable transfection experiments with HeLa Tet-Off cell lines, the 
induction of Tet regulatory plasmid in the absence of Tetracycline was analyzed by 
monitoring of Luciferase intensity after transfecting the pTRE2pur-Luc Control Vector, 
used as a reporter of induction efficiency. HeLa Tet-Off cell were grown in the presence 
of 2 µg/ml Tetracycline in order to keep transcription of Gene X turned “off”.  
 
2.2.5.1. Establishing a Kill Curve (Dose-Response Curve) 
Prior to using G418, Puromycin and Zeocin to establish or maintain stable and 
double-stable cell lines, it is important to titrate with the selection agent (antibiotic) to 
determine the optimal concentration for selection with the particular host cell line being 
tested. It is also acknowledged that the kill curve can be influenced by cell density. 
Therefore, it is recommended performing two experiments for each drug: (1) a 
titration to determine the optimal drug concentration, and (2) an experiment to determine 
the optimal plating density.  
 
Materials and Methods 
 76
1. Titrate at fixed cell density. 
A. Plate 2 x 105 cells in each of six 10-cm tissue culture dishes containing 10 ml of 
the HeLa medium plus varying amounts (0, 50, 100, 200, 400, 800 µg/ml) of G418. For 
Puromycin, add the drug at 0, 1, 2.5, 5, 7.5, and 10 µg/ml. Zeocin was tested at 0, 10, 25, 
50, 100, 200, 400 and 500 µg/ml). 
B. Incubate the cells for 10–14 days, replacing the selective medium every four days 
(or more often if necessary). 
C. Examine the dishes for viable cells every day. 
For selecting the optimal concentration of drug, it is suggested to use the lowest 
concentration that begins to give massive cell death in ~5 days and kills all the cells 
within two weeks. For HeLa Tet-OFF cells, I have found 400 µg/ml of G418 to be 
optimal, the optimal level of Puromycin was typically around 1 µg /ml and for Zeocin 
the level was 80 µg /ml. 
2. Determine optimal plating density. 
Once you have determined the optimal drug concentration, determine the optimal 
plating density by plating cells at several different densities in the presence of a constant 
amount of drug. If cells are plated at too high a density, they will reach confluency 
before the selection takes effect. Optimal plating density is dependent on population 
doubling time and cell surface area. For example, large cells that double rapidly have a 
lower optimal plating density than small cells that double slowly. 
A. Plate cells at several different densities in each of six 10-cm tissue culture dishes 
containing 10 ml of the appropriate selective medium. 
Suggested densities (cells/10-cm dish): 5 x 106, 1 x 106, 5 x 105, 2 x 105, 1 x 105, and 
5 x 104. 
B. Incubate the cells for 5–14 days, replacing the selective medium every four days. 
C. Examine the dishes for viable cells every two days. 
For selecting the optimal plating density, use a plating density that allows the cells to 
reach ~80% confluency before massive cell death begins (at about day 5). This is the cell 
density at which cells should be plated for selection of stable transfectants. For HeLa 
cells, we have found 2 x 105 cells/10-cm dish to be a good plating density. 
Selectable markers: 
G418 (for selection of Tet-Off Cell Lines). G418 is available in powdered form BD 
Biosciences Clontech. The effective weight is about 0.7 g per gram of powder. Make a 
10 mg/ml stock solution by dissolving 1 g of powder in approximately 70 ml of DMEM 
(without supplements). Filter sterilize and store at 4°C. Maintenance (HeLa cells): 400 
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µg/ml. 
Puromycin (for selection of double-stable Tet-Off cells) Available from BD 
Biosciences Clontech. Maintenance (HeLa cells):1 µg/ml; Selection 0.5–5 µg/ml. 
Zeocin™ is the commercial name of a special formulation containing Phleomycin is 
available form Cayla, Toulouse France. This antibiotic of the bleomycin family is 
particularly useful for identification and selection of a variety of cell types harboring 
vectors carrying Zeocin™ resistance genes. Maintenance: 80 µg/ml; Selection 100–500 
µg/ml. 
 
2.2.5.2. Stably Transfection and Selection of Double-Stable Cell Lines 
The next step is to stably transfect the stable HeLa Tet-Off cells line with the 
pTRE-Gene X construct. The goal is to generate a cell line that gives low background 
and high expression of Gene X when tested in Western blot analysis. Both expression 
levels and induction of Gene X can be profoundly affected by the site of integration. 
Insertion near an enhancer may result in high basal expression of Gene X, whereas other 
insertion sites may result in suboptimal induction. To find the clone with the highest 
induction and lowest background, it is recommend growing and analyzing as many 
clones as possible. In general, test at least 15 clones. 
1. Grow the HeLa Tet-Off cells to 60-80% confluency in 10 cm culture dishes, each 
containing 10 ml of the DMEM complete medium. 
2. Transfect cells with pTRE2pur-Gene X (PIAS1 or SP3) by FuGene6 or calcium 
phosphate method. 
3. Replace medium with fresh DMEM complete medium containing the selection 
antibiotic (1 µg/ml Puromycin) every four days. Fresh Tetracycline must be added every 
two days for Tet-Off cells. 
4. After about five days, cells should start to die. Split cells if they reach confluency 
before massive cell death begins. After 2–4 weeks, the Puromycin -resistant colonies 
will begin to appear. 
5. Using cloning cylinders or cloning discs isolate large, healthy colonies and 
transfer them to 3 cm diameter multiwell plates for further propagation in selective 
medium. Isolate as many clones as possible. 
6. Once you have developed a suitable double-stable Tet-Off cell line, prepare 
frozen aliquots to ensure a renewable source of the cells. 
7. When expression constructs for biotin ligase (pBUD-BirA or pBUD-tTA-BirA) 
were cotransfected at step 2 with pTRE2pur-Gene X (PIAS1 or SP3), the medium 
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containing the selection antibiotic for pTRE2pur-Gene X (1 µg/ml Puromycin) is 
supplemented with the selection antibiotic for biotin ligase (80 µg/ml Zeocin). 
 
2.2.6. Luciferase Assay 
1. Wash cells with ice-cold PBS three times (to remove all Ca which inhibits 
luciferin if cells were transfected by calcium phosphate method). 
2. Add 100 µl Cell lysis buffer to the cell pellet from each 35mm dish (350 µl for a 
60mm dish) 
3. Transfer the lysate in an Eppendorf tube. 
4. Spin at 12000 rpm, 40C for 10 min. 
5. Luciferase assay was performed by adding 100 µL of cell lysate into individual 
luminometer tubes containing 360 µL of luciferase assay buffer on ice. Place the tube in 
the luminometer. Light was measured with an AutoLumat 953 luminometer (Berthold) 
by injecting 100 µL of 0.2 mM luciferin solution into the sample tubes and measuring 
light output over 10 sec (Brasier et al., 1989). 
The concentration of total protein in the lysate was determined by the Bradford 
assay.  
Buffers: 
Cell lysis buffer: 1%(v/v) Triton X-100, 25 mM glycylglycine, pH 7.8, 15 mM 
MgSO4, 4 mM EGTA and 1 mM DTT. 
Luciferin solution: For 2,5 ml: 500 µl of 1 mM Luciferin, 1 ml of 50 mM 
glycylglycine, 1 ml bidistilled H2O, 5 µl of 1M DTT. 
Luciferase assay buffer: 25 mM glycylglycine, pH 7.8, 15 mM potassium 
phosphate, pH 7.8, 15 mM MgSO4, 4 mM EGTA, 2 mM ATP and 1 mM DTT 
 
2.2.7. Biochemical Methods 
2.2.7.1. Isolation of Proteins from Eukaryotic Cells 
2.2.7.1.1. High salt nuclear extract preparation by high salt extraction method 
For the immunoprecipitation and Western-Blot analysis. 
Procedure: 
1. Aspirate old media from 90 mm plate of adherent cells.  
2. Wash with PBS. 
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3. Add dropwise 1 ml ice-cold PBS and swirl the plate. 
4. Scrape the cells and transfer in 1.5ml Eppendorf tubes. 
5. Centrifuge 10 sec, 13000rpm. 
6. Aspirate the supernatant and resuspend the pellet in 400 µl Buffer B. 
7. Incubate in ice for 10 min. 
8. Centrifuge 10 sec, 13000rpm. 
9. Aspirate the supernatant and resuspend the pellet in 50 µl Buffer C. 
10. Incubate in ice for 20 min. 
11. Centrifuge 2 min, 13000rpm. 
12. Aliquot the supernatant (nuclear extract) in new 1.5ml Eppendorf tubes. 
 
Proteinase inhibitors PMSF (Phenylmethylsulfonylfluorid) and PIC (Protease 
Inhibitor Cocktail (Roche, Mannheim) were fresh added to the Buffer B und C, along 
with DTT. The purpose of the DTT (Dithiothreitol) is to prevent aggregation due to 
disulfide formation between newly exposed cysteines. Fresh DTT should be present 
through the initial steps of the nuclear extract preparation and immunoprecipitation. The 
reason to use fresh DTT is that it is possible that the DTT will lose its reducing power if 
stored at a dilute concentration.  
10 mM N-ethylmaleimide (NEM) can be added to lysis buffers in order to prevent 
deSUMOylation.  So far, I did not observe augmentation of Sp3 SUMOylation after 
adding NEM or phosphatase inhibitors like 1 mM Sodium orthovanadate (Na3VO4), 10 
mM p-nitrophenylphosphate, 1 mM Sodium fluoride (NaF). 
 
Buffer B: 10 mM HEPES/KOH pH 7.9; 1.5mM MgCl2; 10 mM KCl; 0,5 mM DTT; 
0.2 mM PMSF; 1x PIC; 
Buffer C: 20 mM HEPES/KOH pH 7.9; 1.5mM MgCl2; 420 mM NaCl; 0.2 mM 
EDTA;  25%Glycerin; 0,5 mM DTT; 0.2 mM PMSF; 1x PIC. 
 
2.2.7.1.2 Total SDS Cell Extract Preparation: 
For the immunoprecipitation and Western-Blot analysis. 
Procedure: 
1. Aspirate old media from the plate. 
2. Wash with 1xPBS. 
3. Add dropwise 100 µl Lysis Buffer and swirl the plate. 
4. Scrape the cells and transfer in 1.5ml Eppendorf tubes. 
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5. Boil the lysate for 10 min. 
6. Centrifuge 10 min, 13000rpm at 40C. 
7. Aliquot the supernatant (SDS cell extract) in new 1.5ml Eppendorf tubes. 
Lysis Buffer:  - Mix one part Lysis Buffer I with two parts of Lysis Buffer II (ex: 
1ml Lys I + 2ml Lys II) 
Lysis Buffer I: 5% SDS; 150mM TRIS/Cl pH 6,7; 30% Glycerol. 
Lysis Buffer II: 25mM TRIS/Cl pH 8,2; 50mM NaCl; 0,5% NP – 40; 0,1% SDS; 
0,1% Na Azid. 
Fresh Added: 5mM DTT; 0.2mM PMSF; 1x PIC. 
 
2.2.7.1.3. Total SDS Cell Extracts from Mouse Organs:  
Procedure: 
1. Weigh fresh organs and dice into very small pieces using a clean razor blade.  
2. Disrupt and homogenize tissue in 3 ml SDS Lysis Buffer per gram of tissue with a 
Dounce homogenizer or a Polytron device. When using a mechanical homogenizer, 
begin homogenization at slow speeds until the tissue is broken into smaller pieces and 
then increase the speed to the maximum for 45-60 seconds. Avoid the generation of 
excess heat or foam. Transfer homogenized tissues to new 2 ml Eppendorf tubes. 
3. Boil the lysate for 10 min. 
4. Centrifuge 10 min, 13000rpm at 40C. 
5. Transfer supernatants to new 1.5ml Eppendorf tubes and centrifuge again. Pool 
supernatants in the same tube. The supernatant fluid is the whole-cell lysate. Sometimes 
a longer centrifugation is necessary to obtain a clarified lysate.  
6. Aliquot and store at –80°C. Avoid freeze/thaw cycles.  
 
2.2.7.1.4. Radioimmunoprecipitation (RIPA) Lysate of Cells: 
 
For the immunoprecipitation and Western-Blot analysis. 
Procedure: 
1. Place cells on ice. 
2. Wash cells with ice cold PBS to remove media. 
3. Add 1 ml RIPA buffer to 100 mm plate. Scale up or down as necessary. 
4. Scrape cells into RIPA buffer and transfer to small centrifuge tube. 
5. Let stand on ice for 10 min, vortexing every few minute to dissolve material. 
Lysates can also be passed through a needle several times to ensure adequate 
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solubilization. 
6. Centrifuge 10 min, 13000 rpm at 40C. 
7. Aliquot the supernatant and store at –80°C or use for protein assays. 
 
RIPA Buffer: 150 mM NaCl; 10 mM Tris, pH 7.2; 0.1% SDS; 1% Triton X-100; 1% 
Deoxycholate; 5 mM EDTA. Add protease inhibitors in final concentrations of: 5 mM 
DTT, 0.2 mM PMSF, 1x PIC. 
 
2.2.7.1.5. Nuclear Extract Preparation for Gel Filtration 
 
Procedure: 
1.  Wash the dishes once with PBS at RT. 
2.  Add 5 ml ice cold PBS and harvest the cells with rubber policeman. Then collect 
the cells to 15 ml Falcon tube and centrifuge at 1200 rpm, 40C for 5 min. 
3.  Remove supernatant and resuspend the pellet with 1 ml of hypotonic buffer. 
4.  Incubate in ice for 20 min. 
5.  Transfer the cells to a 5 ml glass Dounce homogenizer and homogenize with 20- 
25 strokes using pestle B. 
6.  Centrifuge at 2800 rpm, 40C for 5 min. 
7.  Remove supernatant and resuspend the pellet with 200 µl of Lysis Buffer. 
8.  Incubate in ice for 20 min. 
9.  Add 200 units Benzonase and incubate at 16 0C for one hour. 
10. Add 100 units Benzonase and incubate at 16 0C for an additional hour. 
11. Centrifuge at 13000 rpm, 40C for 15 min. 
12. Transfer the supernatant in new 1.5ml Eppendorf tube. 
 
Solutions: 
Benzonase (Sigma) is a genetically engineered endonuclease from Serratia 
marcescens. This promiscuous endonuclease attacks and degrades all forms of DNA and 
RNA (single stranded, double stranded, linear and circular) and is effective over a wide 
range of operating conditions. It is ideal for a wide variety of applications where 
complete digestion of nucleic acids is desirable. 
Hypotonic buffer: 10 mM HEPES, pH 7.9; 3 mM MgCl2; 10 mM NaCl.  
Lysis Buffer: 50 mM TRIS pH 8.0; 50 mM NaCl; 2 mM MgCl2; 1 mM EDTA; 0,5 
% (v/v) NP-40. 
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 Add following protease inhibitors to hypotonic buffer and high salt buffer 
immediately before use: 5 mM DTT; 0.2 mM PMSF and 1x PIC. 
 
2.2.7.2. Immunoprecipitation  
Immunoprecipitation (IP) is a highly specific and effective technique for analytical 
separations of target antigens from cell lysates or culture supernatants. 
Immunoprecipitation involves the interaction between a protein and its specific antibody, 
the separation of these immune complexes with Protein G or Protein A, and the 
subsequent analysis by SDS-PAGE. By combining IP with other techniques, such as 
SDS-PAGE and immunoblotting, it can be used to detect and quantify antigens, 
determine relative molecular weights, monitor protein turnover and post-translational 
modifications, and check for enzyme activity.  
  The procedure can be divided into several stages:            
 
 
A. Cell Lysate Preparation 
 Selecting cell lysis conditions is very critical and has to be optimized with regard to 
cell type and how the antigen is to be used. Whereas cells without cell walls (e.g. animal 
cells) are easily disrupted by treatment with mild detergent, other cells may need some 
type of mechanical shearing such as sonication or Dounce homogenization. The choice 
of lysis buffer is critical and dependent on the nature of the protein to be 
studied. Increasing the salt concentration, decreasing the detergent concentration, or 
changing the detergent to Triton X-100, Saponin, Digitonin, CHAPS or others are steps 
that can be taken to optimize conditions for immunoprecipitation.  This protocol is 
optimized for RIPA cells lysates and high salt nuclear extracts. Total SDS cell extracts 
were also successfully used for IP but all procedures were performed at room 
temperature in order to avoid SDS precipitation.  
 
B. Cell Lysate Preclearing 
The preclearing step is incorporated into the procedure to lower the amount of 
non-specific contaminants in the cell lysate and to remove proteins with high affinity for 
Protein G or Protein A. The success of immunoprecipitation depends on the affinity of 
the antibody for its antigen as well as for Protein G or Protein A.  In general, while 
polyclonal antibodies are best, purified monoclonal antibodies, ascites fluid, or 
hybridoma supernatant can also be used.  Protein G coupled to some insoluble matrix 
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(e.g. Sepharose beads) binds well to most subclasses of rat immunoglobulins and mouse 
IgG1, while Protein A binds much better to mouse IgG2a, IgG2b, and IgG3. For the IP, a 
combination 1:1 of Protein G and Protein A Sepharose Fast Flow (Amersham Pharmacia 
Biotech, Freiburg) was used. 
1. Transfer 50µl of each Protein G and A beads slurry to an Eppendorf tube and add 
400 µl cold Lysis Buffer.  Spin at 13000 rpm for 30 seconds and remove the Lysis 
Buffer.  Wash one more time with 500 µl of cold Lysis Buffer.  Resuspend the beads in 
100 µl of cold Lysis Buffer. 
2. Add this 50µl of prepared Protein G and A beads slurry and 500 µl of Cell Lysate to 
an Eppendorf tube and incubate on ice for 30-60 minutes.   
3. Spin at 13000 rpm for 10 minutes at 40C and transfer the supernatant to a fresh 
Eppendorf.  If any bead has been transferred, spin again and carefully transfer the 
supernatant to another fresh Eppendorf tube. 
 
 
C. Immunoprecipitation 
1. Add 5-10 µg of antibody to the Eppendorf tube containing the cold precleared 
lysate. 
2. Incubate at 40C for 1 hour.   
3. Add 50 µl of washed Protein G and A beads slurry in prechilled Lysis Buffer 
(prepared as instructed in Preclearing Step from above). 
4. Incubate for 1 hour at 40C on a rocking platform or a rotator. 
5. Spin the Eppendorf tube at 13000 rpm for 30 seconds at 40C. 
6. Carefully remove supernatant completely and wash the beads 3-5 times with 
500µl of Lysis Buffer. To minimize background, care should be given to remove the 
supernatant completely in these washes.  
7. After the last wash, aspirate supernatant and add 50µl of 2X Laemmli sample 
buffer to bead pellet.  Vortex and heat to 90-100 0C for 10 minutes. 
8. Spin at 13000 rpm for 5 minutes, collect supernatant and load onto the gel. 
Supernatant samples can be collected and kept frozen at this point. 
            
2.2.7.3. Two-Step Affinity Purification 
Usually proteins targeted for purification with their associated partners are modified 
by addition of a peptide suitable for affinity purification. Fusion of the target protein 
sequence and peptide tag coding sequence is done using standard DNA cloning 
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techniques. The recombinant gene thus created is then introduced and expressed in the 
cognate host. For higher eukaryotes transient or stable transfections are performed. In 
our laboratory, was developed a variant of the TAP tandem affinity purification method 
(Rigaut et al., 1999). Our method is based on two successive affinity chromatography 
steps of cell extracts from mammalian cells expressing tagged protein of interest (PIAS1 
or Sp3). The tag fused to a target protein is composed of BiotinTAG having very high 
affinity for Streptavidin, a TEV protease cleavage site and calmodulin binding peptide 
having high affinity for calmodulin (CTB tag). The BiotinTAG becomes biotinylated 
upon coexpression of BirA biotin ligase. 
 
Procedure: 
1. The HEK293 nuclear extract (approx. 100 µl) containing biotinylated CTB tagged 
protein, was diluted 1: 10 in IPP150 buffer in the presence of 5 mM DTT; 0.2 mM PMSF 
and 1x PIC in 1.5 ml Eppendorf tube.  
2. Incubate the diluted nuclear extract with 50 µl Streptavidin Agarose beads (Novagen, 
USA). Slowly rotated the tube for 1 hour at 4°C.  
3. Spin the Eppendorf tube at 13000 rpm for 30 seconds at 40C. 
4. Carefully remove supernatant completely and wash the beads 3 times with 1ml of 
IPP150 buffer and once with TEV cleavage buffer. 
5. Incubate the Streptavidin beads for 2h at 16 0C with 5 units recombinant TEV 
protease (Invitrogen) in 300µl TEV cleavage buffer.  
6. Spin the Eppendorf tube at 13000 rpm for 30 seconds at 40C. 
7. Carefully transfer the supernatant in new 1.5ml Eppendorf tube and equilibrate 1:3 
with Calmodulin binding buffer and 3 µl of 1 M CaCl2. 
8. Incubate with 50 µl calmodulin affinity resin (Stratagene) which had been washed 
with calmodulin binding buffer. Slowly rotated the tube for 1 hour at 4°C.  
9. Spin the Eppendorf tube at 13000 rpm for 30 seconds at 40C.  
10. Carefully remove supernatant completely and wash the beads 3 times with 1ml 
calmodulin wash buffer.  
11. After the last wash, aspirate supernatant and add 50µl of 2X Laemmli sample buffer 
to bead pellet.  Vortex and heat to 90-100 0C for 10 minutes.  
12. Alternatively, elute in five fractions of 100 µl with calmodulin elution buffer 
followed by TCA precipitation. 
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Solutions: 
IPP150: 10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.1 % NP-40. 
TEV cleavage buffer: 10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.1 % NP-40; 0.5 
mM EDTA; 1 mM DTT (freshly added). 
Calmodulin binding buffer: 10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.1 % NP-40; 
10 mM β-Mercaptoethanol; 1 mM MgAc; 1 mM Imidazol; 3 mM CaCl2. 
Calmodulin wash buffer: same as calmodulin binding buffer but 1 mM CaCl2. 
Calmodulin elution buffer: same as calmodulin binding buffer but 2 mM EGTA 
instead of CaCl2.  
TEV Protease. Recombinant (rTEV) is a site-specific protease purified from E. coli 
by poly histidine tag. The protease can be used for the removal of affinity tags from 
fusion proteins. The seven-amino-acid recognition site for rTEV is 
Glu-Asn-Leu-Tyr-Phe-Gln-Gly with cleavage occurring between Gln and Gly. The 
optimal temperature for cleavage is 30°C; however, the enzyme can be used at 
temperatures as low as 4°C. Following digestion, TEV Protease can be removed from 
the reaction via the poly histidine tag sequence (by affinity chromatography). 
 
2.2.7.4. TCA (Trichloroacetic Acid) Protein Precipitation  
To concentrate proteins for analysis by SDS PAGE: 
If a small amount of protein is to be precipitated (less than a few micrograms), add 
Insulin as a carrier protein (10 micrograms of Sigma insulin, per sample works well).  
1.  Add an equal volume of 20% TCA (dissolve 500g TCA into 350 ml dH2O, store 
at RT) to protein sample.  
2.  Incubate 30 min on ice.  
3.  Spin in microfuge at 4°C for 15 min.  
4. Carefully remove all supernatant, leaving protein pellet intact. Pellet should be 
formed from whitish, fluffy precipitate. 
5.  Add 300 µl cold acetone and spin 5 min at 4°C.  
6.  Repeat steps 4-5 for a total of 2 acetone washes. 
7.  Remove supernatant and dry pellet for 5-10 min to drive off acetone.  
8.  Resuspend samples in 2x loading buffer and boil sample for 10 min in 95°C 
before loading sample onto polyacrylamide gel. If the sample color turns yellow (acidic 
pH), add 1-5 drops of 1M NaOH until the sample turn into blue again. 
Materials and Methods 
 86
2.2.7.5. Determination of Protein Concentration  
Protein concentration was determined according to Bradford (Bradford, 1976) using 
the Bio-Rad protein assay (Bio-Rad, München). This measurement is based upon 
Coomassie® Brilliant Blue G-250 dye-binding assay. Acryl-cuvettes (Sarstedt, 
Nümbrecht) were used for the determination of protein concentration. 200 µl Bio-Rad 
Protein Dye (Bio-Rad) were added to samples and standard (BSA, bovine serum 
albumine) (0-50 µg / 0.8 ml H2O with diluted sample isolation buffer), afterwards they 
were gently mixed to avoid bubbles. After 10 min, the measurement was carried out in 
the photometer (Pharmacia LKB) at 595 nm. 
 
2.2.8. Western Blotting 
2.2.8.1. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
For immunodetection of the proteins a Western Blot was performed. 
The denatured polypeptides bind SDS and become negatively charged. Because the 
amount of SDS bound is usually proportional to the molecular weight of the polypeptide 
and is independent of its sequence, the mobility of protein-SDS complexes in 
polyacrylamide gels is inverse proportional to the size of the protein. By using markers 
of known size it is therefore possible to estimate the molecular weight of a protein 
(Rainbow-Protein-marker from Amersham, Braunschweig). 
For most purposes a 6 or 8 % resolving gel was prepared. The gel solution was 
poured into the assembled gel mold between two glass plates separated by 1 mm thick 
spacers leaving some 1 cm space for the stacking gel. The gel surface was overlaid with 
water or n-butanol in order to prevent inhibition of polymerization by oxygen. After 
polymerization was complete (30 min) the stacking gel (always 5%) was poured on top 
of the resolving gel, and the comb was inserted.  
Samples were prepared in 1xSDS gel-loading buffer by means of a 2x concentrated 
stock solution. After having added 5% (v/v) β-Mercaptoethanol or 10% (v/v) 1 M DTT 
all samples were boiled for 3 min to denature the proteins. Both electrode reservoirs 
were filled with SDS electrophoresis buffer, the wells were cleaned and samples loaded. 
Electrophoresis was performed at 25 mA constant power until the bromophenol blue dye 
had reached the bottom of the gel. 
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2.2.8.2. Blotting 
Semidry-Blot was performed with an “Fastblot-apparatus” (Biometra, Göttingen). 
1.  Shortly before the gel is finished running, cut the following: 
One piece of Immobilon (PVDF) the size of the gel to be blotted. Exclude the stacker 
area and any side(s) not used. 
Six pieces of Whatman paper slightly larger (1 mm) than the membrane. 
2.  Wet the PVDF membrane with methanol for 15 seconds. Rinse with distilled 
water for 2 min then wet the membrane with Anode buffer 2. 
Wet two pieces of blotting paper with Anode buffer 1; one piece with Anode buffer 2 
and the last three pieces of Whatman paper with Cathode buffer. 
3.  When the electrophoresis is finished, discard the buffer and remove the 
sandwich from the rig. 
4. Remove side spacers and with a spatula or razor blade "pop" the plates apart and 
allow the gel to fall onto one of the plates. Cut off the stacker and discard. Trim sides if 
necessary. Incubate the gel with Cathode buffer for 5 minutes. 
5. Carefully assembly the “sandwich” without trapping any bubbles between the 
membrane blotting papers and gel. 
6.  Place the two blotting papers wetted with Anode buffer 1on the bottom plate of 
the transfer unit. Place the remaining pieces of blotting on following order: blotting 
papers wetted with Anode buffer 2, the membrane, the gel and last three pieces of 
Whatman paper wetted with Cathode buffer. Put the top plate of the transfer unit, 
carefully. Run for 90 minutes at 2.5 mA/cm2 membrane. 
 
2.2.8.3. Blocking and Incubation With Antibodies 
Non-specific binding sites were blocked by incubating the membrane in blocking 
solution for 2 h at room temperature or ON in the cold under shaking. The blocking was 
then followed by a washing step. Washing steps were performed by successive 
incubations of the membrane in an excess of TBS-T: one time for 15 minutes and three 
times for 5 minutes. Washing was performed at room temperature and under shaking. 
The membrane was then placed into a metal box and incubated with the primary 
antibody for 1 h at room temperature under shaking. After removing the antibodies, the 
membrane was washed, incubated with the (1/10000) diluted secondary antibodies 
(Anti-mouse IgG, HRP linked with whole antibody (from sheep) and Anti-rabbit IgG, 
HRP linked with whole antibody (from donkey) (Amersham Life Science) or 
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Streptavidin conjugate HRP for 1 h at room temperature under shaking and washed 
again. 
2.2.8.4. ECL-Detection 
The solution (1,025 ml per mini blot) was freshly prepared (from ECL™ Plus 
detection system Amersham Biosciences, Freiburg), by mixing 1ml of solution A (0,4 
mM p-coumaric acid (= 4-hydroxycinnamic acid), 100 mM Tris, pH 8,5) and 25 µl 
solution B (2,5 mM luminol (= 3-aminophthalhyrdrazide), 100 mM Tris, pH 8,5) and 
added to the protein side of the blot. After incubating for 3 min, excess detection reagent 
was drained off. The membrane was placed into a film cassette and exposed to a sheet of 
autoradiography film (BioMax X-rayfilm - Kodak) in a dark chamber. The expositions 
were performed from 10 sec to 1 h depending on the strength of the signal. The film was 
immediately developed. 
 
Buffers: 
Cathode buffer: 25 mM Tris/HCl pH 9.4; 40 mM Glycine; 10% Methanol.                          
 
Anode buffer 1: 0.3 M Tris/HCl pH 10.4; 10% Methanol.                                 
 
Anode buffer 2: 25 mM Tris/HCl pH 10.4; 10% Methanol.                                 
 
 
Blocking solution: 0.01% Tween-20 and 5% Skimmed milk in 1xTBS dissolved.                    
 
Wash buffer: 1 x TBS; 0.1 % Tween-20. 
 
Stacking gel:                                                        
 
 
 
 
 
 
 
 
 
H2O                                    13875 µl 
30% Acrylamide:Bisacrylamide (29:1)      600 µl 
0,5 M Tris/HCl pH 6,8                       625 µl 
10% SDS    25 µl 
10% APS (Ammoniumpersulfate)             25 µl 
TEMED                                      2,5 µl 
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Resolving gel:     
   6%           8%  10%     
H2O  3.98 ml         3.48 ml        2.98 ml 
30%Acrylamide:Bisacrylamide (29:1)  1.5 ml            2 ml         2,5 ml 
1.5M Tris/HCl pH 8.8                  1,86 ml         1,86 ml 1,86 ml 
10% SDS   75 µl   75 µl   75 µl 
10% APS    75 µl   75 µl   75 µl 
TEMED   10 µl   10 µl   10 µl 
 
2.2.8.5. Stripping of the Membrane 
Keep the membrane wet if you plan to strip and re-use it. Once a membrane has dried, 
stripping will be ineffective. PVDF membranes may be stripped. Nitrocellulose 
generally does not strip well. 
1. Wash membrane for one hour in Stripping buffer with gentle shaking at room 
temperature. 
2.  Rinse the membrane in blocking buffer, two times for 30 minutes. 
3. Incubate the membrane in blocking solution for 1 h at room temperature. R 
4. Repeat incubation with antibodies step.  
Stripping buffer: 4 ml of 10 % SDS; 1.24 ml of 1M Tris/HCl pH 6,8; 140 µl of 
β-Mercaptoethanol and H2O to 20 ml.  
2.2.9. Immunostaining 
Immunostaining cells on coverslips or minichambers: 
1. Cells should be plated in 24 well Tissue Culture Plates (Greiner Labortechnik) 
containing coverslips (13 mm diameter) or Lab-Tek® Chambered Coverglass (Nalge 
Nunc International Corp., USA).  
Fix cells when the cell density is not too high so the cells will not be crammed 
together. Usually plating at 5x104 cells per well will be acceptable for next day use. 
2. Prepare fixing solution just before use: I usually use 4% paraformaldehyde in 
phosphate-buffered saline PBS cells.  
3. Remove media from wells and rinse cells once in ~1ml PBS (room temperature).  
4. Remove PBS and add 0,5ml of 4% paraformaldehyde in PBS. Incubate at room 
temperature for 25 min. 
5. Remove fixing solution and wash 2 times for 5min with PBS. 
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6. Permeabilize cells by incubation in 0.2 % Triton X-100 in PBS for 20 min at RT. 
7. Block: Incubate fixed and permeabilized cells in blocking solution (3% BSA 
-bovine serum albumin in PBS) for 60 min. 
8. Prepare primary antibody solutions diluted in blocking buffer (150 µl/coverslip). 
9. Transfer coverslips to a box containing moist filter covered with parafilm. Mark a 
grid on the parafilm to help keep track of the coverslips. Lay the coverslips cell-side-up 
on the parafilm. Only transfer a few at time so they don't dry out. 
10. Apply antibody solution to each coverslip. Incubate in primary antibody for 1 
hour at RT or overnight at 4°C. 
11. Wash the coverslips 3 times with PBS, 5 min/wash. 
12. Prepare appropriate secondary fluorescent-labeled antibody solutions and apply 
to coverslips as above. Dilute antibodies in the blocking solution. 
13. Incubate coverslips for 1 hour at RT in a dark cabinet. 
14. Wash coverslips as above in PBS. 
15. Mount the coverslips onto glass slides (can put two on each slide) using 
mounting media that contains an anti-bleaching agent (Vectashield Mounting Media 
with DAPI -4, 6-diamidino-2-phenylindole from Vector Laboratories, Inc., 30 Ingold 
Road, Burlingame, CA 94010 U.S.A.). 
Aspirate excess mounting liquid from the slide and seal coverslip in place with clear 
nail polish. 
Fluorescence was analyzed using a Leica DMLB or Leitz Orthoplan microscope 
using a filter with maximum excitation at 480 nm and maximum emission at 520 nm for 
green fluorescence or one with maximum excitation at 550 nm and maximum emission 
at 600 nm for red fluorescence. 
Confocal images were recorded using the Radiance 2000 confocal system produced 
by Bio-Rad Cell Science Division (Hemel Hempstead, United Kingdom) adapted to an 
Eclipse T300 inverted microscope (Nikon Corporation, Tokyo, Japan). The imaging 
objective was PlanApo, 60x (1.4 N.A., oil immersion, Nikon Corporation, Tokyo, 
Japan). 
10% Paraformaldehyde (PFA) stock (for preparation of 50 ml). Weigh out 2g of 
paraformaldehyde (special EM grade). Add to 50 ml H2O in a 10ml backer glass and stir. 
The PFA will not go in to solution yet. Heat in 65°C water bath. Add 4-5 drops of 1M 
NaOH to the suspension and stir vigorously. The PFA will begin to dissolve. Continue 
heating until most of it is dissolved. Any remaining undissolved PFA can be filtered out 
using a 0.22 disposable filter.
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 3. Results 
3.1. Modification of Sp3 Transcription Factor by SUMO 
3.1.1. Overexpressed Sp3 is SUMOylated in vivo 
At a functional level, there have been reports on the transcriptional properties of 
Sp3 in comparison with Sp1 based on co-transfection experiments into the insect cell 
line SL2. Sp1 acted as a strong transcriptional activator while Sp3 remained inactive or 
acted only as a very weak activator (Hagen et al., 1994; Majello et al., 1994; Dennig et 
al., 1995). The molecular basis for the inactivity of Sp3 has been mapped to an 
inhibitory domain located between the second glutamine-rich activation domain and the 
first zinc finger. Detailed mutational analyses further revealed that a single lysine 
residue (K551) is responsible for the low transcriptional activity of Sp3 (Fig 3.1). A 
database search highlighted that lysine 551 within the inhibitory domain falls into a 
SUMO consensus sequence, namely ϕ -Lys-X-Glu (where ϕ is a large hydrophobic 
amino acid, most commonly isoleucine or valine, and X is any residue), (Hay, 2001). 
 
          
Fig. 3.1. Lysine 551 of Sp3 is responsible for the inactivity of Sp3. Color code: red - 
Activation Domains (AD); blue – Inhibitory Domain (ID); black – zinc finger DNA 
Binding Domain. (Diplomarbeit A. Ertmer). 
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3.1.1.1. Overexpression Systems 
We asked whether Sp3 could act as a substrate for SUMO modification in vivo. The 
experimental approach used to address this question was to examine if overexpressed 
Sp3 in mammalian cells is subjected to SUMOylation. It was reported that 
SUMO-modified proteins have a ~20 kDa higher apparent molecular weight by 
Western blot analysis compared with unmodified proteins (Melchior, 2000).  
In order to investigate SUMOylation of overexpressed Sp3, I first determined the 
best transfection system for mammalian cell lines. Ideally, an overexpression system 
would permit straightforward detection of Sp3 and potentially SUMO-modified Sp3. 
Six different transfection techniques were tested (Fig.3.2), as well as three classical 
methods: the PEI, DEAE-dextran and Ca-Phosphate methods and three commercially 
available transfection reagents: Effectene (based on activated-dendrimer technology), 
FuGene6 (non liposomal transfection reagent) and Lipofectamine (liposomes based 
reagent). Ishikawa cells were transfected with an equal amount of pGL3-control vector 
used for general monitoring of transfection efficiency by the Luciferase Assay Method.  
   
Fig. 3.2. Different transfection methods were tested for Ishikawa cell line. 
One µg of pGL3-control vector was transfected using transfection methods as 
indicated. Luciferase activity was measured from samples containing the equal amount 
of protein. Control is Luciferase assay buffer and NT represents nontransfected cells. 
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Transfections were performed according to standard protocols and manufacturers 
instructions respectively (see Methods 2.2.4. Transient Transfection and Transfection 
Methods). As seen in Fig. 3.2, the best transfection was obtained with FuGene6 non- 
liposomal transfection reagent from Roche. During my experimental work I found this 
transfection method also reliable for other mammalian and Drosophila SL2 cell lines. 
In attempting to discover a better transfection method, I tried out other transfection 
reagents like the commercial available JetPei, Lipofectamine Plus, Lipofectine or self 
prepared liposomes by combining different cholesterol derivatives, but ample 
augmentation in transfection efficiency was not observed. In conclusion, I decided to 
use the FuGene6 for most of the overexpression experiments. 
3.1.1.2. Sp3 is Subject to Posttranslational Modification by SUMO1 and SUMO2 
in vivo 
Having established an appropriate expression system, we tried to answer the main 
question: whether transiently expressed Sp3 is SUMO modified in vivo by the 
endogenous SUMOylation machinery and if this modification is detectable by Western 
Blot analysis. Another key question was which member of the SUMO family is 
involved in Sp3 modification knowing that SUMO proteins from metazoa can be 
divided into two families, SUMO1 proteins and SUMO2/SUMO3 proteins. 
A convenient solution chosen to address these questions applied the use of GFP 
fusion constructs that contained either wt Sp3 cDNA or Sp3 cDNA with a lysine to 
arginine amino acid exchange at the putative SUMO target site K551 (Sp3K/R). GFP 
fusion constructs for SUMO1 and SUMO2 were also used as they were expressed at a 
much higher level than the corresponding CMV-driven fusions with other tags (HA, 
FLAG), (data not shown). The GFP system has many powerful advantages. One can 
verify transfection efficiency by counting living cells expressing fluorescence and 
highly specific antibodies against GFP protein are commercially available. 
I transfected gene constructs encoding GFP-Sp3WT or a mutant thereof 
(GFP-Sp3K/R) into Ishikawa cells alone (Fig. 3.3 lanes 1, 2, 3 and 6) or with 
SUMO1/2 GFP fusion constructs (Fig. 3.3 lanes 4, 5, 7 and 8). To avoid loss of 
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SUMOylation by highly active SUMO specific proteases, whole cell lysate extracts 
were prepared in denaturing SDS lysis buffer. 
Only GFP-Sp3WT but not the GFP-Sp3K/R mutant was modified presumably by 
endogenous SUMO proteins, observed as a slower migrating Sp3 species with the wt 
protein (Fig. 3.3, lane 1, arrowhead). A slow-migrating form of GFP-Sp3WT was also 
detected in the presence of SUMO1 or SUMO2 fusion protein (Fig. 3.3, lanes 7 and 8, 
arrow). It was similarly abundant in the presence of SUMO1 or SUMO-2. Thus, both 
SUMO1 and SUMO2 were efficiently conjugated to Sp3 when overexpressed in vivo. 
In contrast, a slow migrating protein was absent with the GFP-Sp3K/R mutant 
although GFP-SUMO1 and GFP-SUMO2 were expressed at high levels (Fig. 3.3, lanes 
4 and 5). The presence of two GFP-SUMO2 forms is most likely due to incomplete 
processing. 
 
 
 
Fig. 3.3. Sp3 is SUMO modified in vivo.  
GFP fusion vectors (3 µg) for GFP-Sp3WT, GFP-Sp3K/R, GFP-SUMO1 and 
GFP-SUMO2 were transiently transfected in Ishikawa cells as indicated. Cells were 
lysed and equal amounts of total cellular proteins (20 µg per lane) were separated by 
6.0% SDS-polyacrylamide gel and blotted to PVDF membranes. Detection was by 
immunoblotting with anti-GFP antibodies. The arrowhead points to SUMO-modified 
GFP-Sp3WT, the arrow indicates GFP-SUMO-modified GFP-Sp3.  
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3.1.1.3. Posttranslational Modification of Sp3 by SUMO1 and SUMO2 is not 
Temporally Controlled 
SUMO modification of proteins is a reversible process. SUMO moieties can be 
cleaved from their substrates by specific cysteine proteases like the yeast proteins Ulp1 
(Li and Hochstrasser., 1999) and Ulp2 (Li and Hochstrasser., 2003) and their 
mammalian counterparts SUSP1 (Kim et al., 2000) and SENP1 (Gong et al., 2000). 
These enzymes also process the SUMO precursor. 
The aim of this experiment was to determine how long after transfection of 
GFP-Sp3 and GFP-SUMO expression constructs, the GFP signal begins to be 
detectable in Western Blot. It was also designed to find out whether Sp3 SUMOylation 
after transient transfection is time dependent in the context of reversibility of this 
modification due to specific cysteine proteases.  
Expression constructs for GFP-fused Sp3 were transient transfected into Ishikawa 
cell lines using FuGene6 transfection reagent, along with GFP-SUMO1 or 
GFP-SUMO2 respectively. Cell extracts were prepared at different time points in SDS 
lysis buffer with added protease inhibitors to inhibit SUMO-specific proteases (see 
Methods 2.2.7.1. Isolation of Proteins from Eukaryotic Cells). 
The Sp3, SUMO1 and SUMO2 GFP fusion proteins were detectable after 12 hours 
post-transfection. Overexpressed Sp3 (GFP-Sp3 in Fig.3.4) was posttranslationally 
modified by endogenous SUMO (GFP-Sp3-SUMO) and GFP-SUMO1 or 
GFP-SUMO2 (Sp3-GFP–SUMO-GFP). A portion of transfected SUMO1 and SUMO2 
was most likely not involved in the SUMOylation process (Free-SUMO-GFP in 
Fig.3.4). Another fraction of transfected GFP-SUMO1 or GFP-SUMO2 might be 
implicated in SUMOylation of others endogenous target proteins (* asterisk marked on 
the Fig.3.4).  
Transiently transfected GFP-Sp3 and GFP-SUMO1 or GFP-SUMO2 started to be 
detectable by Western Blot analysis 12 hours post transfection. Once it was expressed, 
Sp3 was immediately modified by SUMO. The level of Sp3 SUMOylation appeared to 
be proportional to the level of total Sp3 protein therefore it was concluded that there 
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was not an optimum time point for maximum SUMOylation level. In conclusion, the 
Sp3-SUMO level seems to be constant suggesting a tight regulation of SUMOylation 
in mammalian cells. 
   
 
 
Fig. 3.4. Time course of Sp3 SUMOylation in vivo.  
GFP fusion vectors for GFP-Sp3WT, GFP-SUMO1 and GFP-SUMO2 were transiently 
transfected in Ishikawa cells as indicated. Cells were lysed at different time points as 
indicated and equal amounts of SDS cell extracts (20 µg per lane) were separated on a 
6.0% SDS-polyacrylamide gel and blotted to PVDF membranes. Detection was by 
immunoblotting with anti-GFP antibodies. The asterisk indicates one undetermined 
endogenous protein modified by SUMO-GFP.3.1.2. SUMOylation of Endogenous Sp3 
 
3.1.2.1. Endogenous Sp3 Protein Pattern 
At endogenous expression level, usually three Sp3 isoforms are detected, a 110-115 
kDa Sp3 protein and two other approximately 60-70 kDa Sp3 species. It was shown 
recently, that in vivo four isoforms of Sp3 are expressed differing in the extent of their 
amino terminus part. Detailed mutational analyses suggest that all four isoforms are 
derived from alternative translational start sites. (Sapetschnig et al., 2004). My 
previous results validate that overexpressed Sp3 is SUMOylated in vivo. 
Next we asked whether endogenous Sp3 is modified by SUMO.  
To address this question, protein extracts were prepared from Ishikawa, HEK293 
Results 
 97
and mouse ES (Sp3-/-and WT) (Göllner et al., 2001) cells. Modified 
radioimmunoprecipitation (RIPA) buffer or SDS lysis buffer were used (see Methods 
chapter). To enhance Western Blotting signals, immunoprecipitations were performed 
using anti Sp3 specific antibody (Fig.3.5, lanes 5 and 6). Four distinct species, two 
slow migrating of more than 100 kDa and two fast migrating species of approximately 
72 kDa were detected (Fig.3.5). Additional bands appeared, when cells were lysed 
directly in SDS containing buffer. Under these conditions seven to eight Sp3 species 
were visualized by immunoblots (Fig.3.5, lanes 3, 4 and 6). All signals were specific 
for Sp3 since extracts prepared from Sp3-deficient embryonic stem cells did not 
exhibit any background (Fig.3.5, lane 2). Sp1 transcription factor was also visualized 
and shown to be expressed as no modified and phosphorylated forms (Fig.3.5, lane 1).  
 
 
FIG 3.5. Complexity of endogenous Sp3 protein expression. Western blot analyses 
of Sp1 and Sp3 in wild-type ES (ES-WT, lane 3), Sp3-deficient ES (ES-Sp3-/-, lane 1 
and 2), 293 (lane 4) and Ishikawa cells (lanes 5 and 6). Cells were lysed with 
SDS-containing buffer (lanes 1-4 and 6) or with RIPA buffer (lane 5) and proteins were 
separated through 6% SDS polyacrylamide gels. After blotting, PVDF membranes were 
incubated with Sp1- or Sp3-specific antibodies as indicated. Abbreviations are: Sp3li-1 
and 2, long isoforms of Sp3; Sp3si-3 and 4, small isoforms of Sp3; Sp3li-SUMO and 
Sp3si-SUMO, SUMO-modified long and small isoforms of Sp3. For Sp1, the asterisk 
indicates the phosphorylated form. 
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High resolution immunoblot analyses with antibodies directed to the C-terminus of 
Sp3 resulted in a striking complex protein pattern that allowed detection of four 
different species, contrary to previously published results showing only one long Sp3 
isoform (Suske, 1999). It should be noted that SUMO-modified isoforms were observed 
in all cases where SDS extracts were prepared for Sp3 expression analyses. In those 
cases where nuclear extracts were generated in the absence of protease inhibitors, these 
posttranslational modified proteins were not observed presumably since hydrolases 
cleaved the Sp3-SUMO isopeptide bond. 
 
3.1.2.2. Sp3 in Sp1-Deficient Mouse ES Cells 
The structural similarity between Sp1 and Sp3 as well as their ubiquitous 
expression suggested originally that they have similar properties and exert similar 
functions. However, biochemical and biological studies highlighted significant 
differences, including different knockout phenotypes (Bouwman et al., 2000; Göllner 
et al., 2001), different posttranslational modifications and expression of different 
isoforms (Braun et al., 2001; Sapetschnig et al., 2002; Sapetschnig et al., 2004).  
The following experiments determine whether Sp3-SUMOylation or the Sp3 
expression pattern are affected under Sp1 knockout conditions.  
Mouse ES cells derived from Sp1-/-, Sp1+/- and wt embryos were maintained in 
culture in the presence of LIF to prevent differentiation. SDS total cell extracts were 
prepared in all cases to preserve SUMO modification (see Methods). 
There was no obvious difference in SUMOylation of Sp3 long isoforms 
(liSp3-SUMO) under Sp1 KO conditions as shown in Fig.3.6.A. Interestingly, the 
expression level of the small Sp3 isoforms decreased in Sp1 deficient ES cells while 
expression of the long isoforms remained constant.  
As a control, the membrane was probed with anti Sp1 serum (Fig.3.6.B). The 
expression pattern of Sp1 was seen depicted as follows: in WT ES cells (Sp1+/+) the 
Sp1 protein was detected along with its phosphorylated form (Sp1-P), in heterozygous 
cells (Sp1+/-) the expression of both Sp1 and Sp1-P was reduced and in Sp1 knockout 
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cells (Sp1-/-) only the N-terminus of Sp1 was expressed, resulting in a faster migrating 
Sp1 form (Marin et al., 1997). It should be noted that in Sp1 KO, only the Sp1 DNA 
Binding Domain was deleted. 
In conclusion, Sp3-SUMO modification in ES cells appears not to be altered. A 
significant shift towards the long isoforms of Sp3, however, was observed in Sp1-/- ES 
cells demonstrating that Sp3 isoform expression can change in vivo. In addition, this 
observation suggests that the long isoforms of Sp3 may take over Sp1 functions under 
Sp1 knockout conditions. 
 
 
 
Fig.3.6. Sp3 and Sp1 expression in Sp1-deficient mouse ES cells. 
A. Mouse ES cells derived from embryos as indicated above were lysed with SDS 
containing buffer and Sp3 expression was analyzed by Western blotting using anti-Sp3 
antibody (SC). 
B. The same blot was probed with anti-Sp1serum. 
 Abbreviations are: Sp3li-1 and 2, long isoforms of Sp3; Sp3si-3 and 4, small isoforms 
of Sp3; Sp3li-SUMO and Sp3si-SUMO, SUMO-modified long and small isoforms of 
Sp3. For Sp1, the Sp1-P indicates the phosphorylated form. 
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3.1.3. The Full-Length Overexpressed Sp3 SUMOylation 
3.1.3.1. In vivo Reconstitution of Sp3 Isoforms 
The experiments in all previously published studies about Sp3 (more than 500 
citations in Medline) were performed with N-terminally truncated versions of Sp3. 
Recently however, human genomic DNA sequences were identified that encompass 
three exons coding for additional 85 N-terminal amino acids of Sp3 (Oleksiak et al, 
2002). Within these 85 aa, two AUG codons are present (Sapetschnig et al., 2004). 
The full-length Sp3 open reading frame that starts with a classical AUG initiation 
codon was cloned in our lab.  
We asked then whether expression of the four Sp3 isoforms that were detected at 
endogenous expression levels (see chapter 1.2.1) could be reconstituted in vivo after 
transfection of appropriate expression constructs.  
Full-length Sp3 cDNA and lysine 551 mutant cDNA were cloned into the CMV 
promoter driven expression vector pN3 derived from pEGFP-N3 (Clontech), in which 
the EGFP tag was removed. An Sp3 sequence lacking the codons for the first 13aa (∆13 
Sp3) and its lysine mutant (∆13 Sp3 551K/R) were used. For cloning strategy see 
Methods chapter. 
After transfection of the wild-type full length (FL) Sp3 cDNA, two long isoforms of 
Sp3 were expressed in HEK293 cells at the similar level (Fig.3.7. A-1). In contrast, after 
expression of ∆13 Sp3 (encoding 769 aa from the 781 aa in WT), only one of Sp3 long 
isoforms was detectable (Fig.3.7. A-2).  
The endogenous Sp3 signal by Western Blot was not as strong as the signal of 
overexpressed Sp3 (Fig.3.7 compare line 2 with lines 3-6). For a better comparison of 
endogenous Sp3 expression pattern and Sp3 overexpressed in HEK293 cells, a longer 
exposure of lane 2 is shown in line1- marked Exp in the figure. The two small isoforms of 
Sp3 were produced at low level after overexpression of Sp3 constructs in HEK293 cells 
(Fig.3.7. B lines 3-6). Another important observation that results from this experiment is 
that transfected Sp3 (both full length and ∆13 Sp3) were SUMO modified in vivo (lines 3 
and 5) but the 551 lysine mutants (lines 4 and 6) were not. 
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Fig.3.7. In vivo SUMOylation of transient expressed Sp3. 
A. Separation of long Sp3 isoforms in long running SDS polyacrylamide gel after 
transfection of pN3-Sp3 full length (FL) and pN3-Sp3 ∆13 expressions constructs.  
Schematic drawing: Depicted protein structure of Sp3 full length (FL) and Sp3 protein 
lacking the N- terminus 13 aa (∆13). Arrows indicate the methionine residues 1 and 13 
translated from the in frame start codons. Color code: red - Activation Domains; blue – 
Inhibitory Domain; black – zinc finger DNA Binding Domain. 
B. Transfection of expression constructs encoding full length Sp3 cDNA and Sp3 
cDNA lacking the first 13 aa (pN3-Sp3 FL, pN3-Sp3 551K/R-FL and pN3-Sp3 ∆13, 
pN3-Sp3-551K/R ∆13 as indicated).  
Total cell SDS extracts were prepared and proteins separated through 6% SDS 
polyacrylamide gels. After blotting, PVDF membranes were incubated with Sp3 
specific antibody. 
Abbreviation:  Exp- longer exposure time of control line (2.) in order to detect 
endogenous Sp3 signal. For detection, the PVDF membrane was film exposed for 
additional time.  
Sp3li-1 and 2, long isoforms of Sp3; Sp3si-3 and 4, small isoforms of Sp3; 
Sp3li-SUMO and Sp3si-SUMO, SUMO-modified long and small isoforms of Sp3.  
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Expression of the four Sp3 isoforms was reconstituted in vivo after transfection of 
appropriate expression constructs but the small isoforms are produced at very low level. 
The same phenomenon was observed after Sp3 expression in insect Schneider cells (SL2 
cells) (see Fig. 3.24 D).  
There is only a tiny difference (13 aa) between Sp3 long isoforms (at approx. 115 
kDa) (Fig.3.7. A- schematic drawing), making discrimination among them by Western 
Blot very difficult. Despite that, one can observe the separation of isoforms after 
transfection of full length Sp3 expression construct, but not of a ∆13 Sp3 by Western 
Blot analysis.  
After overexpression, Sp3 was SUMO modified at lysine 551 in vivo in both, the Sp3 
full length and the ∆13 Sp3 proteins. 
 
3.1.3.2. Additional Potential SUMO Sites 
My previous results verify that overexpressed Sp3 is SUMO-modified at lysine 551 
in vivo. Two additional potential SUMOylation sites are present at lysine 9 and 120 
(Fig. 3.9). Lysine 9 is located within the first 13 aa of the Sp3 sequence, which means 
that the consensus site is present only in the longest isoform. Located in the first 
glutamine-rich activation domain, the second putative SUMOylation site, K120 exists 
in both long isoforms. 
 
Fig.3.9 Other potential SUMOylation sites in Sp3. The length of Sp3 refers to the 
full-length isoform (781 aa). Red boxes indicate activation domains (AD) that are rich 
in glutamine residues. The black boxes represent the zinc fingers DNA binding domain 
(DBD). ID in the blue box indicates the inhibitory domain.  
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The next experiments were designed to determine if lysine 9 or/and 120 are 
targets for SUMO modification in vivo.  
 
 
FIG. 3.10. Posttranslational modification of full-length Sp3 by SUMO.  
A. N-terminal amino acid sequence of the Sp3 protein. The potential SUMO target 
sequence VKQE present in the longest Sp3 isoform (Sp3li-1) is boxed. The SUMO 
target consensus sequence reads ΨKXE.  
B. In vivo, Sp3 becomes modified by SUMO exclusively at lysine K551. CMV-driven 
expression plasmids for N-terminally HA-tagged (HA-Sp3WT and HASp3K551R), C 
terminal HA-tagged (Sp3WT-HA and Sp3K551R-HA) or untagged Sp3 (Sp3WT and 
Sp3K551R) as indicated were transfected into Sp3-/- MEFs (lanes 1 to 9) or 293 cells 
(lanes 10 to 12). Cells were lysed with SDS-containing buffer and Sp3 expression 
was analyzed by Western blotting using anti-Sp3 or anti-HA antibodies as indicated.  
C. Schematic drawings of tagged and untagged Sp3. Color code: red - Activation 
Domains; blue – Inhibitory Domain; black – zinc finger DNA Binding Domain. 
 
To address this question, I cloned full-length versions of wild-type Sp3 or the 
K551R mutant in expression vectors such that Sp3 was either HA-epitope tagged at 
the N-terminus or the C-terminus, respectively as seen in Fig.3.10-C. 
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The expression constructs were transfected into Sp3-/- MEFs and HEK293 cells. 
Cell extracts were prepared in SDS lysis buffer and subjected to immunoblot 
analyses.  
SUMO-modified Sp3, visualized as a slower migrating species, was exclusively 
detected with the wild-type Sp3 constructs, but not with the Sp3K551R constructs 
(Fig. 3.10). If one of lysine 9 or 120 were SUMO modified, a slower migrating band 
would have been observed in all Sp3K551R Western Blot lanes in the same range as 
SUMO-Sp3 in Sp3 WT. 
This result strongly suggests that only K551 becomes SUMO-modified and not 
K9 and K120 or any other lysine residue of the Sp3 sequence. In other proteins 
containing multiple SUMO sites one can observe by Western Blot analysis the 
non-modified protein, and a ladder of slower migrating bands that correspond to the 
number of lysines SUMOylated (for example as seen in SUMOylation of 
Topoisomerase I , Mao et al., 2000). 
In Sp3 WT proteins, additional slower migrating bands were not present except 
the band shown to represent SUMO modification of Sp3 at Lysine 551. 
 
3.2. Subcellular Localization of Sp3 
3.2.1. Optimization of the Immunofluorescence Protocol  
The nucleus was one of the first intracellular structures to be identified by 
microscopy, but its functional organization is still poorly understood. It has become 
apparent that the nucleus is highly compartmentalized but extremely dynamic. Nuclear 
factors can display a diffuse nuclear distribution or are localized in distinct structures, 
such as speckles, paraspeckles, nucleoli, Cajal bodies, gems and Promyelocytic 
Leukemia bodies, that show a punctuate staining pattern when analyzed by indirect 
immunofluorescence microscopy (Spector et., 2003). 
The following analysis addresses the subcellular localization of the transcription 
factor, Sp3. Initially, visualization of Sp3 was optimized. Different protocols for 
immumofluorescence and different antibodies were tested in order to determine the 
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most suitable. A detailed immunostaining protocol is described in the Methods chapter. 
Before bringing concrete evidences about Sp3 localization, I want to point out some of 
the problems, which appeared during distinct immunofluorescence protocol steps. In 
principle, I used insect SL2 or different mammalian cell lines plated on round 
coverslips or on Permanox 8 well immunostaining chambers. Fixation of cells was 
performed with freshly prepared 4% paraformaldehyde in phosphate-buffered saline. 
I found permeabilization one of the most critical steps in immunostaining. Any 
alteration in incubation time or permeabilization buffer preparation led to artifacts, as 
demonstrated in Fig.3.11. The permeabilization buffer always contained a strong 
detergent (Triton X, NP-40) able to permeabilize the cytoplasmic membrane and the 
nuclear envelope, in order to allow antibodies and other reagents to reach cellular 
compartments.  
In Fig. 3.11.A, following permeabilization using TritonX the Sp3 signal is 
detectable in the nucleus. However, when a mild detergent (Saponin), able to 
permeabilize cytoplasmic membrane but not the nuclear envelope was used, the Sp3 
signal was detected in the cytoplasm and around nuclear periphery (Fig. 3.11.B). Likely, 
this localization reflects an artifact.  
Different localizations of Sp3 were also observed when the sample incubation with 
permeabilization buffer was less then 10 min.  
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Fig. 3.11. Sp3 localization under different permeabilization conditions.  
A. Nuclear subcellular localization of Sp3 under Triton X permeabilization conditions 
for 20 min.  
B. Sp3 signal at nuclear periphery after replacing 0.02 % Triton X with 0.05 % 
Saponin at membranes permeabilization immunodetection protocol step. 
Sp3 was detected by immunostaining in MEF cells with a rabbit anti-Sp3 antibody and a 
FITC conjugated secondary antibody. Control staining of nucleus was performed with 
DAPI. 
 
 
Another significant step in establishing the immunostaining technique was testing 
the primary antibodies at different incubation concentrations in order to diminish 
background fluorescence. 
Fig.3.12 compares cytoplasmic background caused by anti Sp3 serum with a 
commercial anti Sp3 antibody purchased from Santa Cruz. 
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Fig 3.12. Comparison of Sp3 localization in Ishikawa cells by using two different 
primary antibodies for immunodetection.  
Anti Sp3 serum or anti Sp3 commercial available antibody (from Santa Cruz) and 
AF594 conjugated secondary antibody were used for endogenous Sp3 detection by 
immunostaining. 
 
The final protocol step involves incubation with fluorophores conjugated to a 
secondary antibody. When two different sets of antibodies are used to detect 
simultaneously two different proteins, it is recommended that fluorophores with 
disparate spectra are used. The fluorophores are visualized using fluorescence 
microscopy, and independently distinguished using filter sets specific for each color. 
Images are captured with a charge-coupled device (CCD) camera. 
An observation was that fluorescence emitted by red fluorophores (AF 594, Cy5, 
Texas RED) transmits more clearly through cells than blue (AF350) or green (FITC), 
because cells absorb less energy at longer wavelengths. 
At last, coverslips were mounted onto glass slides using Vectashield mounting 
media with DAPI and sealed with nail polish. 
3.2.2. Endogenous Sp3 Localizes to Nucleus 
Having established an optimized immunostaining technique, I tried to determine 
Sp3 subcellular localization. 
The nuclear distribution of Sp3 was carefully examined and compared to the 
localization pattern of other Sp family members, In addition, the effect of 
overexpression on Sp3 localization was determined.  
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3.2.2.1. Sp3 is Distributed Throughout Nucleus  
I noticed from the preliminary Sp3 immunofluorescence experiments that Sp3 is 
predominantly located within the nucleus. Subsequent analysis investigated whether 
Sp3 displays a particular pattern or is associated with specific structures. 
 
 
 
 
Fig. 3.13.  Endogenous Sp3 is present throughout the nucleus in Ishikawa cells.  
In the upper scheme the principle of this microscopy method is depicted. The cell is 
divided in several confocal planes throughout the Z axis and the images of each plane are 
recorded separately. 
Endogenous Sp3 localization was detected with a rabbit anti-Sp3 antibody (SC) and a 
goat anti rabbit – Alexa Fluor 594 conjugated secondary antibody.  The figure shows 
the image of every third confocal plane.  
Confocal Z-stacks were recorded using the Radiance 2000 confocal system produced by 
Bio-Rad Cell Science Division (Hemel Hempstead, United Kingdom) adapted to an 
Eclipse T300 inverted microscope (Nikon Corporation, Tokyo, Japan).  
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Ishikawa cells were prepared for immunostaining according to the protocol (see 
Methods). Detection of endogenous Sp3 was performed using a rabbit anti-Sp3 
antibody and a goat anti rabbit – Alexa Fluor 594 (GAR-AF-594) conjugated secondary 
antibody. Permanent slides were used for Z series recordings with the Bio-Rad confocal 
system specially designed to record “slices” through the cell, as seen in the upper 
schematic drawing from Fig 3.13. The system was set to record 0.5 µm stacks resulting 
in approximately 60 pictures from one cell.  
Fig.3.13 shows endogenous Sp3 localization in the nucleus of Ishikawa cells by 
displaying every third frame of the Z series. This experiment demonstrates that Sp3 is 
distributed throughout nucleus and this distribution is not uniform, but rather with 
random holes giving the appearance of a “sponge-like structure”. 
 
3.2.2.2. Comparison with Localization Pattern of other Sp Family Members   
The structural similarity of the four Sp family members suggests that they are 
evolutionally closely related, although biochemical and biological studies have 
highlighted significant differences between them (Suske, 1999). To resolve the 
controversy surrounding differences or similarities between subcellular localization 
patterns of Sp family members, subcellular localization patterns were analyzed by 
immunofluorescence assays. 
Endogenous Sp1 and Sp2 were detected in HEK293 cells, using rabbit anti Sp1 and 
rabbit anti Sp2 sera, respectively. The Sp4 transcription factor could not be detected, 
neither with a rabbit serum produced and purified in our lab nor with a commercial 
available antibody from Santa Cruz. One possible explanation could be that the 
expression level of Sp4 in HEK293 cell line is very low. 
Goat anti rabbit secondary antibodies conjugated with two fluorophores: FITC 
(green) and Alexa Fluor 594 (red) were used. 
Sp1 and Sp2 transcription factors were located predominantly in the nucleus and the 
subcellular localization patterns are similar to Sp3 (Fig.3.14). 
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Fig 3.14. Subcellular localization of the Sp family members Sp1 and Sp2 in 
HEK293 cells. Sp1 and Sp2 were detected by immunostaining with a rabbit anti-Sp1 or 
an anti-Sp2 serum as indicated and an AF594 or FITC conjugated secondary antibody. 
Control staining of nuclei was performed with DAPI. 
 
3.2.2.3. Overexpressed Sp3 Localization Pattern 
Next, whether overexpressed Sp3 protein displayed the same localization pattern as 
endogenous Sp3 was established. 
Thus, I cloned the full-length Sp3 cDNA into the MCS of pEGFP-C1 (Clontech), 
which has been optimized for brighter fluorescence. The enhanced GFP variant, EGFP, 
is up to 30 times brighter than wild-type GFP and is more stable. Sp3 full-length was 
expressed as a fusion protein with EGFP (as seen in Fig. 3.15 schematic drawing). The 
expression construct was transiently transfected into Ishikawa cells.  
Visualization of Sp3 was achieved by the intrinsic green fluorescence of the EGFP 
moiety. Transiently transfected Sp3 expressed as a fusion protein with EGFP exhibited 
a similar localization pattern as endogenous Sp3 protein (Fig. 3.15). 
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Fig 3.15. Expression pattern of overexpressed EGFP - Sp3 fusion protein. 
The EGFP -Sp3 expression construct was transiently transfected into Ishikawa cells. 
Visualization of Sp3 was by the intrinsic green fluorescence of the GFP moiety.  
Control staining of nuclei was performed with DAPI.  
 
Conclusions: 
1. The Sp3 transcription factor was predominantly located within the nucleus. 
2. Visualization of endogenous Sp3 by immunofluorescence showed a sponge-like, 
diffuse appearance. 
3. Evolutionally closely related Sp family members Sp1 and Sp2 were also located 
within the nucleus and their subcellular localization patterns were similar to Sp3.  
4. Overexpressed Sp3 displayed a similar localization pattern as endogenous Sp3 
protein. 
 
3.2.2.4. Subcellular Localization of Sp3 Isoforms and SUMOylation – Deficient 
Mutants 
Western blot analysis revealed that four different isoforms of Sp3 are expressed 
(see Results Chapter 3.2.1). The most obvious difference between the two long 
isoforms and the two small isoforms of Sp3 is the presence of either two or just one 
single glutamine-rich domain. Both Q-rich domains can act as strong activation 
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domains on their own when fused to a heterologous DNA-binding domain. The 
transcriptional activity of the two long isoforms strongly depends on the promoter 
settings whereas the small isoforms appear to be inactive (Sapetschnig et al., 2004).  
I wanted to know whether the apparent differences in regulatory properties of the 
small and long isoforms of Sp3 reflected differences in their subcellular localization. 
To achieve this, I examined the localization of Sp3 isoforms in MEF and Drosophila 
SL2 cells. 
Wild-type mouse embryonic fibroblasts (MEF) cells were used to investigate the 
localization of endogenous Sp3 and Sp3-deficient MEFs (MEF KO nr.6- PhD Thesis H. 
Göllner) were included as a negative control. To analyze localization of Sp3 long 
isoforms, I used Sp3 KO MEFs stable transfected with Sp3 FL and the 
SUMOylation-deficient mutant Sp3 K551R FL (Diplomarbeit T. Mennenga). To 
investigate the short isoforms, MEFs KO were stably transfected with constructs 
expressing short isoforms and short isoforms with a small deletion (SD) within the 
inhibitory domain (containing IKEE SUMO motif), (MEF- Ubi-Sp3-W, and MEF- 
Ubi-Sp3-WSD described in PhD Thesis H. Göllner).  
Drosophila appears to have only four SP transcription factors, as opposed to nine in 
mammals (Suske et al., 2005). The reason for using Drosophila - derived SL2 cells 
was the absence of endogenous Sp3 expression. SL2 cells were transfected with the 
appropriate expression constructs for long  (pPac-Sp3 FL new) and small wild-type 
Sp3 isoforms (pPAC-Sp3), as well as with the corresponding SUMOylation -deficient 
mutants (pPac-Sp3 K/R FL new and pPAC-Sp3 K/D), schematically represented in Fig 
3.16.  
Detection of Sp3 protein in both cell types was achieved by immunostaining with a 
rabbit anti-Sp3 antibody and a FITC- (Fig. 3.16 A) or AF594 conjugated (Fig. 3.16 B) 
secondary antibody. 
Immunostaining with anti-Sp3 antibodies revealed that MEFs and SL2 cells types, 
the wild-type isoforms and the SUMOylation-deficient mutants were located in the 
nucleus and exhibited a sponge-like, diffuse appearance. 
These results show that the differences in the activation capacity of the various 
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isoforms and mutants are not due to differences in their subcellular or subnuclear 
localization. 
 
 
FIG. 3.16.  Subcellular localization of Sp3 isoforms and corresponding 
SUMOylation-deficient mutants in MEFs and SL2 cells. 
A.  Sp3-/- MEFs stably transfected with expression constructs for the long or the small 
isoforms (Sp3li-WT and Sp3si-WT, respectively) and corresponding 
SUMOylation-deficient mutants (Sp3li long isoform -K551R and Sp3si small 
isoform-SD) are shown. The Sp3siSD mutants contain a thirteen amino acid deletion 
including the IKEE SUMOylation motif. WT MEFs and mock-transfected Sp3-deficient 
KO MEFs were included in the analyses. 
B.  SL2 cells were transiently transfected with one µg of expression constructs for Sp3 
isoforms and mutants as indicated.  
Sp3 was detected by immunostaining with a rabbit anti-Sp3 antibody and a FITC- (A) 
or AF594 conjugated (B) secondary antibody. Control staining of nuclei was performed 
with DAPI. 
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3.2.3. The Subcellular Localization of Sp3 is NOT Altered Upon SUMO 
Modification 
The cell nucleus is highly compartmentalized and extremely dynamic. Many 
nuclear factors, in addition to being diffusely distributed throughout nucleoplasm, 
accumulate in specific and distinct nuclear subcompartments, such as nucleoli, 
speckles, Cajal bodies and promyelocitic leukemia (PML) bodies (Seeler and Dejean, 
2003). Posttranslational modification by SUMO has been shown to regulate subcellular 
localization of many targets including RanGAP, the IKB kinase regulator NEMO, the 
tumor suppressor PML and many other SUMO-modified proteins including 
transcription factors, chromatin modifiers, and proteins involved in genomic 
maintenance (Zhong et al. 2000).  
It was verified in the previous chapters (1.1, 1.2) that Sp3 is a SUMO target in vivo. 
The following experiments determine if Sp3 subcellular localization pattern is affected 
by SUMO. Two main questions are addressed: firstly do endogenous Sp3 and SUMO 
colocalize? Secondly what is the effect of SUMO overexpression on Sp3 nuclear 
distribution? 
3.2.3.1. Subcellular Localization of Endogenous SUMO1 
To seek out the answer of the first question, several double immunostaining 
experiments were performed to detect subcellular localization of endogenous Sp3 and 
SUMO1 simultaneously. Ishikawa and MEF cells were used for this experiment. 
Fig. 3.17.A shows the subcellular distribution of endogenous Sp3, detected with 
rabbit anti-Sp3 antibody and Goat Anti Rabbit (GAR) conjugated with FITC, and 
endogenous SUMO1, visualized using a monoclonal anti SUMO1 and goat anti mouse 
(GAM)-Texas Red conjugated secondary antibody.  
Fig. 3.17.B details SUMO1 subcellular localization in Ishikawa cells,  detected 
with monoclonal anti SUMO1 and GAM-Texas Red and in MEFs cells, detected with 
rabbit anti-SUMO1 (Santa Cruz) antibody and a Cy3 conjugated secondary antibody.  
Endogenous SUMO1 exhibits a different nuclear pattern than that of the Sp3 
transcription factor and appears to not influence its localization. SUMO1 displayed a 
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diffuse nuclear distribution but in addition appeared do be accumulated at the rim of 
the nucleus and in a few nuclear dots.  
 
  
 
FIG. 3.17. Subcellular localization of endogenous Sp3 and SUMO1.  
A. Sp3 was detected by immunostaining with a rabbit anti-Sp3SC antibody and a FITC 
and SUMO1with anti SUMO1monoclonal and GAM-Texas Red conjugated secondary 
antibody.  
B. Higher magnification of SUMO1 localization in Ishikawa and MEFs cells. In 
Ishikawa cells, SUMO1 was detected with anti SUMO1 monoclonal and GAM-Texas 
Red and in with a rabbit anti-SUMO1SC antibody and a Cy3 conjugated secondary 
antibody. Control staining of nuclei was performed with DAPI.  
 
3.2.3.2. Overexpression of SUMO1 and SUMO2 does NOT Alter Sp3 Subcellular 
Localization  
It was reported that SUMO overexpression may have implications upon subcellular 
localization of certain substrates such as PML, Sp100, IkB, and p53 by recruiting them 
into PML-containing nuclear dots (Melchior, 2000).  
To address this question the effect of SUMO overexpression on subcellular 
localization of Sp3 by recruiting it to nuclear bodies was examined. Two different 
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experiments were performed. Initially, I analyzed the localization of endogenous Sp3 
after SUMO1 and SUMO2 overexpression. Subsequently the effect of Ubc9 and Sp3 
coexpression was examined. 
 
3.2.3.2.1. SUMO1 and SUMO2 Overexpression 
To investigate the subcellular localization of endogenous Sp3 upon SUMO 
overexpression, I performed indirect-immunofluorescence analyses. Ishikawa cells 
were transfected with expression constructs for GFP-SUMO1 or GFP-SUMO2. 24 
hours post transfection, cells were subjected to immunostaining (see Methods chapter). 
Endogenous Sp3 localization was detected with a rabbit anti-Sp3 antibody and a 
GAR-AF-594 secondary antibody and GFP-SUMO1 or GFP-SUMO2 were visualized 
by GFP intrinsic green fluorescence.  
A Bio-Rad confocal system connected to a Nikon inverted microscope designed for 
the precise separation of fluorophore channels was used. The GFP fluorophore was 
excited with 488 nm laser line of an Argon-Ion laser. Fluorescence emission was 
collected through a 500 nm longpass emission filter. AF-594 fluorophore was excited 
with 543 nm laser line of the HeNe-Ion laser. Fluorescence emission was collected 
through a 600 nm longpass emission filter. 
The confocal technique was chosen to prove unequivocally that Sp3–SUMO 
localization avoiding fluorophore interference could lead to unspecific colocalization.  
Fig.3.18 depicts the subcellular localization of Sp3 in Ishikawa cells after 
transfection with a GFP- SUMO1 (A) or SUMO2 (B) constructs. Both proteins, Sp3 
and SUMO, were localized predominantly within the nucleus. Immunostaining 
revealed that SUMO1 and SUMO2 have partially overlapping but distinct patterns of 
localization. However, overexpression of GFP-SUMO1 or GFP-SUMO2 did not alter 
the localization of Sp3. It should be noted that the high resolution of confocal 
microscope direct to acquisition of Sp3 and SUMO images somewhat unusual from 
images taken by using a fluoresce microscope. Confocal Sp3 and SUMO images 
appear more punctuate for the reason that the confocal resolution (discrimination 
between two points) is much higher compared to classical microscopes.         
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In conclusion, there is no similarity between expression pattern of endogenous Sp3 
and overexpressed SUMO1 or SUMO2, but the obvious result of this experiment is 
that the endogenous Sp3 nuclear distribution is not changed following SUMO1 or 
SUMO2 overexpression.  
 
   
 
Fig. 3.18. Subcellular localization of endogenous Sp3 after SUMO1 and SUMO2 
overexpression.  
Ishikawa cells were transfected with 1 µg of an expression construct for GFP-SUMO1 
(A) or GFP-SUMO2 (B). Visualization was by the intrinsic green fluorescence of the 
GFP moiety. Endogenous Sp3 localization was detected with a rabbit anti-Sp3 antibody 
and a GAR-AF-594 secondary antibody. 
The images were recorded with Radiance 2000 confocal system produced by Bio-Rad 
Cell Science Division (Hemel Hempstead, United Kingdom) adapted to an Eclipse T300 
inverted microscope (Nikon Corporation, Tokyo, Japan).  
 
3.2.3.2.2. Ubc9 and Sp3 Coexpression 
Ubc9, the conjugation enzyme for SUMO, is predominantly present in the nucleus 
and at the nuclear pore complex (Schwarz et al., 1998). 
In Fig.3.19.A. Ishikawa cells were transiently transfected with expression 
constructs for GFP-SUMO1 and Ubc9 (described in Materials chapter). Endogenous 
Sp3 was detected with a rabbit anti-Sp3 antibody and a GAR-AF-594 secondary 
antibody and GFP-SUMO1 by the built-in green fluorescence of the GFP tag. 
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In Fig.3.19.B. Ishikawa cells were transiently transfected with expression 
constructs for GFP-Sp3 and FLAG-SUMO1. SUMO1 was detected with an anti FLAG 
monoclonal and GAM-Texas Red conjugated secondary antibody and Sp3 by the 
intrinsic green fluorescence of the GFP. 
When Ubc9, in addition to SUMO1, was overexpressed a striking redistribution and 
accumulation of SUMO1 into punctuated structures was observed, whereas the diffuse 
distribution of Sp3 was not altered (Fig.3.19.A). After overexpression of Sp3 (GFP-Sp3) 
and SUMO1 (FLAG-SUMO1) we found that the GFP-Sp3 pattern appears to resemble 
Sp3 endogenous distribution. Nevertheless, this specific pattern is not affected by 
SUMO1 overexpression (Fig.3.19.B). 
 
 
  
Fig.3.19- A. Coexpression of SUMO1 and Ubc9 does not alter endogenous Sp3 
subcellular localization.  Ishikawa cells were transfected with 1 µg of an expression 
construct for GFP-SUMO1 and Ubc9. Visualization was by the intrinsic green 
fluorescence of the GFP moiety. Endogenous Sp3 localization was detected with a 
rabbit anti-Sp3 antibody and a GAR-AF-594 secondary antibody.  
B. SUMO1 and Sp3 overexpression. Ishikawa cells were transfected with 1 µg of 
expression constructs for GFP-Sp3 and FLAG-SUMO1. SUMO1 was detected with 
anti FLAG monoclonal and GAM-Texas Red conjugated secondary antibody and Sp3 
by the intrinsic green fluorescence of the GFP moiety. 
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Given that SUMOylation at the IKEE motif of the ID is essential for silencing the 
transcriptional activation capacity of Sp3, one could speculate that SUMOylated Sp3 
alters the interaction with other nuclear proteins, which in turn alters the sub-nuclear 
distribution of Sp3. Thus far, we have no indication for such a mechanism. A diffuse 
nuclear distribution of Sp3 was observed even under conditions where a dramatic 
accumulation of SUMO1 in punctuate nuclear structures occurred and even after 
coexpression of Ubc9. 
Taken together, these immunofluorescence experiments reveal that Sp3 is not 
targeted to nuclear bodies even under conditions where SUMO1 becomes 
predominantly accumulated in such structures. 
3.2.3.3. Recruitment of Sp3 to Nuclear Speckles is an Artifact 
The mammalian cell nucleus contains a large number of nuclear bodies that are 
thought to function in a variety of nuclear processes. One of the most prominent 
nuclear structures is the promyelocytic leukemia (PML) nuclear body, also known as 
PML oncogenic domain, nuclear domain 10, or Kremer body. There are usually 
between 5 and 30 PML bodies per nucleus, depending on cell type and stage of the cell 
cycle (Koken et al., 1995).  
So far, almost all SUMO targets are influenced at subcellular localization level by 
SUMOylation in one way or another (Wang et al., 2004). Data presented in the 
previous chapter indicates that Sp3 localization is not affected by endogenous SUMO 
or overexpression of SUMO. However, under certain conditions Sp3 was redistributed 
after SUMO overexpression, but it was unclear whether Sp3 accumulation in dot-like 
structure was specific or not. 
To determine if this localization was specific, Ishikawa cells were cotransfected 
with expression constructs for GFP-SUMO1 and Ubc9. SUMO1 was detected by the 
intrinsic green fluorescence of GFP and endogenous Sp3 localization was detected with 
a rabbit anti-Sp3 antibody and a GAR-CY3 secondary antibody.  
At first glance, the Sp3 localization pattern (Fig.3.20-A) was not affected by 
transfected SUMO1 (Fig.3.20-B). However, if Sp3 localization signal was recorded 
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following GFP observation “a striking accumulation of Sp3 in dot-like structure” was 
observed (Fig.3.20-C). This phenomenon can occur when the emission spectrum of a 
donor fluorophore (GFP) significantly overlaps the absorption spectrum of an acceptor 
- CY3 Fig.3.20-E) and the energy from one fluorophore (‘Donor’) is transferred to a 
different fluorophore (‘Acceptor’).  
We found Sp3 recruitment in nuclear dots only under special conditions when 
fluorescence signal of GFP-SUMO1 additionally excited the Sp3 conjugated 
fluorophore (Fig.3.20-C).  
  
  
 
Fig.3.20. Sp3 and dot-like structures in Ishikawa cells. 
A. Subcellular localization of endogenous Sp3 detected with a rabbit anti-Sp3 antibody 
and a GAR-CY3 secondary antibody. B. Overexpressed SUMO1 visualized by the 
intrinsic green fluorescence of the GFP moiety. C. When emission spectra 
(fluorescence) of the GFP fluorophore is overlapping absorbance spectra of another 
fluorophore (Cy3), the intensity of Cy3 is increased and produces dramatically changes 
in Sp3 localization pattern. D. Control staining of nuclei was performed with DAPI. 
E.  Graphic explanation of the energy transfer from ‘Donor’ fluorophore (GFP) to a 
different fluorophore, CY3 (‘Acceptor’).  
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3.3. Is Sp3 Regulated by SUMOylation? 
3.3.1. Sp3 SUMOylation in Different Cell Lines and Tissues 
In the first chapter of results it was shown that Sp3 is expressed as four distinct 
proteins, two slow migrating of more than 100 kDa and two fast migrating species of 
approximately 72 kDa that differ in the extent of the amino terminal part. All four 
isoforms become SUMO-modified in vivo specifically and exclusively at lysine 
residue 551.  
Based on these findings, I wanted to know whether the relative amount of the Sp3 
isoforms as well as the Sp3-SUMO modification varies in different cell lines. 
In order to solve this question, I used several tumor cell lines of human and mouse 
origin, grown as a monolayer in cell type specific culture conditions. It was necessary 
to opt for cells derived from endometrial tissue (Ishikawa cells), kidney (Phoenix cells), 
colon (CaCo-2 cells and SW620 cells), epithelium (HeLa cells), keratinocyte (HaCat 
cells), bone (Saos-2 cells), neuroblastoma (IMR32 cells) or mouse fibroblasts (NIH3T3 
cells). The cell lines were grown in specific media conditions (see Materials chapter) 
and lysed in SDS containing buffer as soon as the cells become confluent. Equal 
amount of proteins from fresh SDS cell extracts were used for immunoprecipitation 
with anti Sp3 specific antibody and were separated through 6 % PAGE.  
As can be seen in Fig.3.21, the Sp3 protein is expressed in all cell lines analyzed. 
The amount of Sp3 is slightly different between cell lines but the Sp3 SUMOylation 
remains unchanged. Two different exposures (Fig.3.21 A for 10 min and Fig.3.21 B for 
3 min) were shown in order to permit better observation of Sp3 expression and SUMO 
modification. All four Sp3 isoforms are expressed and are SUMOylated. The ratio 
between isoforms is not changed and the percentage of SUMO modification does not 
vary (Fig.3.21).   
The Sp3 expression analysis in various cancer cell lines, derived from different 
organs upon immortalization, did not reveal alterations in isoforms ratio and more 
important, SUMOylation level of Sp3 appears to be not cell type dependent.  
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The next question was whether the SUMO modification of Sp3 is varies in 
different organs.  
 
       
   
Fig.3.21. Non-modified and SUMO-modified Sp3 protein in different cell lines. 
Western blot analyses of Sp3 in different cell lines. Cells were lysed with 
SDS-containing buffer. Equal amounts of protein (100 µg) from cell extracts were 
subjected to IP with anti-Sp3SC antibodies and subsequent separated through 6% SDS 
polyacrylamide gels. After blotting, PVDF membrane was incubated with Sp3-specific 
antibodies.  
A and B- different exposure times are shown.  
Abbreviations are: Sp3li-1 and 2, long isoforms of Sp3; Sp3si-3 and 4, small isoforms 
of Sp3; Sp3li-SUMO and Sp3si-SUMO, SUMO-modified long and small isoforms of 
Sp3.  
 
To get a straightforward answer to this question, the Sp3 expression in organs 
prelevated from mice were analyzed. Mice were killed in agreement with the 
regulations of the local animal welfare committee. The organs were prelevated in ice. 
After weighing, organs were mixed with 5 fold excess of SDS lysis buffer and 
homogenized with a Potter device at variable speed. Homogenized organs were boiled 
for 10 min and centrifuged for 10 to 15 min until complete clearing up of the 
supernatant. Equal amounts of protein from cell extracts were subjected to 
immunoprecipitation with anti Sp3 antibody and separated through 6% PAGE. 
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Immunoblotting was performed with the same commercially available anti Sp3 
antibody from Santa Cruz. 
In Fig.3.22, the Sp3 expression and SUMOylation pattern is shown in various 
mouse organs. Although an equal amount of protein (150 µg) from organ extracts was 
used for immunoprecipitation, the total amount of Sp3 seems to vary. For instance, 
there is less Sp3 in brain and muscle compared to lung or spleen.  
Another observation is that the ratio between Sp3 unmodified and SUMOylated 
Sp3 is not significantly changed. For a better comparison, two different exposure times 
of the immunoblot are shown (Fig.3.22 A for 10 min and Fig.3.22 B for 3 min). 
 
      
 
FIG 3.22. Endogenous Sp3 protein expression and SUMOylation level in different 
mouse organs. Western blot analyses of Sp3 in organs indicated above. Different 
organs were prelevated from adult mice and homogenized in SDS-containing buffer. 
Equal amount of proteins (150 µg) from organ extracts were used for IP with 
anti-Sp3SC antibodies and then separated through 6% SDS polyacrylamide gels. After 
blotting, PVDF membrane was incubated with Sp3-specific antibodies.  
A and B- different exposure times of the PVDF membrane. 
Abbreviations are: Sp3li-1 and 2, long isoforms of Sp3; Sp3si-3 and 4, small isoforms 
of Sp3; Sp3li-SUMO and Sp3si-SUMO, SUMO-modified long and small isoforms of 
Sp3.  
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The Sp3 protein is expressed in all cell lines and in all mouse organs analyzed. All 
four isoforms were detected without shifting the expression ratio between long and 
small isoforms. More importantly, the Sp3 SUMOylation does not point up substantial 
differences among various unrelated cell types and tissues investigated. One can 
conclude that the level of Sp3 modification by SUMO is not cell line or organ 
dependent.  
3.3.2. Is SUMOylation of Sp3 Regulated by Different Stress Conditions? 
Different cells in an individual contain the same genome, but the same cells show a 
different gene expression pattern, even if those cells are of the same cell type. Cells can 
quickly change their expression pattern in response to a plethora of changes in their 
environment, like temperature, light conditions, redox potential, and nutrient supply or 
in response to external signaling molecules like hormones, growth factors and 
cytokines.  
The previous experiments demonstrated that SUMOylation of Sp3 is not 
significantly modulated upon SUMO1 or SUMO2 overexpression and the level of Sp3 
modification is not cell type or tissue dependent. 
Another question was whether Sp3 modification by SUMO is regulated by 
different stress conditions. To decipher this question, I performed further experiments 
in order to find out if the level of Sp3 SUMOylation may change under different 
metabolic stress conditions or after treatment with drugs known to play important roles 
in some regulatory pathways. 
 
3.3.2.1. Serum Induction, Serum Starvation and Heat Shock 
I started with serum induction and starvation of several cell lines and also with heat 
shock treatment in Ishikawa, NIH3T3 and Saos-2 cells.  
All cell lines were grown in recommended medium containing 10% fetal calf 
serum (FCS) in 9 cm Ø culture dishes until 70-80% confluence. The cells were washed 
three times with PBS and the medium was replaced with medium without FCS for 
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periods of time indicated in the Fig.3.23. Cells subjected to heat shock were placed 
into cell culture incubator at 42 0C in the presence of 5% CO2. As a control, cells grown 
in normal media were used. In order to preserve SUMOylation, SDS cell extracts were 
prepared and protein concentration determination was performed. Equal amounts of 
protein were separated through 6% PAGE and after blotting, the membranes were 
incubated with anti Sp3 antibody and anti Sp1 serum, respectively. 
The SUMOylation level of Sp3 was influenced by diverse experimental conditions 
in various cell lines as can be seen in Fig.3.23. Even when the cells were incubated for a 
long time with medium in the absence of FCS (the first two lanes of each blot: - 24hFCS 
and -21hFCS +3hFCS), the total amount of Sp3 was reduced but the ratio between Sp3 
and Sp3-SUMO obviously is not changed. This ratio is not distorted after short term 
starvation (+21hFCS -3hFCS) and heat shock (3h at 42 0C). 
 
 
 
Fig.3.23. SUMO-modification of Sp3 after various stress conditions. Ishikawa, 
Saos2 and NIH3T3 cells were grown in the absence of fetal calf serum in medium for 
24 hours (-24hFCS), in the absence of FCS for 21 hours and the last 3 hours in normal 
medium (-21hFCS+3hFCS), in normal medium for 21hours and then 3 hours in 
medium without FCS (+21hFCS-3hFCS), in normal medium and 3 hours incubated at 
42 0Celsius (3h at 42 0C) and control cells in normal media (FCS). Cells were lysed 
with SDS-containing buffer and then separated through 6% SDS polyacrylamide gels. 
After blotting, PVDF membrane was incubated Sp3 or Sp1-specific antibodies as 
indicated. The star marks the IgG from FCS. 
 
Results 
 126
As well, the expression pattern of Sp1 is not influenced by these experimental 
conditions: the ratio between Sp1 and the Sp1 phosphorylated form remained 
invariable. It can be noticed that the band marked with star (*) in the anti Sp1 blot, 
disappears in starved cells. Most likely, the band is due to the recognition of 
immunoglobulins from FCS by anti Sp1 serum. 
As seen in Fig.3.23, there is no variation in Sp3 expression pattern after serum 
starvation, serum induction and heat shock for three hours. It also can be possible that 
SUMOylation is a very fast event and can occur in a short period of time. To elucidate 
this aspect, I performed additional experiments using a short serum starvation period 
(Fig.3.24) and induction (Fig.3.25) in SaOs-2 cells. These osteosarcoma cells were used  
as Sp3 KO mice display bones and teeth with impaired development (Bouwman et al., 
2000). 
A. Short Period Serum Starvation.  
The experimental conditions were similar to the previous experiment. For serum 
induction, Saos2 cells were grown in medium containing 10% fetal calf serum (FCS) in 
9 cm Ø culture dishes for 48 hours. After intensive washing with PBS, the medium was 
replaced with medium without FCS for periods of time indicated in Fig.3.24. 
    
 
Fig.3.24. SUMOylation pattern of endogenous Sp3 after serum starvation. Saos2 
cells were grown in normal medium for 48 and then, in the absence of FCS for 5-60 
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minutes as indicated. Cells were lysed with SDS-containing buffer. Equal amounts of 
protein (20 µg) were separated through 6% SDS polyacrylamide gels. After blotting, 
PVDF membrane was incubated Sp3 or Sp1-specific antibodies as indicated. The star 
indicates the IgG from FCS. 
 
B. Short Period Serum Induction.  
For the short period serum induction experiments, the Saos2 cell were grown in 
medium containing 10% fetal calf serum (FCS) in 9 cm Ø culture dishes until 70-80% 
confluence and then the medium was replaced with serum-free medium for 24 hours. 
This medium was substituted subsequently with normal medium including 10% FCS 
for time points indicated in Fig.3.25.  
 
  
 
Fig.3.25. SUMOylation pattern of endogenous Sp3 after serum induction.  
Saos2 cells were grown in medium without FCS for 24h and then, in normal medium 
containing 10% FCS for 3-120 minutes as indicated. Cells were lysed with 
SDS-containing buffer and 20 µg of proteins were separated through 6% SDS 
polyacrylamide gel. After blotting, the PVDF membrane was incubated with a Sp3 
-specific antibody. 
 
One can conclude that the experimental conditions illustrated in Fig.3.23, Fig.3.24 
and Fig.3.25, respective serum induction, serum starvation and heat shock does not 
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alter Sp3 SUMOylation. Also the Sp1 expression and phosphorylation status is not 
influenced by the metabolic stress conditions applied to mammalian cells in our 
experiments. 
3.3.2.2. Ultraviolet Radiation, TNF-alpha and MG132 
Exposure of cells to DNA-damaging agents elicits a complex set of acute cellular 
responses. Generally, DNA damage-inducible (DDI) responses serve to protect the cell 
from genotoxic adversity. The most studied component of mammalian DDI responses is 
the “Guardian of the Genome” p53 tumor suppressor gene product. p53 becomes 
activated by genotoxic and other stresses, and in turn p53 activates transcription of 
perhaps as many as 100 other genes. Indeed, treatment of cells with UV radiation and 
other DNA-damaging agents was effective in activating p53 as a transcription factor 
and in turn up-regulating its downstream effectors genes, including p21Waf1/Cip1/Sdi1 
(Vogelstein et al., 2000). 
We wanted to know whether UV radiation may influence Sp3 SUMOylation status. 
HEK293 cells were exposed to UV radiation at time periods indicated in the    
Fig.3.26 A. The medium was partially removed in order to allow the UV to reach the 
cells but to keep cells humid, knowing that the penetrability of short wave radiations is 
reduced compared with long wave radiations (IR for example). I used a UV Bench 
Lamp having two 15 watt long wave bulbs with ensuing technical characteristics: at 30 
cm distance from source, the light intensity is 730 Microwatts / cm2. The wavelength 
range is 315-400 nm with the peak at 360 nm. 
After exposing HEK293 cells with an elevated dose of UV radiation, I did not 
observe an alteration in Sp3 SUMOylation. Even after one hour of UV exposure when 
most of the cells appear to be morphologically affected, the Sp3 expression pattern did 
not change (Fig.3.26 A). 
 
In order to uncover the conditions in which the SUMOylation of Sp3 is influenced, 
I continued to test the effect of two drugs upon this modification, Tumor Necrosis 
Factor alpha and MG-132. 
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TNF-alpha is a pleiotrophic pro-inflammatory cytokine secreted by various cells 
including adipocytes, activated monocytes, macrophages, B cells, T cells and 
fibroblasts. It belongs to the TNF family of ligands and signals through two receptors,  
TNFR1 and TNFR2. Binding of TNF-α to the receptor can promote either cell 
survival or death, depending on the context.  TNF-α can promote a variety of cellular 
responses including the recruitment and activation of Caspase-8 in the receptor 
complex, which initiates a pathway to implement cell death by apoptosis and cell 
survival by activating the transcription factor NF-kB and the JNK pathway, which 
together activate anti-apoptotic genes (Ferri et al., 2001).  In general, if expression of 
these genes is suppressed (e.g., by the protein synthesis inhibitor cycloheximide) 
apoptosis becomes the default response of the cell. TNF-alpha is cytotoxic to a wide 
variety of tumor cells and is an essential factor in mediating the immune response 
against bacterial infections. TNF-alpha also plays a role in the induction of septic 
shock, auto immune diseases, rheumatoid arthritis, inflammation, and diabetes (Yu et 
al., 2004). 
HEK293 cells were treated with 50 ng/ml TNF-alpha, 10 µg/ml cycloheximide or 
both together, according to dosage recommendations of researchers from our Institute 
(who use those drugs currently for apoptosis investigation). TNF-alpha treatment did 
not lead to an alteration in Sp3 SUMOylation pattern. It can be observed that 
cycloheximide treatment reduces the Sp3 expression. Nevertheless, there is no 
detectable alteration in SUMOylation pattern in cells treated with both, cycloheximide 
and TNF-alpha drugs (Fig.3.26 B). 
 
MG-132 - Nα-Benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal [Z-Leu-Leu-Leu-H] 
a leupeptin analogue is a cell-permeable inhibitor of the proteasome that has been shown 
to induce apoptosis in MOLT-4 and L5178Y cells via a p53-dependent pathway1 and 
also to enhance CPP32- like activity in TNF-treated U937 cells (Fujita et al., 1996). 
I tested this proteasome inhibitor drug by treating HEK293 cells with 25 µM 
MG-132 for 24 h. The SDS cell extracts from cells treated with and without MG-132 
were prepared and Sp3 was immunoprecipitated by anti Sp3 antibody.  
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I observed an alteration of endogenous Sp3 SUMOylation (Fig.3.26 C). After 
MG-132 treatment, the intensity of SUMO bands in WB is dramatically reduced.  
I also used the immunoprecipitated Sp3 from cells treated with this drug for 
Western blot detection of ubiquitination of Sp3 by using polyclonal anti Ubiquitin 
antibody from Sigma, but unsuccessfully. 
 
 
 
Fig. 3.26. Sp3 SUMOylation after UV and drugs treatment. 
A. HEK293 cells were exposed to UV radiation at time periods indicated above figure. 
Cells were lysed with SDS-containing buffer.  
B. HEK293 cells were treated with (50 ng/ml) TNF-alpha (TNF), 10µg/ml 
cycloheximide (CHX) or both (TNF+CHX). Control cells are nontreated. Cells were 
lysed with SDS-containing buffer. 
C. HEK293 cells were treated with 25 µM MG 132 for 24 h. Cells were lysed with 
SDS-containing buffer and subjected to IP with anti Sp3SC antibody and no antibody 
for IP Control. 
The proteins were separated through 6% SDS polyacrylamide gels. After blotting, 
PVDF membrane was incubated with anti Sp3 antibody. 
 
UV radiation or TNF alpha and cycloheximide treatment of mammalian cells did 
not alter the SUMOylation level of Sp3 protein in our experimental conditions. A 
significant reduction in Sp3 SUMO modification is observed upon MG-132 treatment. 
There are many causes that could provoke this alteration. Possibly this proteasome 
inhibitor is implicated in preventing proteasome degradation of SUMO specific 
proteases, which subsequently cut off the Sp3-SUMO moiety. 
Results 
 131
3.3.2.3. Trichostatin A  
It has been known for some time that lysine residues in the N-terminal tails of 
histones can be covalently modified by acetylation, which leads to transcriptionally 
active chromatin. More recently it became evident that in addition to histones, other 
nuclear proteins can also be targets of acetylation events. Among them, Sp3 was found 
to be acetylated in vivo (Braun et al, 2001).  
Histone deacetylase (HDAC) inhibitors have shown significant anti-proliferative 
and apoptotic properties on various cancer cells, including prostate cancer, and are 
therefore being evaluated as treatment modalities. Among them, three structurally 
unrelated HDAC inhibitors, trichostatin A (TSA), depsipeptide (FR901228), and 
sodium butyrate are preferentially used in most of the publications. 
In our lab it was shown that Sp3 is acetylated in vivo (after TSA treatment). A 
mutant of Sp3 lacking the K551 SUMO target residue exhibits a far weaker acetylation 
compared with wild type (Braun et al., 2001). 
The purpose of our experiment is to test whether the TSA treatment may influence 
Sp3 SUMOylation in order to determine the connection between this modification and 
acetylation. 
To address this question, I transfected different Sp3 expression constructs (as 
shown in Fig.3.27), wt construct and three others containing point mutations in the 
SUMOylation site, into SL2 insect cell lines. In order to enhance the Western blot 
signal of transfected constructs, I performed immunoprecipitations by using anti Sp3 
specific antibody as can be seen in Fig.3.27 shorter exposure time of Western blot 
membrane (1 min). 
The Sp3 SUMO modification is detected only in the wt construct emphasizing that 
the integrity of the SUMO consensus motif is critical for SUMOylation. But most 
important, the TSA treatment of insect cells does not affect the SUMOylation level of 
transiently transfected Sp3.  
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Fig.3.27. Sp3 and corresponding SUMOylation motif mutants expressed in SL2 
cells in the presence or absence of TSA. 
SL2 cells were transfected with Sp3 expression constructs wt or mutants and treated 
with 1 µM TrichostatinA (TSA) for 24 h as indicated. Cells were lysed with 
SDS-containing buffer and then subjected to IP with anti Sp3SC antibody. Cell extracts 
and IP proteins were separated through 6% SDS polyacrylamide gels. 
After blotting, PVDF membrane was incubated with Sp3 -specific antibody and two 
exposure times are shown (1min and 10 min). 
 
 
3.4. PIAS1- Nuclear Protein and E3 Ligase 
3.4.1. PIAS1 is Located into Nucleus  
Modification of proteins by SUMO is a three-step process that requires three 
classes of enzymes, E1–E3. An E1 activating enzyme and E2 conjugating enzyme 
prime SUMO for ligation to a substrate by an E3 SUMO ligase. There are several E3 
ligases that are responsible for transferring activated SUMO to their substrates. For 
exemple Polycomb Protein Pc2, and nucleoporin RanBP2, which has been previously 
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characterized for its function in nuclear transport and RING-domain containing 
proteins of the protein inhibitors of activated STATs (PIAS) family, have been 
identified as E3 ligase enzymes for SUMO1 (Hilgarth et al., 2004). 
An important mechanism to control the activity of transcriptional regulators 
appears to be their targeting to specific subnuclear sites. Accumulating evidence 
indicates that the PIAS/SUMO system is involved in this process.  
We wanted to know whether PIAS1 displays a particular localization pattern and 
whether PIAS1 affects Sp3 specific nuclear distribution. 
To address this question, immunofluorescence experiments were performed in 
HEK293 cells. Firstly, I did coimmunostaining for endogenous PIAS1 and Sp3. Sp3 
was immunostained with a rabbit anti-Sp3SC (Santa Cruz) antibody and a (Goat Anti 
Rabbit) GAR-FITC conjugated secondary antibody. PIAS1 was detected with anti 
PIAS1 goat and (Donkey Anti GOAT) DAG-AF594 conjugated secondary antibody 
(Fig.3.28.A). The same antibody combinations were used to detect overexpressed 
PIAS1 and Sp3 in HEK293 cells transiently transfected with an untagged PIAS1 
expression construct –pN3- SUMO1 (Fig.3.28.B).  
To observe the influence of overexpressed SUMO1 and PIAS1 on Sp3 localization, 
I cotransfected expression constructs for PIAS1 (pN3-PIAS1) and SUMO1 
(GFP-SUMO1).  Sp3 was detected by immunostaining with a rabbit anti-Sp3SC 
antibody and a GAR-AF594 secondary antibody. Detection of SUMO1 was achieved 
by intrinsic green fluorescence of the GFP moiety (Fig.3.28 -C). 
For PIAS1 subcellular localization control, I cloned PIAS1 full-length sequence as 
a GFP fusion into the MCS of pGFP-N3 (Clontech). HEK293 cells were transfected 
with the new construct-pGFP-N3-PIAS1. In living cells, PIAS1 was visualized by the 
fluorescence of GFP and control cell detection by phase contrast (Fig.3.28 -D). 
PIAS1 was found to be located in the nucleus and displayed a similar localization 
pattern as Sp transcription factors (Fig.3.28.A and D). After overexpression, some of 
the PIAS1 protein was recruited into nuclear dots (Fig.3.28.B). This recruitment did 
not affect subcellular localization of Sp3 even when SUMO1 was overexpressed with 
PIAS1 (Fig.3.28.C). 
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FIG.3.28. Subcellular localization of PIAS1 in HEK293 cells.  
A. Endogenous PIAS1 and Sp3. Sp3 was detected by immunostaining with a rabbit 
anti-Sp3SC antibody and a FITC conjugated secondary antibody.  Detection of PIAS1 
was with anti PIAS1SC goat and DAG-AF594 conjugated secondary antibody. Control 
staining of nuclei was performed with DAPI. 
B. HEK293 cells were transfected with an expression construct for PIAS1 
(pN3-PIAS1). Sp3 was detected by immunostaining with a rabbit anti-Sp3SC antibody 
and FITC, and PIAS1 with anti PIAS1 goat and DAG-AF594 conjugated secondary 
antibody.  
C. HEK293 cells were transfected with expression constructs for PIAS1 (pN3-PIAS1) 
and GFP-SUMO1.  Sp3 was detected by immunostaining with a rabbit anti-Sp3SC 
antibody and an AF594 and SUMO1 by the intrinsic green fluorescence of GFP 
moiety. 
D. HEK293 cells were transfected with GFP-PIAS1 (pEGFP-N3-PIAS1) Visualization 
was by the intrinsic green fluorescence of GFP moiety. In the right figure is shown the 
entire transfected cell by phase contrast. 
Results 
 135
In conclusion, endogenous PIAS1 displayed a diffuse nuclear localization pattern 
similar to the Sp3 transcription factor. After overexpression, one observed a 
redistribution of PIAS1 signal to nuclear dots, that did not affect the Sp3 pattern.  
When PIAS1 was cotransfected with SUMO1, the GFP-SUMO1 signal was enhanced 
in dot-like structures. A lower magnification picture of PIAS1 along with SUMO1- 
GFP cotransfection experiment was exposed (Fig.3.28.C), which demonstrated 
GFP-SUMO1 dots in different cells were variable.  In some cells, one observed 
diffuse nuclear distribution of GFP-SUMO1 and few dots.  
In other cells, SUMO1-GFP exhibited microgranular localization in small foci, or 
was concentrated in fewer, but larger granules. It is important to notice that none of this 
particular SUMO1 pattern observed after PIAS1 coexpression had any influence on 
Sp3 subcellular localization. 
 
3.4.2. PIAS1 is a SUMO E3 Ligase 
Protein inhibitors of activated STATs (PIAS) proteins were initially identified as 
negative regulators of cytokine signaling that inhibit the activity of STAT-transcription 
factors. Evidence that illustrates PIAS proteins function as transcriptional coregulators 
in various other important cellular pathways, including Wnt signaling, the p53 pathway 
and steroid hormone signaling (Goss et al., 2003) is rapidly accumulating. Recent work 
from several laboratories has revealed that PIAS proteins act as E3-like ligases that 
stimulate the attachment of the SUMO to target proteins. Since in most cases the 
SUMO ligase activity and the transcriptional coregulator activity are functionally 
correlated, the PIAS/SUMO pathway appears to be an important mechanism of 
transcriptional regulation (Wormald and Hilton., 2004). 
It was demonstrated in our lab that PIAS1 fulfils all requirements to act as an E3 
ligase for SUMO conjugation to Sp3, in vitro. It interacts with the E2 enzyme Ubc9 
and with Sp3 and most importantly, it strongly stimulates transfer of SUMO1 and 
SUMO2 to Sp3 (Sapetschnig et al 2002).  
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3.4.2.1 E3 ligase Activity in vitro 
Recombinant HA/FLAG-tagged Sp3 was subjected to SUMO modification in vitro 
(Sapetschnig et al, 2002) with limiting amounts of recombinant E1 (Aos1 and Uba2 
subunits), E2 (Ubc9) enzymes and recombinant SUMO1 ((Fig.3.29.A). Addition of 
bacterially expressed GST-PIAS1 increased the conjugation of SUMO1 to Sp3 
(Fig.3.29.B).   
    
 
Fig.3.29. E3 ligase activity of PIAS1 in vitro. 
A. Recombinant HA/FLAG-tagged Sp3 expressed in SL2 cells, was subjected to SUMO 
modification in vitro with limiting amounts of SUMOylation mix (recombinant E1 
(Aos1 and Uba2 subunits), E2 (Ubc9) enzymes and recombinant SUMO1).   
B. Addition of bacterially expressed GST-PIAS1 to SUMOylation mix positively 
influences the conjugation of SUMO1 to Sp3.  
Aliquots of SUMOylation reactions were sampled after zero, 15 30, 45, 60 and 90 
minutes of incubation at 30 C. The SUMOylation reaction was stopped by mixing with 
2x Laemmli buffer and subsequently, the proteins were separated through 8% SDS 
polyacrylamide gel. After blotting, PVDF membranes were incubated with Sp3 SC 
specific antibody. 
 
3.4.2.2. E3 ligase Activity in vivo 
The next question was whether PIAS1 could enhance SUMOylation in vivo 
following overexpression. 
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For this purpose, expression constructs for PIAS1 and SUMO1 were transfected 
into HEK293 cells (Fig. 4.27). 36 hours posttransfection, SDS cell extracts were 
prepared. The same amount of protein from cell extracts was separated by SDS 
polyacrylamide gel electrophoresis. After blotting, PVDF membrane was incubated 
with anti-PIAS1-specific antibody1, then stripped and blotted with anti-Sp3SC as 
indicated (Fig.3.30).  
Overexpression of PIAS1 protein in HEK293 cells did not enhance endogenous 
levels of Sp3 SUMOylation. Coexpression of PIAS1 and GFP-SUMO1 did not lead to 
an enhancement Sp3 SUMOylation.  
Even in conditions in which PIAS1 was expressed at extremely high-levels 
compared to endogenous PIAS1 (Fig.3.30 lower blot probed with anti PIAS1 antibody), 
the Sp3 expression pattern was not altered.  
     
 
Fig.3.30. Overexpression of PIAS1 does not influence the sumoylation level of Sp3.  
HEK293 cells were transfected with expression constructs for PIAS1 (pN3-PIAS1, P1), 
SUMO1 (pEGFP-SUMO1, S1) or both (P1 +S1). NT are nontransfected control cells. 
Cells were lysed with SDS-containing buffer. The same amount of protein from cell 
                                                 
1 Pias1 detection with anti-PIAS1 antibody was possible at the end of my work due to a change in the 
blocking step. Blocking with 1% BSA instead 5% Skimmilk was used. 
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extracts was separated through 6% SDS polyacrylamide gels. After blotting the PVDF 
membrane was incubated with PIAS1-specific antibody, then stripped and blotted with 
anti-Sp3SC as indicated.  
Abbreviations are: Sp3li-1 and 2, long isoforms of Sp3; Sp3si-3 and 4, small isoforms 
of Sp3; Sp3li-SUMO and Sp3si-SUMO, SUMO-modified long and small isoforms of 
Sp3. 
 
3.4.3. Strategies for PIAS1 Protein Complex Purification 
Work by several laboratories has showed that mammalian PIAS proteins exert 
SUMO-ligase activity towards various mammalian SUMO-target proteins.  
Even though Ubc9 binds to the SUMO acceptor site and efficiently transfers SUMO 
to selected targets in vitro, a specific SUMO E3-ligating enzyme might be required for 
efficient and properly targeted modification. E3 ligase activities towards SUMO have 
been identified recently for members of the PIAS family of proteins (Kahyo et al., 2001; 
Sachdev et al., 2001; Sapetschnig et al., 2002). 
Preliminary nuclear extract fractionation studies suggest that PIAS1 is part of (a) 
high molecular weight complex(es) in vivo. PIAS1-associated proteins might confer 
substrate specificity towards Sp3 and other transcription factors and/or regulate PIAS1 
activity in vivo. We suspect the identification of PIAS1-associated proteins to be an 
important step towards understanding PIAS1 protein functions and specificities in vivo. 
One obvious question was whether PIAS1 can form such complexes and whether 
the components of this complex can be identified. The main goal of our work was the 
cloning and subsequent characterization of PIAS1-associated proteins. As a 
prerequisite for the purification and identification of PIAS1-associated proteins, 
establishing a two-step purification method for epitope-tagged PIAS1 was required. 
  
3.4.3.1. Principle of Tandem Affinity Purification  
Proteome analysis, in particular using mass spectrometry (MS), requires fast and 
reliable methods of protein purification. The method most suitable for standardization 
is affinity purification based on the fusion of a tag, usually a peptide or a small protein, 
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to the target protein.  
The so-called tandem affinity purification (TAP) method (Rigaut et al., 1999) can 
be employed to allow a two-step purification of appropriately tagged PIAS1. Briefly, 
PIAS1 was fused to two ligand-binding domains, one derived from a 
calmodulin-binding peptide (CBP), the other from protein A. This arrangement endows 
the bait protein with high affinity for both calmodulin and IgG affinity resins. The 
calmodulin-binding peptide and protein A affinity tags are separated by the recognition 
sequence for tobacco etch virus (TEV) protease, permitting proteolytic elution of the 
fusion PIAS-CBP protein from the IgG affinity resin. The TAP-method has been used 
very successfully to isolate protein complexes from cultured yeast cells (Puig et al., 
2001; Rigaut et al., 1999). Similarly, successful applications in mammalian cells have 
also been reported (Gavin et al., 2002; Westermarck et al., 2002). Currently, the group 
of Prof. Dr. Eilers is establishing the TAP-method at the IMT, in Marburg. 
Although there is no doubt that the TAP-method allows the efficient isolation of 
protein complexes from S. cerevisiae, there remain some potential disadvantages. For 
instance, the epitope-tags used, especially the protein A-epitope, is rather big and may 
interfere with protein interaction surfaces in a protein complex. In addition, IgGs 
present in high amounts in serum might interfere with the protein A tag.  
In order to avoid these problems we decided to use the Biotin-avidin system. 
 
3.4.3.2. The Biotin-Avidin System 
Prominent among the affinity-based purification methodologies is the 
Biotin-Avidin system. Biotin is a naturally occurring cofactor for metabolic enzymes, 
which is active only when covalently attached to enzymes through the action of 
specific protein–Biotin ligases. Any biotinylated substrate can be bound very tightly by 
the proteins Avidin and Streptavidin. Biotin-Avidin binding is the strongest 
noncovalent interaction known in nature (Kd 10-15 M), several orders higher than that 
of commonly used antibodies or other affinity tags. As a result, the Biotin-Avidin 
affinity system has numerous applications in modern biological techniques. For the 
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purposes of protein purification, in particular, biotinylation offers a number of 
advantages. For example, the high affinity of biotin for Avidin-Avidin allows 
purification of the biotinylated protein under high stringency conditions, thus reducing 
background binding often observed with other affinity tags that elute more easily. In 
addition, there are very few naturally biotinylated proteins, thus reducing the chance 
for cross-reaction when using biotinylation in protein purification, as opposed to 
antibodies that may cross-react with several species. The advantages of biotinylation 
tagging has led to the development of sequence tags that are biotinylated in bacterial, 
yeast, insect, and mammalian cells. These tags, however, are large in size (at least 63 
aa) and may thus affect the structure of the proteins they are fused to. Furthermore, 
biotinylation using these tags is not very efficient, particularly in mammalian cells. 
Another approach, so far only demonstrated in bacteria, utilizes small (23-aa) artificial 
tags that have been selected through multiple rounds of screening combinatorial 
peptide libraries for specific biotinylation by BirA biotin ligase. These tags have been 
shown to be biotinylated in vitro with kinetics comparable to those of natural biotin 
acceptor sequences and thus may serve as excellent substrates for efficient 
biotinylation in cells with coexpressed biotin ligases. The BiotinTAG (AVITAG) 
sequence used for construction of our tags was a unique peptide, just 15 residues long, 
which is recognized by biotin ligase (Schatz, 1993). In the presence of ATP, the ligase 
specifically attaches biotin to the lysine residue in this sequence (Fig.3.32).  
 
   
 
Fig.3.32. The BiotinTAG peptide sequence. Biotin is conjugated to the acceptor 
lysine highlighted in yellow. 
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Biotinylation can either occur by the cells endogenous protein–biotin ligases or 
through the coexpression of an exogenous biotin ligase, in most cases that of the 
bacterial BirA enzyme. This biotin-protein ligase activates biotin to form biotinyl 5' 
adenylate and transfers the biotin to biotin-accepting proteins.  It also functions as a 
biotin operon repressor.  The protein is encoded by the BirA gene. 
We used for our experiments the pBUD-BirA (expression construct described in 
DeBoer et al., 2003, kindly provided by Harald Braun).  
 
3.4.3.3. The FLAG - BiotinTAG System 
The second tag chosen for our tandem affinity purification system was the FLAG 
tag. Recently, a 3XFLAG (triple FLAG) tag was developed, which is 10-20 times more 
sensitive than a single FLAG and up to 200 times more sensitive than any other tags 
(6xHIS, HA, GST, c-myc). Another advantage of the FLAG tags is the presence of an 
Enterokinase cleavage site (AspAspAspAspLys↓) at the end of the sequence (for 
details, see FLAG® system homepage at www.Sigma-Aldrich.com). 
The tandem affinity purification system based on BiotinTAG and FLAG design for 
PIAS1 and Sp3 our “proteins of interest” is schematically drawn in Fig.3.33. 
PIAS1 and Sp3 were cloned 5’ upstream to the triple (3X) FLAG – BiotinTAG.  In 
the first step, the BiotinTAG is biotinylated by exogenous Bir A enzyme expressed 
upon cotransfection of BirA expression construct (pBud-BirA). In the second step, the 
biotinylated protein of interest is bound to Streptavidin beads. Avidin, Streptavidin and 
NeutrAvidin biotin-binding proteins each bind four biotins per molecule with high 
affinity and selectivity. We chose to use Streptavidin, a bacterially derived 
biotin-binding protein, because the dissociation constant between biotin and 
Streptavidin is reported to be about 30 times higher than the dissociation constant of 
Avidin (Qureshi et al., 2002). 
After intensive washing, most of the contaminants are anticipated to be removed. It 
is expected that Streptavidin beads bind also endogenous biotinylated proteins.  
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Fig.3.33. BiotinTAG and FLAG based tandem affinity purification system. 
Explanation: see text. Abbreviations: B - Biotin; T - Thrombin cleavage site; E - 
Enterokinase cleavage site. 
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 The PIAS1 or Sp3 protein complex is removed from Streptavidin column in the 
third step by cleaving the BiotinTAG from the fusion protein using site-specific 
protease Enterokinase, able to recognize its cleavage site that is part of the FLAG tag. 
In order to get rid of the last contaminants, the protein of interest containing complex is 
bound in the fourth step to second affinity column. This procedure involves capturing 
the protein of interest protein with M2 anti FLAG specific antibody directly conjugated 
to an agarose resin (Sigma). After washing of the protein-FLAG matrix complex, all the 
remaining contaminants are likely to be washed away. 
To elute the FLAG tagged protein of interest from ANTI-FLAG® M2 Agarose 
Affinity Gel, the addition of the competitor FLAG peptide, glycine and EDTA at pH 
3.5 is normally sufficient. To avoid incomplete elution of 3XFLAG tagged PIAS1, a 
Thrombin cleavage site was cloned between the protein sequence and the tag. The 
PIAS1 or Sp3 protein complex from the second affinity column in step 5 is further 
purified in the last step of the purification scheme depicted in Fig.3.33. 
 
3.4.3.4. In vivo Biotinylation of Tagged Proteins 
In order to verify whether the principle of the protein complex purification strategy 
was reliable, the functionality of each tag component was tested.  
The first question connected to our topic was whether the BiotinTAG is 
biotinylated by endogenous biotin ligases or by exogenous BirA. 
To answer this question the PIAS1 tagged expression construct (pN3-PIAS1FB- 
see protein structure in schematic drawing of Fig.3.34) was transfected into HEK293 
cells independently or with a BirA construct (pBud-BirA). Proteins from cell extracts 
were separated by 6% SDS polyacrylamide gel electrophoresis. HRP conjugated 
Streptavidin was used for detection.  
As is seen in Fig.3.34, in addition to biotinylated PIAS1, endogenous biotinylated 
proteins are detected (bands marked with stars -*- in the figure).  
In conclusion, the BiotinTAG fused to PIAS1 was biotinylated in vivo and the 
biotinylation occurred only in the presence of overexpressed BirA. Apparently, the 
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endogenous biotin ligases played no role when PIAS1 FB construct was transfected on 
its own. It can be seen also that the presence of BirA did not enhance biotinylation of 
endogenous proteins. 
    
 
    
 
Fig.3.34. Biotin ligase BirA is required for BiotinTAG biotinylation.  
HEK293 cells were transfected with expression constructs for PIAS1 (pN3-PIAS1FB) 
and BirA (pBud-BirA) as indicated. Cells were lysed with SDS-containing buffer. 
Proteins were separated by 6% SDS polyacrylamide gel electrophoresis. After blotting, 
the PVDF membrane was incubated with Streptavidin – HRP conjugated. Stars (*) 
indicate the endogenous biotinylated proteins. Schematic drawing represents PIAS1- 
FLAG -BiotinTAG fusion protein. Color code for PIAS1: The blue box represent the 
SAP (SAFA, Acinus, PIAS) domain, the red box indicates the RING-like domain and 
the green box the Serine-rich region.  
 
 
Furthermore, the efficiency of binding to Streptavidin beads of biotin- tagged 
PIAS1 was tested. Cell extracts from HEK293 cells cotransfected with biotin tagged 
PIAS1 and BirA, were incubated with Streptavidin beads and after incubation, 
unbound proteins were analyzed. I did not observed detectable PIAS1- biotinylated in 
flow-through, all biotinylated PIAS is bound to beads in a high efficient manner (data 
not shown).  
In addition to PIAS1, I cloned also Sp3 as fusion to both FLAG and 3XFLAG 
-BiotinTAG. The main reason was the need to use in parallel, during protein 
purification protocols, another protein as a control. Two unrelated proteins are 
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expected to have, at least partially, different protein complex partners. Another reason 
was the possibility to detect Sp3 in Western Blot after removing the FLAG-BiotinTAG 
by site-specific proteases because the PIAS1 detection is difficult due by anti PIAS1 
antibodies low specificity (see 4.3.1, footnote) 
The Sp3 and PIAS1 expression constructs cloned as fusion with FLAG or 
3XFLAG- BiotinTAG are depicted in the schematic drawings of the Fig.3.35.A. Both 
constructs were transfected into HEK293 cells with a BirA expression construct 
(pBud-BirA) and were detected by Western Blot using Streptavidin – HRP conjugated. 
Fig.3.35.B shows that all Sp3 and PIAS1 tagged constructs are expressed, 
biotinylated and detectable by Western Blot analysis. I also used, successfully, 
anti-FLAG antibody for Western Blot detection of those constructs (data not shown). 
 
  
  
Fig.3.35. Tagged PIAS1 and Sp3 constructs.  
A. Schematic drawing of Sp3 and PIAS1 tagged expression constructs.  
B. HEK293 cells were transfected with expression constructs for Sp3 (pN3-Sp3FB 
lane 2, pN3-Sp3-3XFB lane 3), PIAS1 (pN3-PIAS1FB lane 4, pN3-PIAS1-3XFB lane 
2) along with BirA (pBud-BirA). In lane 1 are nontransfected control cells. Cells were 
lysed with SDS-containing buffer. Proteins were separated by 6% SDS polyacrylamide 
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gel electrophoresis. After blotting, PVDF membrane was incubated with Streptavidin – 
HRP conjugated. Stars (*) indicate the endogenous biotinylated proteins.  
 
3.4.3.5. Thrombin and Enterokinase Testing 
As mentioned previously, the antibody against PIAS1 was not as sensitive as the 
anti Sp3 antibody. Therefore, for site-specific protease assessment I used the Sp3 
tagged expression construct (Fig.3.36). The Biotin-FLAG tandem tag contains two 
protease recognition sites, one for Enterokinase (E in the figure) and one for Thrombin 
(T). The commercially available proteases were provided together with capture buffers 
in the Enterokinase Cleavage Capture Kit and the Enterokinase Cleavage Capture Kit 
from Novagen. HEK293 cells were transiently transfected with expression constructs 
for Sp3 (pN3-Sp3-3XFB) and BirA (pBud-BirA). Cell extracts were incubated with 
Streptavidin beads. After washing, the beads were incubated with Enterokinase or 
Thrombin as per manufacturer instructions. Fig.3.36 depicts one of the trial 
experiments for each protease. The input cell extract (I) without any intervention 
contained endogenous and exogenous tagged Sp3 protein. The control (C) was 
Streptavidin beads incubated with cell extracts (S) in the presence of cleavage buffer 
without Thrombin in order to check if the buffer may influence tagged protein-matrix 
binding. It is revealed that all biotin tagged Sp3 is bound to the Streptavidin beads and 
is not detectable in the flow-through (FT).  
The Streptavidin beads coupled with biotinylated Sp3 were incubated with 10U (5 
µl from 2U/ µl stock) of recombinant Thrombin and 10U (5 µl from 2U/ µl stock) of 
recombinant Enterokinase at RT for incubation times noted in the figure. Sp3 tagged 
protein bound to Streptavidin beads after incubation with the proteases (S) and Sp3 
cleaved from beads by Thrombin or Enterokinase detectable in flow-through (FT) 
fractions were analyzed. The site specific proteases Thrombin and Enterokinase did not 
remove the tags with satisfying efficiency (Fig.3.36). Many causes might impair the 
proteases enzymatic activity. I tried to solve a part of them by changing incubation 
times, protease concentration, and cell extract preparation methods but without 
success. 
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Fig.3.36. Site specific proteases Thrombin and Enterokinase testing. 
Sp3–3XFLAG -BiotinTAG and BirA expression constructs were transiently transfected 
in HEK293. Nuclear extracts were subjected to AP (affinity precipitation) with 
Streptavidin agarose beads. Biotinylated proteins bound to beads were incubated with 
Thrombin or Enterokinase. Bound proteins (S) and removed proteins (FT) were 
separated on a 6 % SDS-polyacrylamide gel and blotted to PVDF membranes. 
Detection was by immunoblotting with anti-Sp3 antibody.  
Abbreviation: I input-NE without AP; C control- Streptavidin beads incubated just 
with thrombin cleavage buffer; S Streptavidin beads incubated with nuclear extract; FT 
flow-through after Streptavidin AP. Site Specific Proteases incubation time is indicated 
above.  
 
3.4.3.6. Calmodulin-TEV-BiotinTAG System  
I found that site specific proteases, Thrombin and Enterokinase, did not work in our 
system. The strategy was changed to utilize a site specific protease already successfully 
used in the TAP-TAG method, Tobacco Etch Virus (TEV). I replaced the Thrombin 
recognition site and the FLAG tag with CalBP (Calmodulin Binding Peptide) and a 
cleavage site for TEV protease by recloning from TAP-TAG expression vector. The 
most important aspect is that the TEV cleavage site is required to be flanked by spacer 
sequences for a good functionality. The spacers confer a suitable conformation of the 
TEV recognition site for it to be easily reached by the enzyme. The BiotinTAG was 
maintained at the end of the tag. 
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Fig.3.37. CTB tandem affinity purification system. Explanation: see text. 
Abbreviations: B - Biotin; TEV - Tobacco Etch Virus protease cleavage site; CalBP - 
Calmodulin Binding Peptide.  
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The new purification strategy is illustrated in Fig.3.37. Into the MCS of the 
mammalian expression vector pN3, I cloned full length PIAS1 fused to the tag 
containing CalBP, TEV cleavage site and BiotinTAG (CTB) resulting in the 
pN3-PIAS1-CTB expression construct. The first two steps of the strategy are similar to 
the purification scheme described in Fig.3.33: the tagged protein of interest is 
biotinylated by exogenous BirA enzyme and then bound to Streptavidin beads. Most of 
contaminants are removed after intensive washing of the beads. In the third step, the 
protein of interest containing complex is detached from Streptavidin matrix by TEV 
protease and is bound, subsequently, to Calmodulin beads in the presence of Ca 2+ ions. 
The remaining contaminants not removed after the first affinity column purification 
are expected to be washed away at this step. Elution of the protein complex from 
Calmodulin beads in the next step utilizes Calmodulin Elution Buffer (CEB) containing 
0,5M EGTA. 
To confirm the efficiency of the new purification method, every part of CTB tag 
was tested, including binding ability (CalBP and BiotinTAG) and the functionality of 
TEV cleavage site.  
In these experiments, I used the Sp3-CTB tagged construct (Fig. 3.38 schematic 
drawing) to permit better Sp3 detection by Western Blot following removal of 
BiotinTAG, using anti Sp3 specific antibody.2  
HEK293 cells were transfected with pN3-Sp3 –CTB and pBud-BirA expression 
plasmids. As it can be seen in the Fig. 3.38- input line (I), the Sp3-CTB expression 
band migrated slower following SDS-PAGE and Western Blot analyses compared to 
endogenous long isoform bands (liSp3). In the positive control (C+), the Sp3-CTB 
protein was bound to Streptavidin beads (S) but endogenous Sp3 was found in flow- 
through (FT).  
                                                 
2  The CTB tagged protein of interest is detectable with Streptavidin-HRP. After removing of 
BiotinTAG, an antibody against protein of interest is required. Since PIAS1 detection with anti-PIAS1 
antibody was possible at the end of my work due to changing in blocking step (blocking with 1% BSA 
instead 5% Skimmilk was used), the anti Sp3 antibody for Sp3-CTB construct was used for this 
experiment. 
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In order to test the TEV protease cleavage efficiency, HEK293 nuclear extracts 
containing biotinylated Sp3-CTB tagged protein, were incubated with Streptavidin 
beads. Most contaminant proteins were removed at this step by intensive washing. The 
Streptavidin beads were incubated for 2h at 16 0C with recombinant TEV protease, 
according to manufacturers recommendations. Following TEV incubation, the 
flow-through was equilibrated with Calmodulin binding buffer (IPP-150) and subjected 
to Affinity Precipitation (AP) with Calmodulin beads in the presence of Ca2+ for 2h at 
4 0C. The Streptavidin beads (S), Calmodulin beads (Cal) and flow- through (FT) after 
Calmodulin beads incubation, were analyzed separately in the Fig.3.38 noted as 120 
min TEV. 
   
  
 
Fig. 3.38 Investigation the cleavage activity of TEV – Tobacco Etch Virus 
protease.  
Sp3–CTB (Sp3-CalBP-TEV-BiotinTAG schematically drawn in lower figure) and BirA 
expression constructs were transiently transfected in HEK293. Nuclear extracts were 
subjected to AP using Streptavidin agarose beads. Biotinylated proteins bound to beads 
were incubated with recombinant TEV and the flow through was affinity purified using 
Calmodulin beads. Proteins bound to beads or precipitated from flow-through via TCA, 
were separated by 6.0% SDS-polyacrylamide gel electrophoresis and blotted to PVDF 
membranes. Detection was by immunoblotting with anti-Sp3 antibody.  
Abbreviation: I input-NE without AP; S - Streptavidin beads incubated with NE from 
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Sp3-CTB transfected cells; CAL Calmodulin beads incubated with FT from 
Streptavidin beads after TEV incubation; FT flow-through after AP. TEV incubation 
time is indicated above. 
 
Conclusions: 
1. The pN3-Sp3-CTB construct was expressed following transient transfection in 
HEK293 cells. The expression of Sp3 as fusion with CTB tag led to an increase in its 
molecular weight. This aspect is highlighted in Fig. 3.38 (I-Input line 1) where the 
Sp3-CTB band was discriminated from endogenous Sp3 long isoforms.  
2. Coexpression of pBud-BirA induced efficient biotinylation of the BiotinTAG 
that allow the binding to Streptavidin beads of Sp3-CTB (Fig. 3.38 –line 2). 
3. The TEV protease cleaved the Sp3 tagged construct from the Streptavidin beads  
(Fig.3.38 - line 4). 
4. Exogenous Sp3 with BiotinTAG removed by TEV bound Calmodulin beads (Fig. 
3.38 -120 min TEV- Cal line5) and was not detected in flow- through (FT) after TCA 
precipitation (line 6). 
 
3.4.4. Enzymatic Activity of Overexpressed PIAS1 
It was revealed in the previous experiments that after overexpression, PIAS1 did 
not enhance endogenous Sp3 SUMOylation (Fig.3.30) but the bacterially expressed 
PIAS1 is acting as E3 ligase in vitro (Fig.3.29). 
Having established an overexpression system for CTB-tagged proteins, we asked 
whether overexpressed and affinity purified PIAS1 from mammalian cells can act as an 
E3 ligase in Sp3 SUMOylation. I tested first the E3 ligase activity of overexpressed 
PIAS1 coupled to Streptavidin beads without success (data not shown). The question 
was whether PIAS1 could display the E3 ligase activity after being cleaved from 
Streptavidin beads by TEV protease. 
The same SUMOylation mix consisting of recombinant HA/FLAG-tagged Sp3, 
recombinant E1 (Aos1 and Uba2 subunits), E2 (Ubc9) enzymes and recombinant 
SUMO1 was used like for the experiment depicted in Fig.3.29. The bacterially 
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expressed GST-PIAS1 was incubated with SUMOylation mix (Sapetschnig et al., 2002) 
as a control for Sp3 SUMOylation (Fig 3.39-line2).  
Expression constructs for PIAS1–CTB (pN3-PIAS1-CTB) and BirA (pBud-BirA) 
were transiently transfected into HEK293. Nuclear extract was subjected to affinity 
precipitation with Streptavidin agarose beads. Biotinylated PIAS1bound to beads was 
cleaved from beads by recombinant TEV protease. The free overexpressed PIAS1 was 
incubated with SUMOylation mix (Fig 3.39-line 4). The SUMOylation mix was 
incubated with in vitro SUMOylation buffer Fig 3.39-line1) and TEV cleavage buffer 
(Fig 3.39-line3), as controls, in order to check whether the buffers may possibly 
influence the SUMO modification. 
    
Fig.3.39. Affinity purified PIAS1 from HEK293 cells can stimulate SUMO 
conjugation to Sp3. 
A. In vitro SUMOylation assay. 
 1. SUMOylation mixture containing HA/FLAG-tagged Sp3 was subjected to SUMO 
modification in vitro with limiting amounts of recombinant E1 (Aos1 and Uba2 
subunits), E2 (Ubc9) enzymes and recombinant SUMO1. 
2. SUMOylation mixture incubated with bacterially expressed GST-PIAS1.  
3. SUMOylation mixture incubated with TEV cleavage buffer. 
4. SUMOylation mixture and overexpressed PIAS1CTB, affinity purified by 
Streptavidin beads and cleaved from beads with TEV. 
Proteins were separated on an 8.0 % SDS-polyacrylamide gel and blotted to PVDF 
membranes. Detection was performed by immunoblotting with anti-Sp3 antibody.  
B. Schematic drawing of PIAS1-CTB. Color code for PIAS1: The blue box represent 
the SAP (SAFA, Acinus, PIAS) domain, the red box indicates the RING-like domain 
and the green box the Serine-rich region.  
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One can conclude from this experiment that after releasing of overexpressed PIAS1 
from Streptavidin beads by TEV cleavage, a moderate E3 ligase activity can be 
observed (Fig 3.39-line4) when compared to the strong enzymatic activity of 
recombinant PIAS1 (Fig 3.39-line2). 
 
3.4.5. E3 ligases are High Molecular Complexes Components 
PIAS-triggered SUMOylation induces the transient recruitment of a transcription 
factor to subnuclear structures. In these structures a corepressor complex is assembled 
on the transactivator, leading to inhibition of its activity and gene silencing. As 
described in detail in the text, an analogous model can explain the context-dependent 
coactivator role of PIAS proteins. (Schmidt and Müller, 2003) 
Hence, raises the critical question: whether PIAS1 is a protein complex member or 
is just a monomer protein. 
To address this question, I used SEC (size exclusion chromatography) of nuclear 
extracts from HEK293 cells transfected with expression constructs for PIAS1-CTB and 
Sp3-CTB together with biotin ligase BirA.  
In order to avoid unspecific protein complexes accumulation due to the high level 
of chromatin in the nuclear extracts, I treated the nuclear extracts with Benzonase 
(Sigma). 
Fresh nuclear extracts from HEK293 cells, transfected with CTB tagged expression 
constructs for PIAS1 and Sp3 along with BirA, were subjected to nuclear fractionation 
throughout Superose6 column. The reason to use Superose6 was that this column has a 
broader range of separation than Superdex 200 column. 
Each fraction was equilibrated with Calmodulin binding buffer (IPP-150) and 
subjected to affinity precipitation via Calmodulin beads. The proteins bound to beads 
were separated through SDS-PAGE gels and detection was performed by 
Streptavidin-HRP conjugated. 
The fractionation profiles of CTB tagged PIAS1 and SP3 are depicted in Fig.3.40.  
Both exogenous proteins are clearly detected in blots and were found to be parts of 
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protein complexes. Despite the affinity precipitation with Calmodulin beads, traces of 
endogenous biotinylated proteins are detectable (marked with stars-*).The input 
controls nuclear extracts (NE) was not subjected to fractionation. Because the Sp3-CTB 
control is overexposed, for a better discrimination between endogenous biotinylated 
proteins and Sp3-CTB, a lower exposed band of input was added.  
 
 
 
Fig.3.40. Gel fractionation profiles of PIAS1 and Sp3 overexpressed in HEK293 
cells. 
 Expression constructs for PIAS1 (pN3-PIAS1 CTB) and Sp3 (pN3-Sp3 CTB) were 
transfected in HEK293 cells along with BirA biotin ligase (pBud-BirA). Nuclear 
extracts were treated with Benzonase and then subjected to size exclusion 
chromatography by Superose 6 column. Affinity purification of PIAS1 CTB or Sp3 
CTB tagged proteins was performed with each fraction using Calmodulin beads via 
CalBP tag of PIAS1 (upper blot) and Sp3 (lower blot). Proteins bound to Calmodulin 
beads were separated through 8% SDS polyacrylamide gels. After blotting, PVDF 
membrane was incubated with Streptavidin – HRP conjugated.  
The molecular weigh markers are indicated above the figure. Stars (*) indicates the 
endogenous biotinylated proteins.  
 
PIAS1 and Sp3 appear to form high molecular complexes. According to 
observation of another group (S.Philippsen-Rotterdam, unpublished), just PIAS1 can 
form complexes but not Sp3. To test if these observed complexes are specific or just 
unspecific accumulation of proteins, we analyzed gel filtration fractions by Western 
blotting, probing membranes with specific antibodies against different proteins 
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endogenous proteins Brg1 (A), Tip60 (B), Sp1 (C), and Sp3 (D) in Fig. 4.39.  
The first control blot was performed with specific antibody against Brg1, one of the 
catalytic ATPase subunit of the large SWI/SNF complex protein that is involved to the 
regulation of gene expression by altering the chromatin structure (Muchardt and Yaniv, 
2001). It can be observed in Fig.3.41-A that the Brg 1 is detected at a highest molecular 
range compared to other proteins analyzed.  
Tip60 (Tat interactive protein, 60 kDa), a MYST family HAT first identified as an 
HIV-Tat interacting protein, is an androgen receptor (AR) co-activator and exerts its 
effect via directly acetylating the AR, while it counters the deacetylating repressing 
effect of HDAC1 (Halkidou et al., 2004). This protein (Tip60 B- blot) exhibit an 
different fractionation profile if compared with Sp1 (C) and Sp3 (D). Another 
interesting finding is that phosphorylated Sp1 (Fig.3.41-C-upper band), appear to be 
associated with high molecular protein complexes if compared to unphosphorylated 
form of Sp1 (Fig.3.41-C-lower band). Also one can observe that Sp3 small isoforms 
are detected in almost all fractions if compared with Sp3 long isoforms, found 
predominantly into high molecular weigh fractions Sp3 (D). 
 
 
Fig.3.41.Gel fractionation profiles of endogenous Brg1 (A), Tip60 (B), Sp1 (C), 
Sp3 (D) in HEK293 cells. Nuclear extracts were treated with Benzonase and then 
subjected to size exclusion chromatography by Superose 6 column and then gel 
filtration fractions were separated through 8% SDS polyacrylamide gels. After blotting, 
PVDF membranes were incubated with anti Brg1 SC (A), anti Tip60 SC (B), anti Sp1 
serum (C) and antiSp3 SC (D) specific antibodies.  
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To conclude, the fractionation profiles confirm the association of PIAS1 to protein 
complex(es). This association appears to be specific because different proteins exhibit 
specific fractionation patterns. 
 
3.4.6. Tet-Off PIAS1 and Sp3 Expression Systems 
Our option for PIAS1 protein complex purification was an inducible stable cell line 
system, because for purified complex protein analysis high amount of transfected cells 
is required. Expression of proteins of interest after transient transfection is not the best 
option because it is expensive and on the other hand, transfected protein is expressed in 
very high level and may recruit unspecific proteins to the physiological complex.  
CalBP-TEV-BiotinTAG  tagged versions of PIAS1 and as control, Sp3 were 
cloned in pTRE2pur, a response plasmid that expresses our genes of interest (PIAS1 or 
Sp3) in Clontech's  Tet-Off  Gene Expression Systems and Tet-Off Cell Lines using the 
Tetracycline controllable expression systems (the "Tet Technology"), schematic 
represented in Fig.3.42. 
In E. coli, the Tet repressor protein (TetR) negatively regulates the genes of the 
tetracycline-resistance operon on the Tn 10 transposon. TetR blocks transcription of 
these genes by binding to the Tet operator sequences (tetO) in the absence of 
Tetracycline. TetR and tetO provide the basis of regulation and induction for use in 
mammalian experimental systems. 
The first critical component of the Tet Systems is the regulatory protein, based on 
TetR. In the Tet-Off System, this 37-kDa protein is a fusion of amino acids 1–207 of 
TetR and the C-terminal 127 aa of the Herpes simplex virus VP16 activation domain. 
Addition of the VP16 domain converts the TetR from a transcriptional repressor to a 
transcriptional activator, and the resulting hybrid protein is known as the 
tetracycline-controlled transactivator (tTA). The tTA is encoded by the pTet-Off 
regulator plasmid, which also includes a Neomycin-resistance gene to permit selection 
of stably transfected cells. 
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Fig.3.42. Schematic of PIAS1 gene regulation in the Tet-Off System.  
The TRE is located upstream of the minimal immediate early promoter of 
cytomegalovirus (PminCMV), which is silent in the absence of activation. tTA binds 
the TRE and thereby activates transcription of PIAS1in the absence of Tetracycline.  
 
The second critical component is the response plasmid which expresses a gene of 
interest (PIAS1 or Sp3) under control of the tetracycline-response element, or TRE. 
The pTRE contain the TRE, which consists of seven direct repeats of a 42-bp sequence 
containing the tetO, located just upstream of the minimal CMV promoter (PminCMV). 
PminCMV lacks the strong enhancer elements normally associated with the CMV 
immediate early promoter. Because these enhancer elements are missing, there is low 
background expression of PIAS1 or Sp3 from the TRE in the absence of binding by the 
TetR domain.  
The ultimate goal in setting up a functional Tet System is creating a double stable 
Tet cell line, which contains both the regulatory and response plasmids. When cells 
contain both the regulatory (pTet-Off) and the response (e.g. pTRE- PIAS1-CTB) 
vectors, PIAS1-CTB is only expressed upon binding of the tTA protein to the TRE and 
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activates transcription in the absence of Tetracycline in a precise and dose-dependent 
manner (Fig.3.42). 
Given that each cell line has a different sensitivity to G418, Puromycin and Zeocin, 
titration to determine the optimal concentration of drug for selection was required (see 
Methods - Kill Curves). For HeLa Tet-OFF cells, I have found 400 µg/ml of G418 to be 
optimal, the optimal level of Puromycin was typically around 1 µg /ml and for Zeocin the 
level was 80 µg /ml. 
Before transfection with PIAS1 and Sp3 expression constructs, the HeLa Tet-Off 
cells (stable transfected with the regulatory plasmid), were tested for activity of Tet 
regulatory plasmid already stable transfected by monitoring of Luciferase intensity after 
transfecting the pTRE2pur-Luc Control Vector, used as a reporter of induction efficiency 
(Fig.3.43).  
 
  
 
Fig.3.43. Monitoring the induction of Luciferase activity in HeLa Tet-Off Cells 
when tested by transient transfection with pTRE2pur-Luc. One µg of the 
pTRE2pur-Luc Control Vector was transfected by calcium phosphate (Ca lines 2 and 3) 
and Fugene6 (Fu6 lines 4 and 5) transfection methods, in the absence (-Tetra) or in the 
presence (+Tetra) of Tetracycline. Negative control (C- line 1) represents cells 
transfected with pTRE2pur vector. 
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Transient transfections with pTRE2pur-Luc by calcium phosphate and Fugene6 
transfection methods were performed, in the presence or absence of Tetracycline. In the 
cells used for stable transfection experiments, after Tetracycline removing, the induction 
was significantly high. 
After stable transfection into HeLa Tet-OFF of the pTRE2purPIAS1CTB or Sp3CTB 
constructs (schematically drown in Fig.3.44), selection was performed with Puromycin 
(see Methods). Simultaneously, the selection antibiotic (G-418) for the Tet-Off 
regulatory plasmid was added into the medium. Biotin ligase BirA expression constructs 
(under tetracycline control pBUD-tTA-BirA or normal pBUD-BirA) were transfected 
(Zeocin selection) together with PIAS1 and Sp3 or following pre-selection with 
Puromycin.  
The next step screened for induction and expression of stable transfected PIAS1 and 
Sp3 clones. For PIAS1 I tested fifteen clones, eight double transfected with tetracycline 
controlled BirA and seven double transfected with unregulated (pBUD-BirA). As well, 
ten Sp3 clones were analyzed, five cotransfected with tetracycline controlled BirA and 
five colonies cotransfected with pBUD-BirA. 
In Fig.3.44-A the screening for expression of one stable cotransfected 
pTRE2pur-PIAS1-CTB with pBUD-BirA (the colony nr.5) is depicted. Fig.3.44-B and 
C displays the expression screening of one colony (nr.13) of stable transfected 
pTRE2pur-Sp3-CTB and pBUD-BirA. 
As controls, the same expression constructs (schematically drawn in Fig. 3.44), used 
for making stable transfected PIAS1 and Sp3 cell lines, were transiently transfected in 
HEK293 cells together with Tet-Off regulatory plasmid (pTet-OFF) and Biotin ligase 
BirA (pBUD-tTA-BirA). 
In PIAS1-CTB stable transfected clones there was not inducible expression 
detectable by Western Blot with Streptavidin-HRP. In the example presented in 
Fig.3.43-A, the expression of pTRE2pur-PIAS1-CTB construct was clearly detectable 
after transient transfection with BirA into HEK293 cells (positive control - C+) but not 
in a stable transfected clone. The weak band present in the range of PIAS1-CTB 
expression was an endogenous biotinylated protein. 
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Interestingly, the stable Sp3-CTB exhibited a specific band in Western Blot 
following detection using anti Sp3SC antibody (Fig.3.43-C), which was clearly 
separated from endogenous Sp3 long isoform (liSp3) or endogenous biotinylated 
proteins (Fig.3.43-B). The expression of tagged Sp3 in cells treated with Tetracycline 
was similar to the level seen in induced cells. This observation led us to the conclusion 
that Sp3-CTB expression in Tet-OFF cells appeared not to be Tetracycline controllable. 
 
 
 
Fig.3.44. Examples of stable transfected PIAS1 and Sp3 clones in HeLa Tet-OFF 
cells.  
A. Stable transfected HeLa Tet-Off cells with expression constructs for PIAS1 
(pTRE2pur-PIAS1-CTB) and Biotin ligase BirA (pBUD-BirA) in the presence or 
absence of Tetracycline. C+ represents transient transfected HEK293 with Tet-Off 
regulatory plasmid (pTet-OFF), Biotin ligase BirA (pBUD-tTA-BirA) and PIAS1 
(pTRE2pur-PIAS1-CTB). 
B. and C. Stable transfected HeLa Tet-Off cells with expression constructs for Sp3 
(pTRE2pur-Sp3-CTB) and Biotin ligase BirA (pBUD-BirA) in the presence or absence 
of Tetracycline. C+ represents transient transfected HEK293 with Tet-Off regulatory 
plasmid (pTet-OFF), Biotin ligase BirA (pBUD-tTA-BirA) and Sp3 
(pTRE2pur-Sp3-CTB). 
Proteins were separated by 6.0% SDS-polyacrylamide gel electrophoresis and blotted 
to PVDF membranes. Detection was by immunoblotting with Streptavidin-HRP and 
anti-Sp3 antibody as indicated.  
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 4. Discussion 
 
4.1 Transcription Factors are Substrates for SUMO Modification 
The covalent attachment of the ubiquitin-like SUMO protein to its substrates 
(SUMOylation) represents, in addition to ubiquitination, one of the best-studied 
examples of a posttranslational modification that stably joins one protein to another. 
Although both ubiquitination and SUMOylation have important mechanistic 
similarities and represent evolutionarily ancient and conserved pathways, their 
physiological consequences are quite distinct. Ubiquitination is generally, but not 
always, associated with proteasomal protein degradation. By contrast, SUMOylation 
affects target protein function by altering the subcellular localization of the protein or 
by antagonizing other modifications (Seeler and Dejean, 2003). 
Since the identification of the first SUMO-modified protein, RanGAP, in 1996 
(Matunis et al., 1996), a large number of proteins have been shown to be 
posttranslationally modified by SUMO and new substrates of SUMO-modification 
continue to be identified at a rapid pace. The currently known SUMO target proteins 
fall into multiple categories, such as transcription factors, signal transducers, enzymes 
or viral proteins. Some of the many proteins now known to be modified by SUMO are 
shown in Fig.4.1. 
Recently, a number of transcriptional activators have been recognised as SUMO 
targets (Gill, 2003; Verger et al., 2003) including steroid hormone receptors (Kotaja et 
al., 2002), proteins of the C/EBP family (Kim et al., 2002), p53 (Gostissa et al., 1999; 
Rodriguez et al., 1999), c-jun (Müller et al., 2000) IkBα (Desterro et al., 1998), p73 
(Minty et al., 2000), and LEF-1 (Sachdev et al., 2001).  
One of the evidence for SUMO modification of Sp3 in vivo comes from 
overexpression experiments in which gene constructs encoding GFP-Sp3WT or a 
mutant thereof GFP-Sp3K/R were co-transfected along with expression constructs 
coding for GFP-SUMO1 or GFP-SUMO2 (see Fig. 3.3. Sp3 is SUMO modified in 
vivo). 
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Fig.4.1 SUMO substrates grouped by function.  
Budding yeast, fission yeast, Drosophila and Dictyostelium proteins are indicated by 
(Sc), (Sp), (Dm) and (Dd), respectively; all others are mammalian proteins.  
(Seeler and Dejean, 2003) 
 
A slow-migrating form of GFP-Sp3WT was detected in the presence of SUMO1 or 
SUMO2 fusion protein demonstrating that both SUMO1 and SUMO2 become 
efficiently conjugated to Sp3 when overexpressed in cell culture. In contrast, a slow 
migrating protein was absent with the GFP-Sp3K/R mutant. The slow-migrating band 
was similarly abundant in the presence of SUMO1 or SUMO2, suggesting that the 
attachment of both SUMO3 paralogues to Sp3 occurs with almost equal effectiveness. 
The essential questions about the distinctions between different SUMO family 
members are whether conjugation of particular substrates is restricted to single SUMO 
                                                 
3 SUMO4 was discovered recently as potential transcript with homologies to the SUMO gene family, 
after database searches in intron 6 of MAP3K7IP2 gene (Guo et al., 2004). I will refer further just to 
SUMO1 and SUMO2/3. 
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paralogue, or whether different paralogues can be used interchangeably. For a few 
substrates, strong paralogue preferences have been documented, for instance, 
RanGAP1 is modified almost exclusively by SUMO1 in vivo (Saitoh and Hinchey, 
2000). Other substrates, such as the Promyelocytic Leukemia protein (PML), have been 
reported to be conjugated with both SUMO1 (Sternsdorf et al., 1999) and SUMO2/3 
(Kamitani et al., 1998) in vivo. 
On the other hand, at Sp3 endogenous level, the question of which SUMO 
paralogue is particularly involved in Sp3 SUMOylation is still open. We observed that 
different antibodies raised against SUMO1 or SUMO2/3 are not able to recognize in a 
sensitive manner that would allow detection of SUMO-modified endogenous Sp3 
protein, which was affinity purified from mammalian cell extracts.  
Also, the issue of specificity is complicated by the fact that paralogue preference 
can be compromised when individual SUMO proteins are present at superphysiological 
concentrations (Azuma et al., 2003). Since the conjugation of many proteins to SUMO1 
has been demonstrated under conditions where those SUMO proteins are highly 
overexpressed, categorization of paralogue preference for these substrates cannot be 
considered definitive until their modification is examined under more physiological 
conditions. Second, to the extent that there is substrate specificity, it is not known how 
this specificity arises. This is a particularly interesting question because the same 
SUMO E1 and E2 enzymes are shared between all paralogues. Finally, it is not known 
whether the consequences of conjugation to different paralogues are distinct.  
Attachment of all SUMOs in vitro occurs with almost equal efficiency on the same 
protein substrates in the presence of only two SUMO-specific enzyme activities known 
as E1 activating, and E2 conjugating enzymes (Tatham et al., 2001).  
 
4.2. SUMO Consensus Modification Sites of Sp3  
The major SUMO acceptor lysine in the transcription factor Sp3 has been mapped 
to a previously described inhibitory domain of the protein (Dennig et al., 1996). 
Removal of SUMO from Sp3 by mutation of the acceptor lysine and mutations of other 
residues in the SUMO consensus site, led to a dramatic increase in the transcriptional 
activity of Sp3 emphasizing that the integrity of the SUMO consensus motif is critical 
for SUMOylation (Sapetschnig et al. 2002). 
Study of endogenous Sp3 modification by SUMO is complicated by the existence 
of various Sp3 isoforms. Immunoblot analyses revealed four Sp3 distinct proteins, two 
slow migrating of more than 100 kDa and two fast migrating species of approximately 
Discussion 
 164
72 kDa (see Fig. 3.5. Complexity of endogenous Sp3 protein expression). Seven to 
eight Sp3 bands appear, when cells were lysed in special conditions, the additional 
bands represent SUMO modified Sp3 isoforms. All signals are specific for Sp3 since 
extracts prepared from Sp3-deficient embryonic stem cells did not cause any 
background. The Sp3 SUMOylation takes place at lysine K551 within inhibitory 
domain, present in all four isoforms.  
The SUMO acceptor sites in several other transcription factors such as the 
glucocorticoid receptor (GR), Myb, and C/EBP (CAAT/enhancer binding protein) have 
also been mapped to previously identified inhibitory regions of these proteins, and 
mutation of the major SUMO acceptor sites in these factors leads to an increase in 
transcriptional activation (Tian et al., 2002; Le Drean et al., 2002; Bies et al., 2002). It 
is worth noting that the activity of these SUMO-regulated inhibitory domains is not 
dependent on their position within the protein and the inhibitory function can be 
transferred to other transcriptional activators (Dennig et al., 1996; Kim et al., 2002).  
Many proteins harbor one or multiple SUMO consensus modification sites (KXE), 
but only a fraction of these sites are actually modified. It is likely that the SUMO1 
conjugation site on target proteins is located in flexible surface loops or termini, as 
shown in p53 and as predicted for other SUMO1 target proteins where the conjugation 
sites have been identified.  
Sequence analyses of Sp family members, indicated that Sp1, Sp3 and Sp5 carry 
sequences reminiscent of consensus sites for SUMOylation. As shown in Fig.3.9 (Other 
potential SUMOylation sites in Sp3), three lysines embedded within SUMO consensus 
motifs were noted at amino acids 9 (VKQE), 120 (IKDE) and 551 (IKEE) of Sp3. 
Putative sites of SUMOylation were also noted at lysine 16 and lysine 391 of Sp1 and 
Sp5, respectively. So far, there are no reports concerning Sp1 and Sp5 modification by 
SUMO. Nonetheless, our experiments regarding Sp1 expression in immunoblotting, did 
not give us any indication about Sp1 SUMOylation.  
The well-known example of SUMO target proteins harboring multiple SUMO 
consensus sites is Topoisomerase I (TOP1). Topoisomerase I is required to remove 
negative supercoils from DNA (Watts, 2004) and is a target for the anti-cancer drug 
camptothecin (CPT). Treatment of mammalian cells with CPT results in the appearance 
of at five SUMO modified forms of TOP1 which differ in size by around 20 kDa (Mao 
et al., 2000).  
Despite the fact that Sp3 also bears three SUMO consensus sites, we never 
observed three SUMO modified forms of Sp3 in immunoblotting. The controversy 
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upon additionally potential Sp3 SUMO motifs was elucidated by carefully analyzing 
expressions of the full-length versions of wild-type Sp3 (containing all three potential 
SUMO motifs) or the K551R mutant either HA-epitope tagged at the N terminus or the 
C-terminus (see Fig. 3.10. Posttranslational modification of full-length Sp3 by SUMO). 
SUMO-modified Sp3, visualized in immunoblot as a single, slower migrating species, 
was detected with the wild-type Sp3 construct but not with the Sp3K551R construct. 
This result strongly suggests that exclusively K551 becomes SUMO-modified but not 
K9, K120 or any other lysine residue of the Sp3 sequence.  
Nonetheless, it was reported that Sp3 may have, beside K551, an additional SUMO 
motif (K120) which undergoes SUMOylation (Ross et al., 2002). Western blot analysis 
of extracts from cells transfected with wild-type Gal4-Sp3 or constructs containing to 
arginine mutations  corresponding to position 120 and 551 of full length Sp3, showed 
that there was one major SUMOylated form of wild-type Gal4-Sp3 as well as at least 
one minor form. Mutation of K551 completely abolished the major sumoylated form of 
Gal4-Sp3. In contrast, mutation of K120 had no effect on the major SUMO1-modified 
form of Gal4-Sp3 but appeared to disrupt the slower migrating minor SUMOylated 
form. When both lysines K120 and K551 were mutated to arginine, no 
SUMO1-modified forms of Gal4-Sp3 were detected. Nevertheless, the poor quality of 
immunoblots as well as abnormal migration of SUMOylated Sp3 bands led us to 
conclusion that the assertion of Ross and coworkers regarding SUMOylation of lysine 
120 within Sp3 sequence is not convincing at all.  
 
4.3. Competition for Target Lysines  
As lysine residues can act as acceptors for a range of protein and non-protein 
modifiers (e.g. SUMO, ubiquitin, NEDD8, methylation and acetylation) it is entirely 
plausible that covalent addition of SUMO or other modifiers to particular lysine 
residues could act as a switch to direct the modified proteins into complexes with 
different functions. 
The alternative modification by SUMO or ubiquitin at the same lysine residue has 
been described for PCNA (proliferating cell nuclear antigen) protein (Hoege et al., 
2002). PCNA acts as a ‘sliding clamp’ on DNA, and is involved in several different 
processes associated with replication, including leading and lagging strand DNA 
synthesis, mismatch repair, nucleotide- and base-excision repair, post-replicative 
error-prone and error-free repair and cell cycle arrest. Ubiquitination of PCNA, 
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however, is not implicated in protein degradation, but plays a pivotal role in DNA 
repair. Intriguingly, SUMOylation seems to inhibit the role of PCNA in DNA repair. 
This led to the idea that lysine residues that are affected by alternative modifications 
may function as regulatory switchboards that can direct proteins to alternate functions 
(Hoege et al., 2002). The switch of modifications may allow the exchange of binding 
partners and thus control protein-protein interactions. However, biochemical analysis of 
the modification status of PCNA in yeast indicates that only a small proportion of 
PCNA contains covalently attached SUMO or ubiquitin (Hoege et al., 2002). 
The role of SUMO in protein stabilization has most convincingly been illustrated 
on the inhibitor of nuclear factor kappa B alpha (IkBα). In this particular case SUMO 
modification occurs at the same lysine residue that is used for ubiquitination (Kagey et 
al., 2003).  Whereas ubiquitination of Lys-21 in IkBα requires phosphorylation of the 
adjacent Ser-32 and Ser-36 residues, SUMO1 preferentially targets the stable, 
unphosphorylated form of IkBα, indicating that it acts antagonistically to ubiquitin to 
protect IkBα from degradation (Desterro et al., 1998). 
Another example of antagonism of posttranslational modifications to a particular 
lysine is regarding Sp3 transcription factor. Originally, it was demonstrated that Sp3 is 
an acetylated protein in vivo. Strikingly, a mutant of Sp3 that lacks the inhibitory 
domain containing the lysine residue of the IKEE sequence exhibited a far weaker 
acetylation compared to wild type (Braun et al., 2001). This result suggested originally 
that acetylation of this lysine is responsible for silencing.  
Nevertheless, the experiments described later on (Sapetschnig et al., 2002) which 
identify the lysine of the IKEE sequence as a substrate for SUMO modification, led to 
reconsideration of the role of acetylation. At that time, the experimental data suggested 
that the same lysine residue can be modified by either acetylation or SUMOylation. 
Since both covalent modifications occur at the ε-amino group of the lysine, acetylation 
would prevent SUMO modification and vice versa. SUMO modification silences Sp3 
activity since all mutations that prevent SUMOylation relieve inhibition. However, 
recent experiments indicate that antibodies highly specific for the acetylated IKEE 
motif of Sp3 did not recognise endogenous Sp3 or Sp3 over-expressed in 293 cells or 
SL2 cells, suggesting that lysine residue K551 is not acetylated in vivo or the 
acetylation level of this particularly lysine is under detection limit of the antibodies. 
Most likely, the acetylation happens at other lysine residues in the DNA-binding 
domain. 
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Other Sp/KLF factors are also acetylated in the zinc finger DNA-binding domain 
(Suzuki et al., 2003). EKLF/KLF1 is acetylated by p300 and its homologue CBP at two 
lysine residues, one residing in the DNA-binding zinc finger domain and the other in 
the transactivation domain. The mutation of the zinc finger acetylated residue does not 
affect DNA binding activity and the individual role of its acetylation is unclear, but 
mutation of the transactivation domain lysine residue results in decreased 
transactivation and acetylation collectively increased affinity for the SWI/SNF 
chromatin remodeling factors (Zhang and Bieker, 1998; Zhang et al, 2001). 
 
4.4. SUMOylation and Subcellular Localization 
Depending on the target protein, SUMOylation can occur in the cytoplasm or 
nucleus, and this modification could be involved in regulating the subcellular 
localization of a number of substrate proteins (Hilgarth et al., 2004). 
Posttranslational modification by SUMO has been shown to regulate subcellular 
localization of many targets including RanGAP, the first identified SUMO substrate 
(Matunis et al., 1996). RanGAP is a small GTP transactivating protein that plays a role 
in nuclear import. Unmodified RanGAP is cytoplasmic, whereas SUMO modified 
RanGAP is associated with the nuclear pore (Matunis et al., 1996; Mahajan et al., 
1997). SUMO modification of RanGAP greatly increases its interaction with RanBP2 
(also known as Nup358), a component of the nuclear pore complex and a SUMO E3 
ligase (Pichler et al., 2002). Localization of the RanBP2 SUMO E3 ligase at the nuclear 
pore may contribute to a broad role for SUMO in regulation of nuclear trafficking 
(Melchior et al., 2003). In mammalian cells, SUMO modification of several substrates 
has been linked to nuclear import. In the case of the IkB kinase regulator NEMO, for 
example, fusion of NEMO to SUMO was sufficient for localization to the nucleus 
(Huang et al., 2003).  
As well as controlling protein subcellular targeting, SUMO has a role in controlling 
gross subnuclear architecture. This is best exemplified by the PML NBs, the integrity 
of which is dependent on the SUMOylation of their principal component, PML.  
The promyelocytic leukemia (PML) nuclear bodies (NBs), also known as ND10 or 
PODs (PML oncogenic domains), represent one of the best-studied examples of a 
subnuclear structure, the integrity of which is altered in human disease. PML was first 
discovered as part of the PML–RAR-α oncogenic fusion protein with the retinoic acid 
receptor-α (RAR-α) in cells from patients with acute promyelocytic leukemia (APL), in 
which expression of PML–RAR-α provoked the striking desegregations of the PML 
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NBs (Seeler and Dejean, 1999).  
Visualization of PML body dynamics in living cells, lead to define three classes of 
PML bodies, based on their mobility (Muratani et al., 2002).  
Stationary PML bodies, and those that exhibited limited localized movement, are 
indicative of structures that are stably associated with an underlying nuclear structure 
or with a specific nucleic acid or protein complex, and therefore may represent a 
mechanism of epigenetic control of gene expression. For example, several studies have 
previously shown an association between PML bodies and centromeres or other 
heterochromatin-enriched regions (Seeler et al., 1998). Alternatively, these bodies may 
be involved in transcriptional regulation by modulating local pools of soluble factors 
that may be essential for transcription. A variety of such proteins (Sp100, PML, Daxx, 
pRB and p53) have been reported to localize at least partially to PML bodies (Zhong et 
al., 2000).  
The PML dots (PODs) have also been described also as ‘‘proteolysis centers’’ or 
‘‘aggresomes’’ to which misfolded proteins are recruited for degradation under normal 
conditions. Expression of a mutated form of influenza nucleoprotein that was misfolded 
and rapidly degraded by proteasomes led to the accumulation of the protein in the 
PODs upon inhibition of proteasome activity. This was followed by the attraction of 
proteasomes and poly-ubiquitin to the same structures, suggesting that the PODs may 
function as a site for proteasomal degradation of ubiquitinated proteins (Misteli et al., 
2001). 
The most intriguing class of PML bodies was revealed to exhibit metabolic 
energy-dependent dynamics within the cell nucleus. This group of nuclear bodies, 
although small at any given time, may act as nuclear ‘sensors’, traveling within nuclear 
regions and associating with populations of foreign or ‘suspect’ proteins, including 
viral proteins. The previously observed initial association between PML bodies and 
nuclear sites of viral DNA transcription and replication, and their subsequent break-up, 
as well as the increased number of PML bodies present after interferon treatment, is 
consistent with the possibility that PML bodies act as ‘nuclear sensors’ and could 
constitute a nuclear defense mechanism. Alternatively, this group of bodies may be 
involved in associating with or marking misfolded or aggregated proteins within the 
nucleus (Muratani et al., 2002). 
However, Sp3 transcription factor emerge as one of exceptions of SUMO-targets 
association with PML bodies. Visualization of endogenous Sp3 by 
immumofluorescence showed a sponge-like, diffuse appearance along with closely 
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related Sp family members Sp1 and Sp2 that are also located into the nucleus and the 
subcellular localization patterns are similar to Sp3. Moreover, overexpressed GFP-Sp3 
displays a similar localization pattern as endogenous Sp3 protein. Also, the wild-type 
Sp3 isoforms and the SUMOylation-deficient mutants were located in the nucleus 
exhibiting the same sponge-like, diffuse appearance. Indubitable, the differences in the 
activation capacity of the various isoforms and mutants are not due to differences in 
their subcellular or subnuclear localization. 
As well, we found that endogenous SUMO1 shows a different nuclear pattern than 
Sp3. SUMO1 exhibits a diffuse nuclear distribution but in addition appeared do be 
accumulated at the rim of the nucleus and in few nuclear dots and emerged not to 
interfere with Sp3.  
Ectopic expression of GFP-SUMO1 led to the accumulation of this fusion protein 
within PODs, whereas endogenous or overexpressed Sp3 remained diffusely distributed 
throughout nuclei (see Results 2. Subcellular localization of Sp3). The evident 
conclusion of these experiments was that the Sp3 was diffusely distributed throughout 
nuclei and did not accumulate within subnuclear “dots” or PODs after SUMO 
overexpression or Ubc9 coexpression.  
The metabolic energy-dependent nuclear bodies involved in so called “defense 
mechanism” previously mentioned (Muratani et al., 2002) might enlighten the tough 
regulation of Sp3 SUMOylation level. One can speculate that SUMO is traveling (as 
small energy-dependent nuclear body) within nucleus and associate quickly with any 
“suspect” Sp3 (overexpressed or damaged and misfolded upon stress treatment) leading 
to rapid degradation of the “suspects” and keeping the Sp3 SUMOylation level 
constant. 
Very quick interaction with energy-dependent nuclear bodies and also difference in 
size compared with stationary PML bodies may explain why we did not find any 
redistribution of Sp3 upon SUMO1 overexpression. 
In contrast to our results, another group (Ross et al., 2002) utilized anti-Sp3 
antibodies and indirect immunofluorescence to detect endogenous Sp3 proteins in 
mouse P19 embryonal carcinoma cells. These studies localized Sp3 to the nuclear 
periphery as well as PODs depending on the method of fixation employed. The ectopic 
expression of a GAL4-Sp3 fusion protein in P19 cells faithfully reproduced these 
localization results, whereas a mutated construct lacking lysine 551 localized diffusely 
within the nucleoplasm. Finally, co-expression of a SUMO1 protease with Gal4-Sp3 
mobilized Gal4-Sp3 to the nucleoplasm. The same effect was observed when the 
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SUMO1 was fused of to the amino-terminus of a lysine 551-deficient Sp3 (Ross et al., 
2002). 
Nevertheless, we found that in several mammalian cells used for our experiments, 
the Sp3 protein is distributed throughout nucleus and this distribution is not uniform, 
but rather with randomic holes in a “sponge-like structure”. Most possible, the Sp3 
localization to the nuclear periphery observed by Ross and coworkers was a peculiar 
artifact due to lack of experience in immunofluorescence technique (see Fig. 3.11. Sp3 
localization under different permeabilization conditions). Moreover, this bizarre Sp3 
localization was never confirmed by another reference. 
Regarding Sp3 relocalization in NBs upon SUMO overexpression, the accurate 
design of the immunofluorescence experiments is crucial for obtaining undoubted 
results (see Fig.3.20. Sp3 and dot-like structures in Ishikawa cells). In this experiment, 
Sp3 was forcibly recruited to dots. However, this abnormal recruitment is most likely a 
forgery produced by fluorophore excitation-emission interference.  
One can deduce that many of the experiments exhibiting the relocalization of 
different SUMO targets to the PODs by employing indirect immunofluorescence 
methods should be reconsidered. New and accurate microscopy methods which are 
now available also for investigation of protein-protein interactions (Shav-Tal et al, 
2004) hopefully will edify the relocalization of SUMOylated targets controversy.   
 
4.5. Regulation of SUMO Modification at Ligation Step of the SUMOylation 
Cascade 
The initial doubts as to the existence of SUMO E3 ligases were put to rest with the 
demonstration that members of the SIZ/PIAS protein family fulfill the defining criteria 
of such factors. First, they have the capacity to interact with both Ubc9 (the E2 enzyme) 
and the substrate and, second, they can increase the rate of substrate modification. It is 
considered that E3 ligases likely arose later, during the evolution, achieving the task of 
substrate discrimination (Hochstrasser, 2000).  
Members of the PIAS protein family (PIAS1, PIAS3, PIASx und PIASy) can act as 
SUMO-specific E3 ligases for certain substrates. Possibly, PIAS proteins exert also 
functions that are independent of their E3 ligase activity. PIAS1 and PIAS3 were 
originally described as specific inhibitors of the transcription factors STAT1 and 
STAT3, respectively, by interfering with DNA binding (Chung et al., 1997; Liu et al., 
1998). 
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PIAS1 was identified in our lab in a two-hybrid screen using the inhibitory domain 
of Sp3, which contains the SUMOylation motif IKEE, as bait, initially cloned as 
protein designated SIF-1 (Sp3-interacting protein 1). Sequencing revealed later on that 
the encoded protein was identical to PIAS1 (Liu et al., 1998). PIAS1 fulfils all 
requirements to act as an E3 ligase for SUMO conjugation to Sp3. It interacts with the 
E2 enzyme Ubc9 as well as with Sp3 and SUMO-conjugated Sp3. Most importantly, it 
strongly stimulates transfer of SUMO1 and SUMO2 to Sp3 in vitro (Sapetschnig et al., 
2002). It was reported that the nucleoporin RanBP2 that is not related to PIAS proteins 
also has E3 ligase activity. RanBP2 interacts with the E2 enzyme Ubc9 and enhance 
SUMO transfer to Sp100, a component of PML nuclear bodies (Pichler et al., 2002). It 
is worth mentioning that RanBP2 does not act as an E3 ligase for SUMO conjugation 
of Sp3 (G.Suske and F.Melchior, unpublished data).  
Thus far, overexpression of PIAS1 protein in mammalian cells does not enhance 
endogenous level of Sp3 SUMOylation (see Results- Fig.3.30. Overexpression of 
PIAS1 does not influence the SUMOylation level of Sp3). The contradiction between 
the in vitro results where PIAS1 strongly enhanced Sp3 SUMOylation and the absence 
of this effect upon overexpression in cell lines, directs to the idea that the function and 
specificities of PIAS1 might be regulated by PIAS1-associated proteins.  
Recent analyses revealed that PIASxβ, but not PIAS3 and PIASy, could also act as 
an E3 ligase towards Sp3 in vitro (Diplomarbeit B. Stielow). Nevertheless, PIAS 
proteins enclose an important function in specifying the substrate for modification, 
although whether, for example, a given PIAS protein can be matched to specific 
substrates under physiological conditions in vivo remains unclear. More likely, 
additional proteins that control substrate specificity could be involved, as is also the 
case for ubiquitin E3 ligase complexes (Seeler et al, 2003).  
Following analysis of gel fractionation profiles of tagged PIAS1 (Fig.3.40. Gel 
fractionation profiles of PIAS1 and Sp3 overexpressed in HEK293 cells), we observe 
that PIAS1 is part of a protein complex(es) within the cell, being detected in a high 
molecular protein fraction. The identification and subsequent characterisation of the 
proteins that are part of the observed PIAS1 protein complex will probably unravel 
partially the SUMOylation mechanism.  
Beside the specific SUMO ligase undertakings, PIAS proteins have been found to 
control the activity of a variety of transcriptional regulators in SUMO independent 
manner (Schmidt and Mueller, 2002). Transcriptional repression is in many cases 
mediated by corepressor complexes that contain histone deacetylase activity. The 
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finding that PIAS proteins can directly interact with histone deacetylase (HDACs) 
provides further evidence for a role of PIAS proteins in the assembly of such a complex 
(Tussie-Luna et al., 2002).  
Accumulating evidence indicates that the PIAS/SUMO system is involved in 
targeting to specific subnuclear sites of SUMO-target proteins. PIASy has been shown 
to inactivate LEF1 possible by inducing its compartmentalization into PML NBs 
(Sachdev et al., 2001). Considering that NBs are unlikely active sites of transcription, 
the most simple interpretation of these data is that recruitment to NBs via PIAS/SUMO 
sequesters LEF1 away from its target genes, thus neutralizing its transcriptional activity. 
Examination of a tagged LEF1 protein showed localization throughout the nucleus in 
transfected mammalian cells. Coexpression of PIASy strongly redistributed LEF1 to 
nuclear bodies, an effect enhanced by coexpression of SUMO1 or SUMO-2. To test 
whether this effect required the SUMO ligase activity, the authors also transfected the 
RING mutant of PIASy. Not only did this RING mutant fail to target to nuclear bodies, 
but it was also unable to redistribute a mutant of LEF1, suggesting that the RING finger 
and likely the SUMOylation activity of PIASy are important for both the localization of 
both PIASy and its targets to nuclear bodies. Moreover, this targeting strongly 
correlated with transcriptional repression by PIASy (Sachdev et al., 2001).  
An obvious question is what determines whether the PIAS/SUMO system 
ultimately leads to the formation of a coactivator or corepressor complex on a given 
transcription factor. One possibility might be that distinct PIAS forms function as 
targeting factors to specific subpopulations of NBs, which may contain either 
corepressors or coactivators. This idea is supported by the observation that at least upon 
overexpression distinct PIAS forms show a different pattern of subnuclear localization. 
Hence, PIAS1 exhibits microgranular localization in small foci, whereas PIAS3 
concentrates in fewer, but larger granules (Kotaja et al., 2002). 
However, my results did not support such observations. I have shown that the Sp3 
subcellular localization in HEK293 cells is not affected upon SUMO1/PIAS1 
coexpression (FIG.3.28. Subcellular localization of PIAS1 in HEK293 cells). Moreover, 
the observation that distinct PIAS forms show a different pattern of subnuclear 
localization could be inaccurate. I observed that upon SUMO1/PIAS1 overexpression, 
dots in different cells are variable in number and size, microgranular localization in 
small foci and also larger granules previously described (Kotaja et al., 2002) could be 
observed in the same slide (FIG.3.28-C). 
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4.6. How does SUMO Mediate Sp3 Transcriptional Repression? 
In attempting to find condition in which Sp3 SUMOylation may alter, we observed 
that the ratio between Sp3 unmodified and SUMOylated Sp3 is not significantly 
changed in different cell lines or mouse tissues (see Results-3.3 Is Sp3 regulated by 
SUMOylation?). Also, metabolic stress conditions, respective serum induction, serum 
starvation and heat shock were found not to alter Sp3 SUMOylation.  
Nevertheless, there is no detectable alteration in SUMOylation pattern in 
mammalian cells treated with both, cycloheximide and TNF-alpha drugs and 
trichostatin A (TSA) treatment of insect cells does not affect the SUMOylation level of 
transiently transfected Sp3. 
Treatment of cells with the proteasome inhibitor MG-132 dramatically reduces Sp3 
SUMOylation level.  
It was shown that PML, SUMO-1, Sp100, and proteasomes localized to the nucleoli 
in the proteasome inhibitor-treated cells with MG-132, suggesting that nucleoli may be 
involved in the regulation of proteasome-dependent protein degradation. The nucleolar 
accumulation may also reflect a natural turnover of these proteins that involves 
trafficking through the nucleoli (Mattsson et al., 2001). Contrary, another report shows 
that upon MG-132 treatment one can observe a slight increase in SUMOylation of PML 
and Sp100 (Everett et al., 1998). 
However, the overall amount of Sp3 is not reduced upon advising that Sp3 is not 
degraded via proteasome-dependent pathway. 
One possible explanation of altering of Sp3 SUMOylation could be that the 
MG-132 proteasome inhibitor prevents proteasome degradation of SUMO specific 
isopeptidase, which subsequently remove the Sp3-SUMO moiety. Ross and coworkers 
reported that the SUMO-1 protease SuPr-1 catalyzes the removal of SUMO-1 from Sp3 
in vivo and stimulates transcriptional activation by Sp3 (Ross et al., 2002). On the 
other hand, I observed that upon MG-132 treatment of insect cells transfected with wt 
Sp3 and a corresponding reporter containing four Sp3 binding sites, the Sp3 
transcriptional activation is not enhanced, suggesting that this proteasome inhibitor 
might be implicated in other steps of Sp3 SUMOylation.    
While many explanations have been proposed for SUMO-mediated Sp3 
transcriptional repression, a model must accommodate two apparently contradictory 
observations. Only a small proportion of Sp3 transcription factor appears to be 
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SUMOylated. However, under these conditions the Sp3 transcription factor is 
maximally repressed and mutation of the acceptor lysine for SUMO modification 
relieves repression. A convenient model for Sp3 transcription factor regulation by 
SUMO that accommodates these observations is outlined in Fig.4.2. 
In this model newly synthesized Sp3 is rapidly SUMOylated and incorporated into 
a repression complex constituted in a SUMO-dependent fashion. Constitutively active 
SUMO-specific proteases can then catalyze removal of SUMO, but the transcription 
factor is retained in the repression complex (in a SUMO-independent fashion). Under 
normal circumstances a relatively slow dissociation of the stable repression complex 
would release sufficient unmodified Sp3 transcription factor to allow basal 
transcription. Thus, SUMO is required for the initiation of repression, but not for the 
maintenance of repression. The presence of enzymes involved in SUMO conjugation 
and deconjugation at the same sites within the cell nucleus (Zhang et al., 2002) suggest 
that SUMO modification is a highly dynamic process with substrates undergoing rapid 
SUMO modification and deconjugation. Also, expression of an Sp3 mutant, where the 
SUMO acceptor lysine has been altered, is transcriptionally active and refractive to 
SUMO-dependent repression.  
 
  
 
Fig. 4.2. Model for Sp3 transcriptional repression by SUMO. (Adapted after Girdwood 
et al. 2004) 
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Studies of the mechanisms by which SUMO modification regulates 
transcription-factor activity are complicated by the fact that in many cases not only the 
activator but also its associated coactivators, and/or corepressors, are modified by 
SUMO. It is possible that association of multiple SUMO-modified proteins in a 
complex may amplify effects of experimental alterations in the SUMOylation 
machinery or mask effects of mutation of individual SUMO acceptor lysines. If SUMO 
functions to promote interactions important for transcriptional repression, it may not 
matter exactly which subunit in a transcription factor complex is SUMO modified, so 
much as that SUMO is conjugated to one or more subunits in the complex. According 
to this view, it is modification of the complex per se that is important for regulation 
(Jackson, 2001). However, the mechanism(s) of transcriptional repression mediated by 
SUMOylation is still unclear.  
 
4.7. Conclusion and Future Directions 
The large and growing number of SUMO substrates that are now available for 
detailed studies demonstrates a previously unexpected diversity of physiological 
processes affected by this modification. Many of the SUMO-modified proteins 
identified to date are promoter-specific transcription factors, coactivators, or 
corepressors. Although the effects of SUMO modification on transcription factor 
activity are varied, in the majority of cases that have been described to date, attachment 
of SUMO appears to repress the activity of transcriptional activators (Gill, 2003; 
Verger et al., 2003).  
The transcription factor Sp3, for example, has been shown to be SUMO modified in 
vivo and removal of SUMO by mutation of the Sp3 acceptor lysines or cotransfection 
with a SUMO protease dramatically increased transcriptional activity of Sp3 
(Sapetschnig et al. 2002; Ross et al., 2002). These findings suggest that SUMO 
modification may contribute to the complex activity of Sp3, which has long been 
known to function as both an activator and a repressor of transcription dependent on the 
promoter context. Furthermore, Sp3 SUMOylation is one of the most recent found 
significant differences (Fig.4.3) between Sp1 and Sp3, considered for long time as 
redundant transcriptional regulators (Sapetschnig et al., 2004). 
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Fig. 4.3. Comparison of known structural, biological and biochemical features of 
the transcription factors Sp1 and Sp3. (Sapetschnig et al. 2004). 
 
The only site of SUMO modification in Sp3 lies within a previously defined 
inhibitory domain. Similarly, the sites of SUMO attachment in some of the 
transcription factors, including C/EBP proteins, Elk-1, c-Myb, and steroid hormone 
receptors, have also been mapped to regions previously shown to function as inhibitory 
domains (Poukka et al. 2000; Abdel-Hafiz et al. 2002; Tian et al. 2002; Subramanian et 
al. 2003; Yang et al. 2003).  
If the transcriptional responses (and many other regulatory events) require rapid 
activation and inactivation, it may be that the reversibility of SUMO addition and 
removal is critical for the dynamic assembly of regulatory complexes. Indeed, in some 
cases, SUMOylation might simply be a promiscuous process (intensified by substrate 
overexpression) that is normally kept in check by SUMO proteases, and for which a 
specific, SUMO-related function might not exist. On the other hand, it is also possible 
that, under physiological conditions (without artificial overexpression of the substrate 
and/or SUMO) the bona fide effects of SUMOylation might be more pronounced, or 
even quite different from what is observed using current experimental methods. 
Moreover, it must be considered that SUMOylation is a dynamic, reversible process, 
perhaps also explaining why, in many cases, only little or no modified protein can be 
detected under physiological conditions. Thus, SUMO modification may function to 
repress activation by many transcription factors. 
 
Discussion 
 177
How SUMOylation influence Sp3 transcriptional repression, and whether PIAS1 
participate in the transcriptional repressor complex is also an interesting challenge for 
future studies. Analyzing transgenic animals expressing Sp3 isoforms and 
SUMOylation mutants could give important information concerning the function of 
individual Sp3 isoforms and furthermore the role of Sp3 SUMO modification in living 
animals. Identification and characterisation of Sp3- and Sp3-SUMO-associated proteins 
could unravel the prospect that Sp3-SUMO or non-modified Sp3 recruit enzymes that 
modify Sp3 itself or chromatin (potentially kinases, acetylases, deacetylases, 
methylases etc.). Moreover, addressing the function of a given 
Sp3/Sp3-SUMO-interacting protein by transient over-expression studies in various cell 
lines (SL2 cells, HeLa cells or fibroblast cell lines) is demanding. Vice versa, important 
informations about SUMO mediation of Sp3 transcriptional activity will also be 
obtained by knock-down the Sp3/Sp3-SUMO-interacting proteins using the siRNA 
technology.
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